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ABSTRACT 
AAA+ proteins (ATPases Associated with various cellular Activities) are a sub-family of P-
loop NTPases which convert chemical energy into physical motion to carry out a multitude of 
functions. The AAA+ protein phage shock protein F (PspF) is a bacterial enhancer binding 
protein (bEBP) for the major variant transcription factor sigma 54 ( 54) in E. coli. PspF binds 
to and remodels the promoter DNA bound 54-RNA polymerase holoenzyme (E 54), inducing 
isomerisation from a transcriptionally silent closed complex to an open complex. Without 
binding to and concurrent ATP hydrolysis by the bEBP, E 54 is unable to spontaneously form 
the transcriptionally competent open complex, thus maintaining tight control over its 
associated genes. 
Conformational changes in the PspF ATP binding site upon hydrolysis are communicated 
through a pathway of conformational changes in PspF, resulting in the reorganisation of two 
mobile loops – termed Loop 1 and Loop 2. Loop 1 contains the GAFTGA motif, highly 
conserved across bEBPs, which forms a stable interaction with 54. Thus far, traditional 
approaches such as site-directed mutagenesis and cryo-EM have been used to probe the 
conformational changes produced at each stage of nucleotide hydrolysis. 
In this work, the PspF/ 54 interaction is investigated using a chemical genetic approach. The 
interactions of designed synthetic peptides with 54 are investigated using in vitro techniques 
including a dansyl-based fluorescence binding assay, isothermal titration calorimetry (ITC) 
and traditional activity based transcription assays. Maltose binding protein fusions of the 
PspF fragments carrying Loop 1 were also investigated using an in vivo -galactosidase 
assay. Finally, Split-Intein Mediated Circular Ligation of Peptides and Proteins (SICLOPPS) 
was used to create two plasmid-borne cyclic peptide libraries, one random and the other 
containing the GAFTGA motif. To select for peptides inhibitory to the PspF- 54 interaction, a 
selection system was developed based on a promoter-lacZ fusion and the conditionally toxic 
lactose analogue phenyl- -D-galactose (Pgal). To confirm hits, a secondary screen based 
on a structurally and functionally related 54-bEBP interaction was developed and several 
peptides active in vivo were identified. 
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ABBREVIATIONS 
3-amino-1,2,4-triazole 3-AT 
aa Amino acid 
AAA+ ATPase Associated Activities 
ADP Adenosine diphosphate 
APS  Ammonium persulfate 
ATP Adenosine triphosphate 
bEBP Bacterial enhancer binding protein 
bps Base pairs 
Cor Corallopyronin 
Da daltons 
DctD C4-dicarboxylic acid transport protein D 
DIPEA  Diisopropylethylamine 
DMF  Dimethylformamide 
DMSO  Dimethylsulfoxide 
DOS Diversity-oriented synthesis 
DTT  Dithiothreitol 
E RNAP holoenzyme 
E. coli Escherichia coli 
EDT  1,2-ethanedithiol 
EM Electron microscopy 
ESI  Electrospray ionisation 
E RPCC Holoenzyme, promoter DNA closed complex 
E RPOC Holoenzyme, promoter DNA open complex 
F2 PspF Fragment 2 (PspF69-102) 
F4 PspF Fragment 4 (PspF69-93) 
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Fmoc Fluorenylmethyloxycarbonyl 
GS Glutamine synthetase 
HATU  
o-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate 
HBTU 
o-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate 
HPLC High pressure liquid chromatography 
HRP  Horseradish peroxidase 
HTH Helix-turn-helix 
IHF Integration host factor 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
ITC Isothermal titration calorimetry 
LC-MS Liquid chromatography-mass spectrometry 
MALDI-TOF 
Matrix-assisted laser desorption/ionization - time of 
flight 
MBP Maltose binding protein 
mRNA messenger RNA 
Myx Myxopyronin 
NtrC Nitrogen regulatory protein C 
OD600 Optical density measured at 600 nm 
Pgal Phenyl- -D-galactoside 
pmf Proton motive force 
PPI Protein-protein interaction 
PspA Phage shock protein A 
PspB Phage shock protein B 
PspC Phage shock protein C 
PspD Phage shock protein D 
PspE Phage shock protein E 
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PspF Phage shock protein F 
PspG Phage shock protein G 
pspAp The pspA promoter 
glnAp The glnA promoter 
R-finger Arginine finger 
Rif Rifampicin 
RPCC 
Pre-initiation promoter DNA bound holoenzyme 
complex 
RPOC Melted promoter DNA bound holoenzyme complex 
RTH Reverse two hybrid 
RTHS Reverse two hybrid system 
Saccharomyces cerevisiae S. cerevisiae 
SDS  Sodium dodecyl sulphate 
SICLOPPS Split-Intein Circular Ligation of Proteins and Peptides 
smFRET 
Single molecule Fluorescence resonance energy 
transfer 
SPPS Solid phase peptide synthesis 
SRH Second region of homology 
TIS  Triisopropyl silane 
Tris Tris(hydroxymethyl)aminomethane 
tRNA transfer RNA 
UAS Upstream activator sequence 
UAS Upstream activator sequences 
WT Wild type 
WT Wild type 
54 Sigma 54 transcription factor 
70 Sigma 70 transcription factor 
Standard amino acid 1 and 3-letter codes are used throughout. 
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1 INTRODUCTION 
To introduce this thesis, background information about the system targeted for investigation 
will be discussed in the first section (1.1 Bacterial Transcription: Regulation), followed by 
discussion of the chosen approach and potential methodologies (1.2 Chemical Genetics). 
Finally, reported examples of small molecules or chemical genetic approaches targeting 
transcription and gene regulation will be discussed (1.3 Targeting Protein-DNA Complexes) 
before the specific aims of this project are outlined (1.4 Targeting PspF-Sigma 54: Project 
Aims). 
1.1 BACTERIAL TRANSCRIPTION: REGULATION 
Gene regulation is of critical importance to organism survival and adaptation to 
environmental changes. By example, Escherichia coli bacteria (such as E.coli MG1655, the 
first fully sequenced K12 strain), which have around 4,500 genes (GenBankTM, E. coli 
MG1655), need to respond to specific changes in environment, such as sugar source 
alteration or nitrogen limitation, whilst maintaining an appropriate level of expression for 
housekeeping genes. Of equal importance, is conservation of energy and appropriate use of 
resources, in other words, limited or no expression of genes which are not required at a 
particular time. Transcription, and therefore RNA polymerase (RNAP) activation or 
repression, are levels at which gene expression is regulated. With approximately 2000 
different promoter sequences, a core facet of transcriptional regulation in E. coli is regulatory 
nucleotide sequence identity [6]. In addition to promoter strength, RNAP activity is 
modulated by other factors including small effector molecules (such as guanosine 3‟, 5‟ 
biphosphate, ppGpp) [7], nucleotide elements (such as UP-elements located approximately 
20 base pairs (bps) upstream from promoter regions) [8] and a range of small proteins which 
directly bind to it [6, 9]. Another key element in regulation involves a protein subunit which 
makes up the transcriptional machinery of RNAP itself, the  factor. 
1.1.1 70 AND 54 DEPENDENT TRANSCRIPTION INITIATION 
Bacteria have a single multi-subunit core RNAP, responsible for transcription of all genes, 
which is comprised of four subunits to make up the catalytic core (E), ‟  [6, 10]. Whilst 
the core RNAP is transcriptionally competent, it is unable to initiate transcription at specific 
promoters, but must form a complex known as the holoenzyme (E ) with an auxiliary sigma 
( ) factor [6, 10]. The  subunit confers specificity to RNAP by recognising and positioning 
RNAP at specific promoter elements [6]. Only the presence of the  factor in the holoenzyme 
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allows initiation of DNA duplex unwinding close to the transcription start site to form the 
transcriptionally competent open complex (RPOC) [6, 11]. 
In addition to the housekeeping sigma factor ( 70), six alternative sigma factors have been 
identified in E. coli belonging to two distinct classes; those with sequence and structure 
similarity to 70, and the unrelated sigma 54 ( 54) [12, 13]. For 70 and its related sigma 
factors ( 38, 32, 28, 24 and 18) formation of the holoenzyme with RNA polymerase and 
binding to promoter DNA will often lead to spontaneous DNA melting and formation of the 
open complex (see Figure 1.1). Regulation of this process is achieved by proteins which 
either encourage or prevent 70 from binding to two conserved hexanucleotide promoter 
sequences at -35 and -10 upstream from the transcription start site at +1 [6, 9]. Once the 
holoenzyme is formed and bound to DNA, both E  and promoter DNA undergo multiple 
conformational changes before the initiation complex is formed [14]. Conformational 
changes of E , investigated using single molecule FRET, reveal that the RNAP ‟ subunit 
(clamp) remains in an open conformation relative to the  subunit. This allows loading of 
double stranded DNA, which subsequently triggers clamp closure resulting in a motion of the 
b‟ subunit of ≥20 Å relative to the subunit tips [15]. Principal to this large conformational 
change is DNA unwinding to form a bubble, which occurs between around -10 and +2, 
therefore encompassing both promoter hexamer and transcription start site [11, 14, 16]. 
The major variant transcription factor, 54, has no sequence similarity to 70, and has a 
different mechanism of operation, requiring activation by a transcription activator protein 
belonging to the AAA+ (ATPase Associated with various cellular Activities) family of proteins 
[17-20]. The holoenzyme first forms a transcriptionally silent closed complex (E 54-RPCC) by 
binding to promoters at -24 (GG) and -12 (GC) base pairs (bps) upstream from the 
transcription start site [21], but cannot spontaneously isomerise to give the active, open 
complex [18]. Despite contact between the sigma subunit and RNAP catalytic subunits  and 
‟ [22], E 54-RPCC remains in a repressed state, caused by interactions of 
54 with the -12 
promoter element which prevent promoter DNA from accessing the RNAP catalytic site [23-
26]. It cannot proceed to the open complex until activated by the AAA+ regulatory protein, 
known as a bacterial enhancer binding protein (bEBP) [27-29]. 
The bEBP itself binds to the DNA at remote promoter elements typically 150 bps upstream 
and DNA looping, aided at some promoters by DNA bending proteins such as the integration 
host factor (IHF) [30, 31], allows the interaction between the bEBP and E 54-RPCC [24]. 
Interaction between 54 and bEBP alone is not sufficient for open complex formation; 
instead, concurrent ATP hydrolysis by the bEBP causes remodelling of the holoenzyme by 
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acting on the repressive interactions made at -12 by the holoenzyme, to allow DNA melting 
and formation of a transcriptionally competent E 54 (E 54-RPOC) [10, 15, 18, 29, 32]. 
1.1.1 BENEFITS AND SCOPE OF 54-DEPENDENT PROMOTERS 
54 is traditionally associated with nitrogen assimilation, fixation and metabolism, but in fact 
is responsible for the tightly controlled expression of a diverse set of genes across a variety 
of organisms (reviewed in [33], [34], [35]). Whilst 70-type transcription provides loose control 
over its associated genes, the requirement by 54 for an activator to remodel the promoter 
bound E 54 complex provides far more stringent control over gene expression. This can be 
considered as a wider dynamic range: from completely nothing to high level expression, 
which in turn provides the cell with a wide range of control over resource management. It 
would therefore be expected that 54 be linked to genes required under specific growth 
conditions or demands. In terms of two well-studied cases, stress response and nitrogen 
usage this is true, but 54 has also been linked to pathogenesis and virulence. 54 is more 
commonly found in pathogenic bacteria [34] and is essential for managing virulence related 
resources and some virulence genes themselves [33]. In Pseudomonas aeruginosa, 
mutation or knockout of the 54 gene, rpoN, resulted in bacteria with reduced pathogenesis 
Figure 1.1 The 
70
 vs 
54
 mechanism of open complex formation. In 
70
 dependent transcription, the closed 
complex often spontaneously isomerises to the transcriptionally competent open complex. In 
54
 dependent 
transcription a AAA bEBP is required form and intermediate complex, which then isomerises to the open complex. 
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and virulence, whilst in Pseudomonas syringae, rpoN controls the expression of the 
virulence-related gene hrp [33]. This link undoubtedly makes 54 a target for antimicrobials 
and study of bacterial virulence and pathogenicity. 
1.1.2 FEATURES OF THE BACTERIAL ENHANCER BINDING PROTEIN 
1.1.2.1 AAA+ PROTEINS ARE MECHANOCHEMICAL ENZYMES 
Walker type (or P-loop) NTPases, the most abundant class of proteins accounting for 
between 10 and 18% of predicted gene products in sequenced prokaryotic and eukaryotic 
genomes [36], are defined by the characteristic P-loop and core β-strand [37]. AAA+ proteins 
are a subfamily of Walker-type NTPases which convert chemical energy, stored as ATP, into 
biological activity via mechanical force. They may be defined by a highly conserved region of 
approximately 200 amino acids containing the Walker A and B motifs for ATP binding and 
hydrolysis, as well as the Second Region of Homology (SRH) [37-40]. Found in eubacteria, 
archaebacteria and eukaryotes, the key feature of this functionally diverse superfamily of 
proteins is the coupling of chemical energy to physical movement which leads to a wide 
array of cellular functions, including protein unfolding and organelle biogenesis [38, 39]. 
The P-loop itself is an inserted loop between a -sheet and -helix that forms a pocket 
together with the Walker A motif (GxxxxGKT, x = any residue) and the Walker B motif 
(hhhhDExx, h = hydrophobic residue) to position the NTP and phosphates [39]. The 
conserved nucleotide binding pocket is well tailored to both sensing the presence of ATP 
and its hydrolysis. The Walker A conserved lysine is positioned such that it can interact with 
the β– or γ–phosphate oxygen, whilst threonine may coordinate the cofactor Mg2+. The two 
conserved carboxylic side chains of the Walker B motif project into the ATPase active site. 
The aspartate side chain may aid coordination of Mg2+ whilst glutamate acts as a catalytic 
base in the activation of a water molecule which subsequently attacks the ATP γ-phosphate 
[39]. For side-chain positions in the active site of AAA protein PspF, see Figure 1.3, C. By 
example, in the well-studied AAA + protein nitrogen regulatory protein C (NtrC) (from 
Salmonella typhimurium) mutations of the highly conserved Walker B aspartate cause loss 
of ATP hydrolysis activity. However, the mutants were found to still bind ATP, with and 
without Mg2+, and to a higher degree than wild-type NtrC [41]. The Walker B is therefore 
necessary for nucleotide hydrolysis, but is not the major determining factor in nucleotide 
binding; rather Walker A residues dominate binding. 
The expected negatively charged penta-coordinate transition state formed after nucleophilic 
attack by the water molecule requires that an Mg2+ ion be present to balance the negative 
charge; without it, ATP hydrolysis will not reach the transition state [39, 42]. The „Sensor 1‟ 
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residue, positioned at the top of β-sheet 4 which becomes the SRH, is commonly highly 
conserved as a polar residue in AAA proteins. It is thought to contact the -phosphate during 
ATP hydrolysis and binding, and to be important for the differentiation between bound ATP 
and ADP [37]. Sensor I is an example of a sensing residue in the catalytic site which relays 
information to nearby structural motifs. The resulting in conformational change thus causes 
an event, such as release of ADP, to be triggered. 
The terms AAA+ and AAA proteins are often used interchangeably, with the determining 
factors between the two families of proteins often debated. However, AAA proteins may be 
identified by the presence of the SRH as well as the „Sensor 2‟, a conserved arginine 
residue, which is also thought to contact the γ-phosphate and to translate changes in the 
ATPase domain into conformational changes elsewhere in the protein [39]. AAA+ proteins 
form a larger superfamily of proteins, which contain the Sensor 2 arginine, but may not 
contain the SRH [37]. 
AAA+ proteins predominantly form ring-shaped oligomers, frequently hexamers from inactive 
dimers, and oligomer formation is vital for enzymatic function. The catalytic site is located at 
the interface between subunits and NTP is often required for or assists oligomer formation 
[39, 43-47]. 
1.1.2.2 DOMAIN STRUCTURE AND REGULATION OF AAA+ BEBPS 
The majority of bEBPs consist of three separate domains; the carboxy-terminal helix-turn-
helix (HTH) containing DNA binding domain, the central AAA+ domain responsible for 
catalytic activity, and an amino-terminal regulatory domain [48]. The HTH domain is 
responsible for binding of the bEBP at upstream activator sequences (UAS), the first step in 
contacting E 54-RPCC, but has also been shown to be a factor in inducing the oligomer 
formation necessary for ATPase activity [46]. In a limited number of cases however, no DNA 
binding domain is present, examples include activators for 54-dependent flagellar genes 
flgR (Helicobacter pylori) [49] and developmental cycle regulator CtcC (Chlamydia 
trachomatis) [50]. 
Regulation of the activity of the catalytic AAA+ domain of bEBPS can be achieved with or 
without an amino-terminal regulatory domain and in a cis- or trans-acting manner. The NtrC 
protein is positively regulated by the phosphorylated form of its amino-terminal domain. 
Phosphorylation of a key aspartate residue induces the receiver domain of one subunit to 
form a stabilising interaction with the catalytic domain of the preceding subunit, thereby 
stabilising the otherwise transient oligomeric state of NtrC [48, 51]. Conversely, for C4-
dicarboxylic acid transport protein D (DctD) and NtrC homolog NtrC1 from hyperthermophile 
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Aquifex aeolicus, phosphorylation disrupts regulatory contacts resulting in dimer 
reorganisation to an oligomerisation competent form; thus the amino-terminal domain is a 
negative regulator [48, 52, 53]. 
PspF however, belongs to a small subset of constitutively active bEBPs which lack an 
amino-terminal regulatory domain, and is negatively regulated in trans by another product of 
the psp regulon, phage shock protein A (PspA) [54-56]. Whilst variation in domain 
composition and regulatory mechanism exists between the most-studied bEBPs, the 
fundamental ATP hydrolysis dependent mechanistic details have pronounced cross-over. 
Inevitably then, what can be learned from one bEBP will have implications for the study of 
the field as a whole. 
1.1.2 PHAGE SHOCK PROTEIN F AND THE PSP RESPONSE 
1.1.2.1 THE PSP RESPONSE 
The phage shock protein (psp) response, found across enterobacteria, is activated in 
response to extracytoplasmic stress induced by factors such as heat and ethanol shock, 
extreme temperatures and filamentous phage infection [2, 57-59]. In E. coli, the psp 
response is comprised of the pspABCDE operon and pspG gene whose 54-dependent 
expression is controlled by the psp protein, phage shock protein F (PspF) [60, 61]. PspF, 
whose expression is 70-dependent [61], is a AAA+ and bEBP [59]. 
Figure 1.2 outlines the current view of the E. coli psp response. Under non-inducing 
conditions, PspA and PspF form a cooperative negative regulatory complex which results in 
low levels of expression from the psp regulon [55]. This regulatory complex may be 
associated with the inner membrane psp proteins PspB and PspC, which are thought to be 
involved in stress signal transduction [57]. In vitro data suggest that the PspA-F complex is a 
hetero near-dodecamer, likely two homo-hexamers of PspA and PspF [62]. Under inducing 
conditions which are linked to, but not exclusively dependent upon loss proton motive force 
(pmf) [63], the PspA-PspF complex disassociates, leaving PspF free to activate transcription 
at the pspA-E operon and pspG gene [60, 61]. In vitro data show that PspA is able to form a 
higher order oligomer, thought to be a 36-mer ring or clathrin-like structure, with molecular 
weight around 2 MDa [62, 64-66]. In addition to its negative regulatory role, PspA is also an 
effector protein of the psp response [2] and since this higher order oligomer is able to block 
proton leakage by binding inner membrane phospholipids [64], the 36-mer was identified as 
the active species in pmf restoration. However, in vivo visualisation of GFP-PspA expressed 
from promoter conditions equivalent to psp induction and uninduced point towards a more 
complicated pathway. Whilst lower and higher order oligomers were visualised, PspA was 
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found localised at the cellular poles during non-stressed conditions, and both at the poles 
and moving in a helical pattern along the length of the cell, dependent on the MreB 
cytoskeleton under inducing conditions [67]. Its activity has also been linked the activity of 
other proteins, and physical interaction between PspA and the protein translocase TatA has 
been identified [68]. 
The psp response, including the roles of the regulon‟s individual proteins, is not completely 
understood, but that cell membrane integrity is essential for bacterial survival is clear. It is 
also noteworthy that the psp response is vital for the virulence of some pathogens, such as 
Yersinia enterocolitica [57, 69] and psp has been postulated to play a role in maintenance of 
Figure 1.2 Schematic outlining the psp response. In an uninduced state, PspA and PspF form a complex 
which may or may not be associated with the membrane bound PspC. Induction of the psp response results in 
loss of the PspA-PspF inhibitory complex. PspA forms a higher order oligomer which might bind the inner 
membrane, whilst PspF is free to activate the pspA-E operon and pspG gene. PspD is an effector of the psp 
response, much like PspA and PspG [2]. PspE is a periplasmic rhodanase, but it‟s role in the psp response is 
unclear. 
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cell integrity during pathogenic infection. The psp response has also been implicated in the 
survival of E. coli persister cells, which exist in bacterial populations as cells resistant to the 
effects of added antibiotic agents [70, 71]. Whilst the mechanism of their resistance is 
unknown, they have been implicated in biofilm formation during infection and have induced 
psp expression [70]. 
1.1.3 PSPF STRUCTURE AND ATPASE ACTIVITY 
1.1.2.3 PSPF DOMAIN AND PROTEIN STRUCTURE 
As previously stated (Domain Structure and Regulation of AAA+ bEBPs) most bEBPs 
consist of three domains. PspF however, is missing the expected amino-terminal regulatory 
domain and consists of only two domains, the AAA+ ATPase domain (residues 1-275) and 
DNA binding domain responsible for binding to UAS (residues 296-325) [61]. The catalytic 
AAA+ domain contains the seven regions typically conserved across bEBPs [72]. These 
include the AAA+ determinant Walker A and B motifs and the second region of homology 
(SRH) [46]. Other functionally important motifs are Loop 1, an insert into helix 3 that contains 
the 54-interacting GAFTGA motif; Loop 2, joining helix 4 to -sheet 4 and the glutamate 
switch residue N64 [46, 73] (Figure 1.3, A). These functional motifs are thought to be 
involved in the relaying of information about the nucleotide hydrolysis state from the catalytic 
site through a network of intra-molecular interactions, ultimately to E 54RPCC. Figure 1.3 B. 
and C. show the key residues mapped onto structures of PspF1-275 bound to ADP (B.) and 
rotated and enlarged to see only the catalytic binding pocket containing ATP (C.). The side 
chains of key residues, which will be discussed later, are also shown in Figure 1.3, C. 
demonstrating their orientation with respect to the ATP -phosphate. 
Due to the extent to which it has been studied, PspF is a model system for both bEBPs and 
AAA+ proteins. As is typical for proteins of the AAA+ family, PspF forms hexameric rings in 
its active state (Figure 1.4, A.) with the ATPase catalytic site located at the interface between 
subunits [3, 74, 75]. Oligomerisation of the AAA+ domain PspF1-275 is promoted by the 
presence of either ADP or ATP [74], probably due to changes at the interface surface 
between protomers. 
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1.1.3.1 ATPASE ACTIVITY 
The ATPase activity of any bEBP is key to its ability to act as a transcriptional activator. One 
fundamental requirement is formation of the hexamer, however, the exact nature of 
nucleotide occupancy and hydrolysis is still under investigation. Since substoichiometric 
levels of ATP have been shown to produce highest PspF1-275 catalytic output, and an excess 
Figure 1.3 Domain map of PspF and regions of conservation mapped onto the PspF1-275 monomer. A.  
PspF has two domains; the AAA+ catalytic core contains the 7 conserved bEBP motifs C1 – C7 and the carboxy-
terminal DNA binding domain contains the HTH. The AAA+ domain contains the Walker A and B motifs, N is the 
PspF glutamate switch aspartate N64, Loop 1 contains the 
54
–interacting GAFTGA motif, SI and SII are the 
sensor I and II and R-fingers are the arginine fingers. B. Key residues are mapped onto the PspF1-275 monomer 
bound to ADP. ADP is shown in pink. The Walker A motif (WA) is in blue, Walker B (WB) in green, glutamate 
switch N64 in black, SII in purple, the second region of homology (SRH) contains the SI and R-fingers. The 
stems of Loop 1 are shown in red, Loop 2 is in orange. C. The PspF1-275 monomer is rotated 90º counter 
clockwise and the nucleotide binding pocket, with ATP bound (pink), is enlarged. Sidechains of the WA lysine, 
WB aspartate and glutamates, asparagine 64, SII arginine 227 and SI threonine and asparagine are shown. Also 
shown is the residue W56 (in cyan), a determinant for binding of PspF by PspA. 
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of ATP inhibits ATPase activity it appears that the optimum and likely in vivo state is 
heterogeneous with respect to nucleotide bound state. Additionally, the presence of ADP at 
theoretical physiological levels stimulates PspF1-275 ATPase activity [59, 74]. 
The conserved residues which form the nucleotide binding pocket, including those of the 
Walker A and B motifs, are key to both ATP binding and hydrolysis. The conserved Walker A 
lysine (K42) (shown in Figure 1.3, C. in blue) forms ionic interactions with the oxygen of the 
ATP - and -phosphates [76] and mutation to alanine gives a monomer-dimer PspF unable 
Figure 1.4 Structures of the PspF1-275 hexamer. A. Model structure of ATP bound PspF1-275 hexamer. ATP is in 
red, the central β-sheet is in yellow, Loop 2 is in orange and the stems of Loop 1 are in cyan. B. Cryo EM 
structure of PspF1-275 bound to 
54
. There are several patches of overlapping connecting densities between the 2 
proteins, and these are proposed to match the positions of Loops 1 and 2 when the PspF1-275 crystal structure is 
overlaid onto the electron density of PspF1-275. Adapted from [3]. 
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to hexamerise and with reduced ATP binding, which ultimately affects ATP hydrolysis levels 
[62, 75]. The conserved residues of the Walker B motif also coordinate ATP and Mg2+ in the 
binding pocket (Figure 1.3, C. in green). Aspartate D107 coordinates Mg2+, whilst glutamate 
E108 provides the catalytic base to activate the water molecule required for hydrolysis of 
ATP [10, 38-40, 42, 73, 77]. Mutations of these two residues, known as the „glutamate 
switch‟ produce mutant PspF with reduced ATPase activity and altered hexamerisation 
profiles [75, 78]. Further contacts are made in the ATP binding pocket by the Sensor I 
residues (T148 and N149) and Sensor II residue (R227), which contact the ATP -phosphate 
and sense its hydrolysis to ADP (Figure 1.3, C. in yellow and purple respectively) [37, 39]. 
Finally the putative arginine finger (R-finger) residues R162 and R168 are thought to be 
involved in stabilising the negative charge formed as ATP hydrolysis reaches the transition 
state [46]. For PspF, large numbers of mutational substitutions have been used to study the 
roles of these key residues, which are detailed further in [59]. 
Significant conformational changes are evident upon comparison of structures of PspF1-275 
bound to ATP, ADP and the apo form. When ATP binds to the active site, the Walker B 
residue E108 undergoes significant movement, perhaps forming an interaction with N64, 
which senses the presence of ATP in the binding pocket and relays this to helix 3 [79]. 
Movement of linker 1 induces rotation of helix 3, disrupting possible interactions between 
H80 and H92, located on the Loop 1 stem, and several residues located on helix 3. The 
outcome is an upward rotational movement of Loop 1 to a perpendicular position (Figure 1.5) 
[42]. The initial movements in the catalytic site also cause movement of linker 2, helix 4 and 
finally Loop 2. Using structural studies, it has been proposed that disruption of a salt bridge 
between Loop 2 residue R131 and Loop 1 residue E81 and the possible formation of one 
between R131 and helix 3 R97, shifts Loop 1 up further [42]. The post-hydrolysis state 
shows that both loops undergo a shift back down, with Loop 1 undergoing the largest 
movement. The positioning of Loop 1 is key to E 54-promoter dependent activation; as the 
loop shifts position it relieves repressive 54-promoter interactions and the complex is 
remodelled to a state competent for open complex formation [80]. Comparison of apo, ADP 
and ATP structures of NtrC (Aquifex aeolicus) confirm the importance of movements located 
within the catalytic site with those of Loop 1. These structures indicate a rigid body roll 
occurs as the R-finger engages the ATP -phosphate, repositioning the loops for interaction 
with 54. ATP hydrolysis releases the R-finger which in turn allows the reverse 
conformational shift to occur, in turn moving the loops downwards [81]. 
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1.1.4 LOOP 1 AND THE GAFTGA MOTIF 
The GAFTGA motif, located at the tip of Loop 1 is a highly conserved sequence across 
bEBPs and is essential for an interaction with 54 [1, 46]. Thought to contact 54 Region 1 
[82-84], a productive interaction capable of remodelling E 54RPCC requires ATP hydrolysis in 
the catalytic core [1]. In the absence of ATP hydrolysis, weak interactions between E 54 and 
PspF have been reported, but are insufficient to activate transcription [3, 75, 85]. 
Loop 1, located at the top of the bEBP hexamer (Figure 1.4, B. and Figure 1.5) is presented 
to E 54RPCC
 at the point of nucleotide hydrolysis [3, 51]. Cryo-electron microscopy (cryo-EM) 
(Figure 1.4, B.) of PspF1-275 with the transition state analogue ADP.AlFx and 
54 shows six 
PspF monomers forming a well-defined hexameric ring and coordinated to one 54. In 
addition, the EM map also shows some connecting densities between the two protein 
structures, which it can be assumed represents the point of ATP hydrolysis. Fitting the apo 
hexameric crystal structure model into the map, it is possible to match the positions of these 
densities to those of certain Loops 1 and 2 of adjacent PspF protomers, supporting the 
suggestion that at the point of nucleotide hydrolysis the loops are raised and in contact with 
54 [3]. Crystal structures of the bEBPs zinc resistance-associated regulator (ZraR) 
(Salmonella typhimurium) and NtrC1 (Aquifex aeolicus) show the positions of the flexible 
Loop 1 with ATP and ADP bound respectively, orientated towards the central core of the 
oligomer [52, 86]. 
GAFTGA residue T86 has been shown to be significant for maintaining a productive and 
energetically favourable binding interaction with 54. Mutation of PspF T86 to alanine, results 
in a PspF1-275 species incapable of interacting with 
54 or activating transcription [1]. The 
critical nature of this residue has also been demonstrated for other bEBPs, including NtrC 
[51], NtrC1 [52] and ZraR [86]. When T86 is mutated to serine, PspF is no longer able to 
interact with 54 in contact with an optimal DNA fork junction structure, but can form stable 
interactions with 54/RNAP without promoter DNA [87]. This preservation of interaction 
suggests that the residue plays some role in sensing conformational changes within the 54 
holoenzyme/ promoter DNA complex [88]. 
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GAFTGA residue F85 is also highly conserved across bEBPs and its position may indicate a 
significant role. Mutations of PspF1-275 F85 disrupted interaction with 
54, except for the 
occasionally naturally occurring F85Y, and none of the mutants were capable of activating 
transcription from the nifH promoter. Additionally, the mutants had severely affected ATPase 
activity compared to wild type (WT) [89]. F85 may therefore be important for interactions 
which occur after the initial formation of a bEBP.E 54.DNA complex, but also in the 
communication between bEBP catalytic site and Loop 1. 
A critical requirement for the presence of GAFTGA motif for interaction with 54 is also 
demonstrated by the properties of the NtrC protein from Rhodobacter capsulatus. Unlike 
other NtrC proteins, it does not have a GAFTGA motif, and is not a 54-dependent 
transcriptional activator. It activates transcription using the 70 holoenzyme, and activation is 
not ATP hydrolysis dependent [90]. 
 
Figure 1.5 Structures of ATP- (in blue, PDB 2C96) and ADP-bound (in yellow, PDB 2C98) monomer PspF1-
275 overlaid. ATP is shown in pink. The loop region is shown expanded. The GAFTGA-containing Loop 1 is 
thought to undergo a large shift downwards in conformation as hydrolysis is completed. Due to the flexibility of 
Loop 1 it is not elucidated from crystal structures; the predicted movements have been added as a dashed line 
based on the movements of the Loop 1 stem regions. The central -sheet is shown in red. 
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Table 1.1 Mutations of Loop 1 and their effects on bEBP function in vitro. Where the study has not been 
performed on PspF, position numbers for equivalent residues in PspF are given in brackets (). 
Mutation of the GAFTGA G83 to alanine or phenylalanine results in hexamers with limited 
ATPase activity and unable to form RPOC, but able to form the „trapped‟ complex with 
54 in 
the presence of ADP.AlFx, although to a lower extent than WT [91]. Likewise, substitution of 
G83 with the unnatural photoreactive amino acid p-benzoyl-L-phenylalanine (pBpa), gave 
BEBP/ 
ORGANISM 
GAFTGA/ 
LOOP 1 
MUTATION 
CRITICAL EFFECTS 
REF. 54 
INTERACTION 
ATPASE 
ACTIVITY 
RPOC 
FORMATION 
PspF 
(E. coli) 
G83A Reduced Reduced None [91] 
G83F Near WT Reduced Almost none [91] 
F85A None Reduced None [89] 
F85Y Near WT Reduced Reduced [89] 
F85 W, H, I None WT-like None [89] 
F85 C, E, L, 
Q, R 
None Reduced None [89] 
T86A None WT-like None [1] 
T86S Near WT WT-like 
None, but 
relieved by 
mutation of 54 
Region I (G4L) 
[88] 
DctD 
(Rhizobium
 meliloti) 
H217R (H80) None None None [85] 
G220V (G83) 54 interaction Reduced None [85] 
G220D (G83) 54 interaction None None [85] 
A221V, D 
(A84) 
54 interaction Reduced None [85] 
F222L (F85) 54 interaction Reduced None [85] 
F222I, S 
(F85) 
54 interaction None None [85] 
T223I (T86) 54 interaction Reduced None [85] 
A225A (A87) 54 interaction Reduced None [85] 
F222-A225 
(F85-A87) 
54 interaction Reduced None [85] 
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PspF1-275 with reduced ATPase activity and unable to form RPOC as a homohexamer, but still 
able to trap 54 with ADP.AlFx. Exposure of the trapped complex to UV light gave multiple 
cross-linked complexes and aided identification of two patches within 54 Region I that are 
able to form stable complexes with PspF [91]. Furthermore, mixing the mutant pBpa PspF 
with WT, gave hexamers able to form stable complexes with 54 on the nifH early-melted 
DNA promoter probe in the presence of ADP.AlFx and crosslinking these identified 
interactions between PspF Loop 1 and promoter DNA at between -30 and -27 (just upstream 
from the -24 promoter element) [91]. These data confirm the importance of Loop 1 in RPOC 
formation, as it potentially forms contacts with 54, promoter DNA, other PspF protomers as 
well as intra-subunit interactions. 
Table 1.1 shows mutations of Loop 1 and the GAFTGA motif for PspF (E. coli) and DctD 
(R. meliloti), studied in vitro. Mutations of this motif are of varying effect on the ability of the 
protein to bind 54, but mostly result in reduced ATPase activity and abolition of RPOC 
formation. Additionally, mutants of the NifA (Bradyrhizobium japonicum) Loop 1 were unable 
to activate transcription in vivo, with the exception of the tolerated substitutions F307→Y 
(PspF F85) and A310→S (PspFA87) which had WT promoter activity and T308→S (PspF 
T86) and E298→D (PspF 81) which had low levels of promoter activity [92]. 
1.1.5 PSPF FRAGMENTS 4 AND 2 
A fragmentation approach has previously been used to investigate required sequences 
within PspF for interaction with 54 [1]. Four fragments, which contained the Walker B motif 
and/ or the GAFTGA motif (Figure 1.6), were chosen to include sequences previously shown 
to be important for interactions with 54 [41, 85, 93]. Purified as maltose binding protein 
Figure 1.6 Domain map of PspF showing positions and sequences of MBP fusion Fragments 1 to 4 (MBP-
F1 to MBP-F4). Three fragments contain the GAFTGA motif (highlighted in red), required for stable interaction 
with 
54
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(MBP) fusions, the fragments were tested for interaction with 54 in the presence of ADP.AlFx 
and Sinorhizobium meliloti promoter DNA, but no complexes were visible. 
S. meliloti early-melted DNA, employed as a promoter DNA probe in such studies, has a 
base pair mismatch and is opened one base pair downstream from the consensus GC 
promoter sequence, itself located at -13 base pairs upstream from the transcription start site 
(Figure 1.7, A.). Binding of 54 to the early-melted promoter probe mimics the initiation of 
DNA melting within the closed promoter complex (observed in DNA foot-printing experiments 
[94]), but in the absence of RNAP and the usually required bEBP [24, 95]. The MBP-fusion 
fragments were tested for interaction with this early-melted complex, and one fragment, 
known as Fragment 4 (MBP-F4/ MBP-PspF69-93) was found present in a slower migrating 
complex (Figure 1.7, B.). 
The detection of a Fragment 4 containing complex in the presence of early-melted DNA but 
not homoduplex promoter DNA, suggests that its binding is highly sensitive to changes in 
promoter probe conformation. Further to this, examination of other promoter probes 
suggests that the DNA fork-junction structure is critical for stable binding of Fragment 4, 
potentially via their effects upon 54 conformation [1]. 
Fragment 2 (MBP-F2/ MBP-PspF69-102) has a carboxy-terminal nine amino acid extension 
over Fragment 4, but was not found to form a stable interaction with 54. Nevertheless, it was 
the only one of the four fragments which inhibited PspF1-275 oligomerisation and PspF1-275 
dependent 54.DNA isomerisation [87]. Limited mutational analysis was performed on the 
Figure 1.7 MBP-F4 and the early-melted DNA probe. A. Sinorhizobium meliloti early-melted promoter DNA. 
A base pair mismatch at -13 means it is stably open one base pair downstream from the consensus GC 
promoter sequence. It mimics the pre-melted DNA complex between the holoenzyme and PspF [1]. B. Native 
gel showing the MBP-F4.
54
 complex. 
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nine amino acid tail extension which Fragment 2 possesses over Fragment 4, as well as T86 
in the GAFTGA motif. In PspF1-275, mutations of R95 and F96 to alanine result in mutants 
that are unable to activate transcription in vivo and in vitro, hydrolyse ATP and form the 
ADP.AlFx induced oligomer. Fragment 2 T86A, R95A and F96A mutants were unable to 
inhibit PspF1-275 dependent 
54.DNA isomerisation, demonstrating the importance of these 
residues in the trans inhibitory effect of Fragment 2 [87]. Further to this, Fragment 2 was also 
able to inhibit PspF1-275 dependent transcription initiation and ATP hydrolysis and binding at 
low ATP concentrations. 
1.1.6 LIMITATIONS OF THE CURRENT METHODOLOGY 
PspF is a well-studied member of the AAA+ family, and much is known about how hydrolysis 
of ATP in its active site is communicated to 54 in order to remodel the RPC. Furthermore, 
the study of E 54 interaction with promoter DNA is a vast field which encroaches into a 
variety of arenas, from basic understanding of transcriptional activation to development and 
study of antibiotics that target bacterial transcription (this will be discussed further in Section 
1.3 Targeting Protein-DNA Complexes). 
Thus far, the system has been investigated with classical genetic, microbiological and 
biochemical approaches. Non-hydrolysable and slowly hydrolysable nucleotide analogues 
and site directed mutagenesis have been used effectively to examine ATP hydrolysis 
induced conformational changes and important residues in processes such as 
hexamerisation, ATPase activity and formation of RPC. However, the use of a mutant protein 
to investigate aspects of WT function often produces results which are not straightforward. 
Over the past 10-15 years, an approach which aims to use chemical modulators to study WT 
protein function has been developing. Chemical genetics, the scope and range of which is 
discussed in the next section, aims to utilise small molecules to play the role of permanent 
genetic mutation for study of systems in vitro and in vivo. But how would chemical genetics 
be applied to the study of PspF and 54? Loop 1 is an obvious target for interaction, since it 
has interactions with both 54 and Loop 2 and contains the GAFTGA motif crucial to 
interaction with 54. Mutagenesis of Loop 1 to a certain extent has been explored in PspF 
and other bEBPs [87-89, 96-98], but mutation of the loop often results in a protein deficient 
either in ATP hydrolysis, interaction with 54 or unable to form RPOC. (for examples see [59]). 
Study of the WT protein whose activity is modulated using targeted small molecules should 
eliminate unwanted loss of function and consequent pleiotropic effects in vivo. Furthermore, 
because the study of the PspF. 54 interaction is potentially interesting due to implications for 
general AAA+ proteins, other bEBPs and the activation of bacterial transcription, chemical 
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modulators developed to study this system will likely be of multiple uses. This is particularly 
true for the GAFTGA motif which is highly conserved across bEBPs (1.1.2 Features of the 
Bacterial Enhancer Binding Protein) and because it is required for 54-dependent 
transcription which has been implicated as a target for antimicrobials (1.1.1 Benefits and 
Scope of 54-Dependent Promoters). The interaction between bEBP and 54 is as yet 
unexplored as an antimicrobial target, but since the number of antibiotic resistant pathogens 
is increasing, novel targets and novel small molecules to inhibit them are required [99, 100]. 
1.2 CHEMICAL GENETICS 
1.2.1 FORWARD AND REVERSE CHEMICAL GENETICS 
In chemical genetics, as with a classical approach, either a phenotype of interest is studied 
to identify the gene responsible, or a specific gene is studied to examine the phenotypic 
consequences of its alteration or deletion. These two types of methodology are known as 
forward and reverse classical or chemical genetics (Figure 1.8). 
In classical forward genetics a mutated population is created by random mutagenesis (by 
addition of DNA damaging chemical agents or radiation) and then screened for a phenotype 
of interest. Once isolated, the gene causing the altered phenotype is identified. The 
equivalent chemical genetic approach, forward chemical genetics, applies a library of small 
molecules to the whole cell or organism to produce an altered protein/ gene product function, 
which is then selected for by observation of the desired phenotype. The target protein is then 
identified. Classical reverse genetics involves the mutation of a target gene and observation 
of the resultant phenotypes. In reverse chemical genetics, a protein (or gene product) is 
screened with a library of small molecules, binding ligands are identified, and their modes of 
action and resultant phenotypes are studied. For reviews on chemical genetics see [4, 101-
104]. 
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Whilst a classical approach has been used successfully for many years, both forms of 
chemical genetics offer some distinct advantages over the classical counterparts, especially 
in some situations where the classical approach is either difficult, or impossible; for example 
due to lethality where genes are essential, or the lack of genetic tools. These advantages 
are summarised in Table 1.2. Perhaps the greatest advantage of utilising small molecules is 
the reversible nature of their titratable addition. Natural metabolism by the WT whole cell or 
organism, or buffer exchange of the target protein in vitro allows complete removal of the 
Figure 1.8 Classical vs Chemical Genetics. A. Forward classical and chemical genetics seeks the mutation or 
small molecule underlieing a phenotype. B. Reverse classical and chemical genetics starts with a target gene or 
protein and observes altered phenotypes caused by mutation or small molecule respectively. Adapted from [4]. 
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exogenous agent over time, leading to re-instatement of the WT phenotype. The 
consequences of ligand addition and removal could therefore also be studied kinetically in 
vivo, which is not possible with mutagenesis. 
CHEMICAL GENETICS CLASSICAL GENETICS 
Allows for study in „real-time‟: the 
induction time for the probe is dependent 
only on transport to the target. 
Mutations are dependent on transcription 
and often translation, a much longer 
timescale. 
The probe may be removed from the 
target by washing. 
Mutations are (largely) irreversible. 
A probe may be found to disrupt specific 
interactions, either within a protein or 
between proteins, whilst other aspects of 
function are unaffected. 
Mutations of specific residues often result 
in multiple interactions and functions 
being lost. 
The effect of the probe as a function of 
dose may be observed. 
Mutations are „all or nothing‟. 
Multiple probes may be applied 
sequentially and the effect of each 
addition observed. 
Multiple mutations may be applied, but all 
must be performed initially, this may lead 
to complicated effects and it may be 
difficult to pinpoint the particular 
mutational cause. 
Can be used in live animals. Use of live animals not possible. 
Table 1.2. Advantages of chemical genetics over a classical genetic approach. 
As an expansion of this idea, whilst classical mutations are usually introduced into the cell or 
organism long before the experiment occurs, a ligand can be added during the experimental 
process at specific time points. For example, in vivo, looking at the effect of protein inhibition 
during a specific growth phase, or, in vitro, when the order of addition in binding competition 
assays might be critical. 
Classical genetics results in mutants which in the majority of cases cannot be readily or 
quickly reverted to their wild-type form. However, some techniques, which create conditional 
alleles, do provide an illusion of reversibility. Conditional alleles are genetic manipulation 
such that a gene functions normally until certain conditions are reached and may overcome 
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some problems caused by the constitutive nature of classic mutations and in the loosest 
sense, achieve reversibility. The conditional allele may be temperature dependent, such that 
the mutated protein is non-functional or degraded at a specific temperature [105]. 
Alternatively, the gene may be conditionally deleted by the introduction of recombinase sites 
such as the inducible bacteriophage recombinase Cre/loxP or Flp/FRT systems. In this case, 
the mutant gene is flanked by recombinase recognition sites which results in deletion of the 
gene when the appropriate recombinase is induced [106]. 
Other methods which exist somewhere between a true chemical genetic approach and 
classical genetics are RNA interference (RNAi), antisense oligonucleotides and intracellular 
ribozymes. They are not true chemical genetics approaches, since the molecules they utilise 
are not small and closely mimic natively existing species, but they do provide a greater 
degree of temporal control over gene/ protein targeting. 
RNA interference (RNAi) utilises synthetic double stranded RNA molecules with sequences 
designed to be complementary to a target gene. Introduction of the synthetic RNA into the 
cell activates the RNAi pathway and results in reduced levels of expression of the target 
gene, but not usually complete loss. Whilst RNAi has found many uses in recent years [107], 
the method can suffer from off-target effects. If the exogenous RNA binds to other genes, 
the result will be reduced expression of multiple genes and this can lead to a confusing 
phenotypic picture. Similarly, antisense oligonucleotides are single stranded synthetic DNA, 
RNA or chemical equivalents which bind to target messenger RNA (mRNA) and prevent 
translation [108]. 
Engineered synthetic ribozymes, known as intracellular ribozymes, can be artificially 
engineered to target and cleave specific gene transcripts, preventing translation [109]. The 
drawbacks of this method are effective targeting of the transcript, since ribozyme and RNA 
must be co-localised, and possible interactions between artificial ribozyme and other cellular 
proteins [109]. These techniques may be used to reverse or time the effects of a mutant 
gene without hands-on DNA manipulation, but their effectiveness is determined by the half-
life of existing cellular protein. 
Study of protein activity as a function of dose is also only possible using a chemical genetic 
approach. Whilst DNA modification is absolute and creates 100% mutated protein, treatment 
with a ligand will give a response in a dose dependent manner until saturation is reached. 
Dose-dependency is particularly useful where the desired mutation is lethal to cell or 
organism survival, where application of a sub-lethal ligand dose should give a degree of 
phenotypic response, but not complete cell or organism death. Compensation for a gene 
deletion and masking of the deletion‟s effect might also occur in some cells or organisms 
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which may be difficult to detect in the classical approach. Using a small molecule inhibitor 
however, gives the researcher avenues to pursue to confirm or invalidate this possibility. 
The complexities of protein-protein interactions often mean that mutagenesis results in off-
target or pleiotropic effects. Single point mutations may not only result in a protein unable to 
bind to its target, but also one that is mis-folded or unable to make other critical interactions 
which were not the target. Taking a chemical genetic approach however, it should be 
theoretically possible to find a small molecule ligand for one interaction, but which leaves all 
other protein functions unperturbed.  
The greatest advantage of chemical genetics is the experimental flexibility it affords and the 
ability to tune experiments. Not only can ligands be added and removed at any time, but a 
combination of small molecules can be used sequentially and the effect of each addition 
observed.  
Finally, the scope of utility of chemical genetics expands even into live animal research 
which is difficult or impossible in classical genetics, due to the large, diploid genome and 
long gestation times that occur in mammals [101, 102]. 
Additionally, one library of small molecules could be applied to a wide range of proteins for 
study and may even produce potential drug targets. The use of libraries and small molecules 
also lends itself to combinatorial techniques and high throughput screening. Systems which 
are more complex, especially where multi-protein interactions are under investigation, can 
particularly benefit from the use of small molecules. 
1.2.2 THE TOOLS OF CHEMICAL GENETICS  
Although the two areas have some common ground, chemical genetics is not the same as 
drug discovery. Chemical genetics seeks to study systems in order to understand their 
functions and roles, especially for questions which classical genetics has not been able to 
provide a complete answer. This means that it is often used to study targets which would be 
considered „undruggable‟, that is, protein-protein or DNA-protein interactions. Additionally, 
because the final aim is not necessarily a drug, the small molecules used do not have to 
obey rules which would be applied when looking for a drug candidate; i.e. they do not have 
to obey Lipinski‟s rule of five, or have good pharmacokinetics. With this in mind, the first key 
stage in a chemical genetic screen has less constraint than when performing a drug- 
discovery screen.  
The small molecule library is typically comprised of organic molecules with molecular weight 
of less than 500 Da, making them significantly smaller than their targets, DNA, RNA and 
proteins [110]. Three types of small molecule libraries obeying this rule are widely available: 
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natural products, combinatorial commercial and diversity-oriented synthesis (DOS) libraries 
(Small Molecule Libraries).  
Departing further from drug-like molecules, peptides have been widely used in chemical 
genetics [111, 112]. They are more likely to have higher molecular weights, but are 
comprised of the same building blocks as their protein targets, and represent a middle-
ground between biologics and traditional small molecules (Peptides and Chemical Genetics). 
1.2.2.1 SMALL MOLECULE LIBRARIES 
In this section, the types of traditional small molecule libraries available are discussed, as 
well as both their advantages and short-comings. When buying or designing a library for 
chemical genetics, there are several requirements which must be fulfilled. Ideally, the library 
should have a high initial hit rate, that is, lots of small molecules should bind the target. It is 
intuitive that library size and structural diversity will increase the likelihood that at least some 
members will bind the target. Clemons et al. studied the three types of small molecule library 
(natural product, commercial combinatorial and DOS) and looked at the link between shape 
and stereochemical complexity and binding ability against 100 diverse proteins [113]. 
Increasing complexity of shape (proportion of sp3 hybridisation), displayed by natural 
products, and the intermediate amount of stereochemical complexity found in DOS libraries 
were found to increase relative hit rates of the libraries [113]. In order to assemble the 
perfect small molecule library, we therefore look not only for library size, but also complexity 
and stereochemistry. 
1.2.2.2 NATURAL PRODUCT LIBRARIES 
Natural products are small molecules made and modified by proteins and are therefore 
certain to bind at least some proteins. The starting point of modern drug-discovery, large 
libraries of compounds exist and are a potential resource for chemical genetics. However, 
chemical genetics is not drug discovery, and additionally, recent years have seen the 
desired targets of drugs move into molecule types such as transcription factors, protein-
protein interactions and DNA-protein interactions, which are not classically targeted by 
natural products [114]. 
The potency and attraction of the natural product is due to structural complexity. They often 
have multiple stereocentres and are therefore likely to form stereospecific interactions with 
proteins [115]. Libraries of natural product are typically more structurally diverse than their 
combinatorial equivalents [116, 117], and tend to give a higher relative hit rate for activity in 
biological screens [115]. Creation of natural product libraries does have some distinct 
disadvantages however. They can be difficult to obtain in large enough quantities in optically 
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pure forms or may exist in mixtures with structurally related compounds [118]. Isolation of 
large enough quantities may even place the source plant or organism under survival 
pressure [118] and chemical modification may be problematic. 
1.2.2.3 COMMERCIAL COMPOUND COLLECTIONS 
Commercially available collections of small molecules might be an attractive first point of call 
for a new screen, especially if the long-range target is to create a drug-like molecule to 
perturb the target. Typically created using combinatorial chemistry, they are often drug-like 
[119, 120], meaning initial hit discovery could facilitate an easier drug-discovery approach at 
a later date. The downside to these commercial libraries however, is their limited structural 
diversity. Their combinatorial origins mean that they often contain a limited number of central 
scaffolds, around which appendages have been varied [120], and have low levels of shape 
(sp3 hybridisation) and stereochemical complexity [113]. Due to their commercial 
foundations, they also are generally biased towards traditional drug targets, often giving 
higher than expected hit rates for these narrow targets, but performing poorly against 
protein-protein or protein-DNA interactions [119]. 
1.2.2.4 DIVERSITY-ORIENTED SYNTHESIS 
In order to combat the propensity of synthetic libraries to have limited scaffold, shape and 
stereochemical complexity, library design moved away from a combinatorial approach 
towards what became known as diversity-oriented synthesis (DOS) [114, 116, 121]. DOS 
aims to synthesise libraries which cover a greater proportion of the chemical space in 
typically no more than five synthetic steps [120]. Key differences between combinatorial and 
DOS libraries are the number of sp3 hybridised centres, which confer complexity of shape, 
types of scaffold, and numbers of stereogenic carbons [113]. 
Two approaches to DOS library design exist: reagent- or substrate-based approaches. In a 
reagent-based approach functional groups are used which may be transformed into multiple 
products by using different reagents and reactions. A substrate-based approach introduces 
diversity by using many different substrate types under a single reaction condition [120]. 
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1.2.2.5 DNA-ENCODED MACROCYCLES 
DNA-templated synthesis, in which reaction substrates are tethered to complementary 
strands of DNA, allows one-pot small scale synthesis of libraries of compounds [122, 123]. 
Many standard reactions can be incorporated and are performed in a sequence specific 
manner. Multi-step DNA-templated synthesis has been applied to the synthesis of libraries of 
macrocycles, which can then be screened in a one-pot in vitro selection for binding to a 
protein target. Hits are then identified by PCR amplification and DNA sequencing of the 
attached template DNA strand [124]. 
1.2.2.6 PEPTIDES AND CHEMICAL GENETICS 
Since the wide proclamation that scaffold- and not appendage-diversity is the key element to 
creating a diverse, and therefore potent, library for screening against biological interactions 
[120], it might be surprising that peptides form a large area of research in chemical genetics 
[111]. Despite only having a simple backbone and being comprised of the same relatively 
small number of building blocks, they possess stereochemical diversity and complexity due 
to -amino acids. Many methods for peptide library creation and screening exist, including 
phage display, peptide aptamers, on-bead split and mix synthesis and peptide arrays. 
1.1.2.3.1 PEPTIDE APTAMER LIBRARIES 
Peptide aptamers are libraries of random peptide sequences, each individually bound to a 
stable scaffold protein, which can be screened for binding against a target [125, 126]. The 
peptides are constrained at both amino and carboxy termini, meaning they are loop-like 
conformationally constrained. Library selection against a target can identify high affinity 
interactions, similar to those achieved antibodies, using either in vivo or in vitro selection; 
selection is always made however, against the combination of peptide and scaffold protein. 
The library is created by introducing randomised DNA codons at specific amino acid 
positions in the peptide-scaffold construct. 
The benefits of this method include the potential to synthesise the hit peptides chemically 
and to select for small peptides which display high selectivity and affinity for a target. 
Although the presence of the scaffold protein in the assay means that the combination of 
peptide and scaffold are being selected for, attachment of the peptide also allows expression 
of the peptide-scaffold in E. coli, and makes the peptides more stable in vivo against 
proteases [127]. Peptide aptamer libraries are also now commercially available (Clontech 
and Invitrogen) and so are freely available to those who have little or no experience with 
DNA library cloning [125]. 
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1.2.2.6.1 PEPTOIDS 
Peptoids are N-substituted oligoglycines that combine a peptide-like backbone with 
chemically diverse side-chains not limited to the 20 natural amino acids [128]. Unlike 
peptides, the side-chain is attached to the imino-nitrogen not the carbon which is 
incorporated as a substituted amine resulting in large chemical diversity [129] and resistance 
to proteolysis [130]. The synthesis is also amenable to solid-phase synthesis and a „split and 
pool‟ approach (see 1.1.2.3.4 Synthetic Peptide Libraries.) so that large libraries of 
compounds, representing an alternative chemical space to -peptides but having similar 
structural spacing are accessible [129]. Reddy and Kodadek reported on the synthesis of 
peptoid libraries on microarrays [131] that can be screened for interaction with protein 
targets. 
1.1.2.3.2 PHAGE DISPLAY 
Similar to a peptide aptamer library, phage display creates a combinatorial peptide library. 
However, instead of fusion to a scaffold protein, the peptide is fused at the C-terminal to a 
phage coat protein, usually the M13 gene III [132]. Due to the numbers of phage that may be 
produced, phage display can create a large library (108-109) where each phage carries an 
individual library member [111, 133]. In vitro screening of the library is performed by 
„panning‟ or incubating the phage against an immobilised target to identify binders. Phage 
carrying peptides able to bind the target will remain behind after a washing step is performed 
and can be amplified by allowing infection into E. coli. Repetition of this process, typically 
four to six times, results in isolation of the best binding peptide-carrying phage [111]. As with 
peptide aptamer libraries, phage display libraries are now commercially available 
(NEB),[134] including libraries in which peptide cyclisation is possible by inclusion of 
disulphide bond forming cysteines (NEB) [135]. 
As with any randomised peptide library, some combinations of amino acids will produce 
hydrophobic peptides which will non-selectively bind to any protein. An additional 
consideration when performing phage display is ensuring these „greasy‟ peptides do not give 
false positives by binding to the solid support. Phage display can produce linear and 
disulphide bond cyclised peptides which are easily synthesised chemically for off-phage 
testing. However, peptides which bind when bound to the phage are not guaranteed to bind 
when resynthesized, as they will contain an extra negative charge, owing to the newly free 
C-terminal carboxyl group. Additionally, in some cases, the surround phage may contribute 
to binding. 
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1.1.2.3.3 MRNA DISPLAY 
mRNA display creates peptide libraries which are covalently linked via a puromycin linker 
and DNA primer to its encoding mRNA [111, 136]. Puromcyin is an antibiotic which prevents 
translation by mimicking the amino acyl tRNA and binds covalently to the translated peptide 
[137]. The library is created at the DNA level, transcribed to mRNA and ligated to the 
puromycin-DNA linker before translation [136]. The value of linking the peptide to its mRNA 
is easy identification of binding peptides. After screening in vitro against the immobilised 
target, the mRNA tags bound to hit peptides are reverse transcribed and amplified in a PCR 
reaction. 
A completely cell-free technique, it allows for creation of very large library sizes (1014-1015 
members) independent of a DNA transformation step [136, 138]. Unnatural amino acids can 
also be incorporated into the library, creating peptides with the potential to be cell-stable and 
more diverse [139, 140]. Hit peptides can also be easily mutagenized during the PCR 
amplification step, allowing in vitro evolution. 
1.1.2.3.4 SYNTHETIC PEPTIDE LIBRARIES. 
The one-bead one-peptide approach creates combinatorial synthetic peptide libraries with 
potentially millions of unique members attached to a functionalised resin [141-144]. Each 
bead contains many copies of the same linear peptide, attached via its C-terminus, which 
can be screened against a non-immobilised target protein. The peptides are synthesised by 
a „split and pool‟ approach in which the beads are split into 20 pots, to each pot is added one 
activated amino acid and coupling performed. When the reaction step is complete, the beads 
from each of the pots are pooled, mixed and the process is repeated in this way until the 
peptide chain is complete. Chemical synthesis of a peptide library makes incorporation of 
any non-natural amino acid facile, however sequence analysis of hits can be difficult 
especially since the amount of hit peptide on each bead is very small. Additionally, because 
the peptide synthesis is random, some hydrophobic sequences will be contained in the 
library; these may bind a target non-selectively and result in false positives and a high 
background. 
1.1.2.3.5 PEPTIDE ARRAYS 
Peptide arrays are also synthetic peptide libraries attached to a solid support, but they have 
several key advantages over their one-bead one-peptide counterparts. The peptides are 
arranged in spots on a cellulose support and are screened by incubation with a target in 
solution, followed by antibody treatment [145]. Because many peptides are spotted on a 
single support, screening with different proteins can easily identify which peptides are 
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binding non-selectively. Although often expensive, custom-made libraries are also available 
commercially [145]. 
1.1.2.3.6 SPLIT-INTEIN MEDIATED CIRCULAR LIGATION OF PEPTIDES AND PROTEINS 
(SICLOPPS) 
As previously stated, introducing constraint into peptide structure can increase binding 
affinity be reducing the entropic penalty of binding. Peptide aptamers, arrays and phage 
display can be used to create large libraries of peptides which are cyclised by disulfide 
bonds, but these would not be expected to be stable in vivo. Likewise, disulfide-constrained 
synthetic libraries might be useful for in vitro screens, but in vivo work requires an alternative 
method for constraining structure, such as backbone cyclisation. 
Split-intein mediated circular ligation of peptides and proteins (SICLOPPS) is a methodology 
that allows creation of backbone-cyclised peptide libraries in vivo and can be combined with 
an in vivo screen to isolate hit peptides. The peptide library is created by PCR using 
degenerate oligonucleotides to create a mixed population of inserts which are ligated into a 
plasmid between two DnaE split inteins from Synechocystis sp PCC6803, a cyanobacterium 
[5, 146]. dnaE, encoding for the catalytic subunit of bacterial DNA polymerase III, is a split 
gene comprised of two parts dnaE-n and dnaE-c which undergo post-translational splicing to 
form the mature protein [147]. After translation, the internal protein (intein) fragments are 
removed by rapid splicing followed by ligation of the two external protein (extein) units to 
form a peptide bond and the mature protein (Figure 1.9, A., for mechanism see Figure 1.10). 
The SICLOPPS technology utilises only the intein fragments, and they are rearranged on the 
Figure 1.9 Splicing of DnaE and SICLOPPS. A. Synechocystis sp PCC6803 gene dnaE consists of two gene 
segments dnaE-n and dnaE-c. IN and IC are known as inteins and perform a specific autocatalytic post-
translational reaction to form a peptide bond between EN and EC. B. The SICLOPPS system uses the inteins IN 
and IC with their order reversed, so that an intervening peptide sequence is cyclised by the autocatalytic reaction 
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plasmid such that post-translational splicing results in cyclisation of the intervening target 
peptide sequence [5]. The intein IN (intein segment of dnaE-n) also has a C-terminal fusion 
to a chitin-binding domain tag to allow easy characterisation and purification of library 
members (Figure 1.9, B.). 
The library is introduced by using random oligonucleotides in the forward primer of the PCR 
reaction using the codon NNS, where N may be any of the four DNA bases and S may be G 
or C. Using this modified code, there are 32 possible codons for the library segment (see 
Appendix C Codon Chart for SICLOPPS); all 20 amino acids are coded for, whilst the ochre 
(UAA) and opal (UGA) stop codons are eliminated, leaving only amber (UAG). 
When designing the peptide library, the SICLOPPS methodology requires only one fixed 
attribute: inclusion of nucleophilic serine or cysteine at position one, [5] although threonine 
has also been found in native protein ligation systems [147, 148]. The initial expression 
product contains the linear peptide precursor flanked by the IC and IN fragments which fold to 
form the active intein. A side-chain thiol of the IN fragment attacks the carbonyl group of the 
preceding amino acid and undergoes and N-to-S acyl shift to form the thioester intermediate. 
Figure 1.10 Mechanism of cyclic peptide formation by SICLOPPS split-intein splicing. The translated 
fusion protein folds to form the active intein which undergoes an N-to-S acyl shift, forming the thioester. The 
nucleophilic side-chain of peptide position 1 serine or cysteine (XH) transesterifies the thioester to the lariat. An 
asparagine side-chain cyclises, releasing the lactone, which finally rearranges to the cyclic peptide. 
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The required nucleophilic position one amino acid then attacks the thioester to form a lariat. 
An asparagine residue at the C-terminal of IC is then able to cyclise, irreversibly forming a 
lactone, which then undergoes an O/S-to-N acyl shift to the more thermodynamically 
favoured cyclic peptide [5, 148] (Figure 1.10). 
Thus far, SICLOPPS has been used to identify inhibitors of bacterial Dam methyltransferase 
[149], the Gag-TSG101 interaction required for budding in HIV infection [150] and the AAA 
protease ClpX [151]. Cyclic peptides capable of disrupting the homo- and heterodimerisation 
of HIV-1 protease and ribonucelotide reductase respectively [152] and the homodimerisation 
of AICAR Transformylase, involved in purine biosynthesis [153], have also been selected 
from SICLOPPS libraries, demonstrating the application of this method to protein-protein 
interactions (PPIs). In these cases, where protein function is dependent on dimerization, a 
bacterial reverse two hybrid (RTHS) positive selection system has been used [152, 153], 
based on the bacteriophage regulatory system [154]. In this system (Figure 1.11), induction 
and subsequent dimerization of the target proteins results in repression of a promoter from 
which three reporter genes are expressed. The expression of S. cerevisiae gene HIS3 
(imidazole glycerol phosphate dehydratase), required for histidine biosynthesis, is selectable 
for on histidine free media, with potency increased by addition of competitive inhibitor 3-
amino-1,2,4-triazole (3-AT) [155, 156]. KanR (aminoglycoside 3‟-phosphotransferase) 
confers kanamycin resistance and lacZ ( -galactosidase) can be used in a chromogenic 
assay to quantify the PPI. Therefore, on selection media contain kanamycin and 3-AT but 
lacking histidine, repression of the promoter by dimerisation of the target-bacteriophage 434 
repressors results in cell death. However, if an inhibitor of target dimerization is present, 
HIS3, KanR and LacZ are expressed, the cell survives and the plasmid bearing the inhibitory 
peptide isolated and sequenced. A survival-based selection system should decrease the 
number of false-positive hits, although some are inevitable in a genetic screen. The limitation 
of the RTHS is the requirement for tethering the target protein to the 434 repressor protein. 
The resultant fusion protein may not faithfully represent a native conformation or interaction 
of the target system, especially in cases involving self-assembling multimeric proteins. 
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Recently, Young et al. coupled the SICLOPPS technology to an orthogonal aminoacyl-tRNA 
synthetase/-tRNACUA pair to introduce the unnatural amino acid p-benzoylphenylalanine 
(pBzF) into a library of cyclic hexapeptides [157]. The approach utilises the pEVOL 
MjRS/MjtRNATyrCUA expression system which consists of a plasmid bearing an orthogonal 
aminoacyl-tRNA synthetase and an amber suppressor that introduces a 21st amino acid at 
the amber codon UAG [158, 159]. The group were able to screen this expanded library for 
inhibitors of HIV protease to identify 6 unique inhibitory peptides from 12 hit isolates. Three 
of the peptides contained pBzF, with one peptide isolated six times, demonstrating an 
enrichment for the unnatural amino acid above the expected 17% occurrence [157]. 
The SICLOPPS system has several key advantages over other DNA encoded or synthetic 
peptide libraries. Large libraries are accessible, with the only limitation being the practicality 
of E. coli transformation efficiency. Coupled to this, small rings, down to four amino acids, 
have been shown to cyclise [160] and the system can be coupled to a variety of in vivo 
selection systems. The expression and in vivo cyclisation of the peptide also means that 
problematic delivery of synthetic peptides into E. coli cells can be avoided. Furthermore, the 
Figure 1.11 Schematic of the RTHS with a cyclic peptide PPI inhibitor. A. The target proteins are 
expressed as fusions to the bacteriophage 434 repressor. Dimerisation prevents expression of three marker 
genes, HIS3, Kan
R
 and LacZ and cells are unable to grow on histidine free media supplemented with 3-AT and 
kanamycin. B. The presence of a cyclic peptide inhibitor of protein dimerization prevents formation of the 
promoter bound repressor complex and HIS3, Kan
R
 and LacZ are expressed and support cell survival. Adapted 
from Horswill et al. 
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method is the most facile system for generation of many, diverse, backbone cyclised 
peptides. Backbone cyclisation not only produces constraint, leading to lower binding 
entropy for peptide and protein target, but it increases peptide stability in vivo, making them 
resistant to proteolysis [146]. Furthermore, unlike disulfide constrained peptides, backbone 
cyclisation generates peptides stable in the E. coli cytoplasm [161]. 
Whilst it is possible to make a theoretically very large SICLOPPS library, it is clear that not 
all sequences will cyclise, and there will be differences between individual members in 
cyclisation efficiency [160]. Moreover, an in vivo screen may not always isolate the peptide 
having the best binding affinity, but one which combines a multitude of attributes including 
cyclisation efficiency, half-life and specificity; something which is both a positive and 
negative aspect of the approach. As with all genetic selection approaches, false positives 
are inevitable and a robust and facile hit secondary screening method is imperative.  
1.3 TARGETING PROTEIN-DNA COMPLEXES 
RNAP is an essential enzyme for bacterial survival and, as previously discussed (1.1 
Bacterial Transcription: Regulation), bacterial RNAP displays a degree of functional and 
structural similarity to eukaryotic RNAP but has little sequence conservation. These two 
facets make RNAP a target for inhibition by several well-studied examples of antibiotics that 
target bacterial RNAPs, but not those of the host organism, including the conventional 
treatment for tuberculosis with rifampicin, a cyclic peptide and a series of synthetic small 
molecule inhibitors [162, 163]. 
These antibiotics all target the core RNAP enzyme, but there is some sense behind pursuing 
the sigma factor for inhibition. Initiation of all bacterial transcription requires sigma factors 
(1.1.1 70 and 54 Dependent Transcription Initiation) and whilst eukaryotic RNAP requires 
transcription factors, there are no eukaryotic proteins homologous to the bacterial sigma 
factor [162]. Additionally, there is some evidence that 54 affects the pathogenicity (1.1.1 
Benefits and Scope of 54-Dependent Promoters) and cellular resistance to antibiotics which 
target RNAP. 
1.3.1 ANTIBIOTICS TARGETING RNAP 
Antibiotics represent examples of molecules which can be tools towards both understanding 
protein function through identification of resistant mutants and structural investigation by co-
crystallisation. For RNAP, many examples of antibiotics exist which target different regions 
and they are varied in their structure (Figure 1.12) from traditional small molecules, to cyclic 
peptides. 
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Part of the current standard chemotherapeutic treatment for tuberculosis, rifampicin (Rif) 
(Figure 1.12 A.) is a rifamycin antibiotic which targets bacterial RNAP [162]. Rif binds to 
bacterial, but not eukaryotic, RNAP and is bactericidal. It is known to bind into the DNA 
channel and its activity has been proposed to stem from its binding position blocking the 
elongating transcript beyond 2-3 bps [164, 165]. An alternative theory is that it allosterically 
influences conformation such that the bound  factor dissociates [166], which is supported 
by the observation that its efficacy is influenced by the identity of the  factor [167]. 
Spontaneous mutations of RNAP in cells treated with Rif have allowed elucidation of its 
mechanism of action, but this also underlines one of its problems. Developed resistance is 
common, and highlights the continuing need for antibiotic development. 
Lipiarmycin [168] (Figure 1.12, B.) is an interesting antibiotic, active against bacterial RNAP, 
because its activity is dependent on the  factor [162] and is specifically against transcription 
initiation [162]. The mechanism of its inhibition is yet to be resolved, but an isolated RNAP 
mutant (R326L) which is resistant has a mutation in the DNA binding channel, hinting at the 
Lipiarmycin binding pocket [169]. 
Examples of synthetic RNAP inhibitors, are the CBR703 (Figure 1.12, C.) and SB (Figure 
1.12, D.) series. CBR703 inhibits RNAP by preventing nucleotide addition, possibly 
allosterically; it binds to the area between the bases of  and ‟ subunits [170]. SB2 is part of 
a series of bacterial RNAP inhibitors developed to specifically target the core RNAP 
interaction with 70 and is active by dissociating the interaction and presumably therefore 
preventing RPOC formation [171]. 
The 21 amino acid cyclic peptide Microcin J25, (Figure 1.12, E.) produced by 
Enterobacteriaceae, is an antibiotic active against gram negative bacteria [172]. The peptide 
is not head-to-tail cyclised, but is rather an eight residue macrolactam with a C-terminal tail, 
which then forms a lasso structure by threading through the ring [173, 174]. The tail is held in 
a -hairpin structure by the large side-chains of its phenylalanine and tyrosine residues 
[175]. J25 is thought to have two possible in vivo targets, and its mode of action may vary 
depending on the bacterial species [172]. In E. coli the target has been shown to be RNAP, 
with the peptide possibly inhibiting activity by blocking access to the active site [176] and 
amino acid mutations in the  and ‟ subunits of RNAP have been identified which confer 
immunity [162, 177]. The second target of Microcin J25, and its mode of action against 
Salmonella enterica serovars, is inhibition of cell respiration, possibly by binding and 
penetrating phospholipid monolayers which leads to disruption of membrane potential [172]. 
A second lariat lasso peptide is Capistruin, which is produced by Burkholderia thailandensis 
E264 [178] and has antibacterial activity against both Burkholderia and Pseudomonas. 
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Cross-over between J25 and Capistruin resistant strains suggest that the in vivo target of 
Capistruin is also RNAP. 
Microcin J25 validates the use of structurally constrained, especially cyclic, peptides in the 
search for novel antibiotics and reinforces bacterial RNAP as a potential target. One 
interesting aspect is the potential other targets for Microcin J25. In this instance the peptide 
Figure 1.12 Antibiotics that target bacterial transcription. A. Rifampicin is an integral part of the 
chemotherapy treatment for tuberculosis. B. Lipiarmycin inhibits transcription initiation. C. The CBR703 series are 
a set of synthetic antibiotics that inhibit nucleotide addition. D SB2 dissociates core RNAP from 
70
. E. Microcin 
J25 is a cyclic lasso peptide active against gram negative bacteria. F. and G. Myxopyronin and Corallopyronin 
are -pyrone antibiotics that inhibit transcription initiation by binding to the RNAP switch region. 
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is naturally occurring, but had it been identified from a screen for cyclic peptide inhibitors of 
RNAP, its dual mode of inhibition could be described as an off-target effect. This example 
perhaps highlights the difficulty in selecting substrates which are specific only for one in vivo 
target, and advocates the use of an in vivo screen, where small molecules/ peptides active in 
vivo against the whole cell are selected for. 
The antibiotic myxopyronin (Myx) (Figure 1.12, F.), produced by the myxobacterium 
Myxococcus fulvus Mxf 50 [179], also targets the core RNAP, specifically the „switch region‟ 
located at the base of the ‟ subunit [180]. The targeted RNAP switch region undergoes 
significant conformational change upon initiation of transcription, and can be thought of as a 
hinge, on which the ‟ catalytic subunit moves [181, 182]. Binding of Myx to the switch region 
prevents interaction of RNAP with promoter DNA and inhibits the initiation step [180]. Since 
the identified binding site of Myx to RNAP has been shown to be unique from rifampicin, 
development of resistance to both antibiotics is unlikely; a helpful tool in antibiotic targeting. 
Corallopyronin (Cor) (Figure 1.12, G.) is related to Myx in structure and mechanism of 
inhibition and targets the  and ‟ subunits of RNAP [183]. 
1.3.2 54 IS A TARGET FOR ANTIMICROBIALS AND A TOOL IN THE STUDY OF 
ACTIVATION OF TRANSCRIPTION 
1.3.2.1 ANTIBIOTIC RESISTANCE 
Whilst both RNAP core and E 70 have been targeted for inhibition by a variety of antibiotic, 
no inhibitors or small molecule binders for E 54 have thus far been reported. As discussed 
earlier (1.1.1 Benefits and Scope of 54-Dependent Promoters), 54 has been implicated as 
having a role in virulence and survival of several pathogens. Further to this, knockout of 54 
has been shown to increase the susceptibility of E. coli to the antibiotics gentamicin, 
tobramycin, neomycin, cephradine, cefoxitin and colistin [184]. In the pathogen Listeria 
monocytogens, 54-dependent transcription is responsible for strain sensitivity to 
antibacterial peptides [185] and in Enterococcus faecalis JH2-2, sensitivity to mesentericin 
Y105 is rpoN dependent [186, 187]. 
Small molecules targeting 54 will therefore have the potential to be starting points for the 
development of further antibiotics which target 54 dependent transcription, with the potential 
to affect pathogenicity as well as cell survival. Furthermore, the unique mechanism of 54 
transcriptional activation makes it a model system for the study of bacterial RNAP. 54, in 
conjunction with nucleotide analogues, including the ground state (ADP.BeFX) and transition 
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state (ADP.AlFX), makes various stages of the path to the initiation complex accessible for 
study. 
1.3.2.2 54 AND PROBING TRANSCRIPTION 
Recently, Chakraborty et al. reported on their single molecule FRET (smFRET) work in 
which the  and ‟ subunits of RNAP were labelled with a FRET pair. This enabled the study 
of RNAP conformation in solution and showed that for both 70 and 54 dependent 
transcription, RNAP exists in a predominantly open complex until promoter DNA is melted to 
form RPOC [15]. Here, study of 
54 allows the conformational changes to be probed further, 
since isomerisation of RPCC to RPOC is entirely dependent on hydrolysis of ATP by a bEBP. 
The non-hydrolysable nucleotide analogues ADP.BeFX and ADP.AlFX are purported to trap 
the bEBP in conformations equivalent to the ground state or transition state of ATP 
hydrolysis respectively. This therefore results in a trapping of E 54 in one of these states, 
whose conformation can therefore be probed. Using smFRET and the nucleotide analogues 
the point of RNAP conformational change was pinpointed down to DNA melting after full 
ATP hydrolysis [15]. 
1.3.3 TARGETING THE TET REPRESSOR 
Antibiotics targeting RNAP are not the only instances in which a protein-DNA complex or 
interaction has been probed with small molecules or peptides. In 2005 Klotzsche et al. 
reported the selection of a peptide (TIP) capable of inducing the Tet repressor (TetR) in vivo 
[188]. This peptide was selected, along with several others from and in vitro phage display 
screen but was the only one to also be active in vivo, where it acts allosterically on the TetR, 
remodelling it and causing dissociation from the promoter DNA [188-190]. Further to this, 
Goeke et al. report on a secondary in vivo screen targeting TetR, which aimed to isolate 
further peptides able to allosterically influence TetR [191]. Using a yeast two hybrid (Y2H) 
screen with the reporter gene lacZ under the control of the Tet operator, peptides with 3 
types of activity were isolated. Peptides were either TIP-inducers of TetR, anti-inducers or 
agonists or acted as co-repressors with reverse TetR and further investigation revealed 
diversity in the binding profiles of the active peptides [191]. 
This screen highlights several key points in the use and selection of peptides in chemical 
genetics. Using an in vivo screen isolated a larger number of peptides active in vivo 
compared to an earlier in vitro screen with a larger library size, demonstrating the 
importance of the selection set-up. Additionally, peptides are shown not only to be rarely 
active against a protein-DNA complex, but in more than one instance and with several 
mechanisms. In contrast small molecule targeting of TetR using structural derivatives of 
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tetracycline has been comparatively unsuccessful, with the requirement for modification of 
TetR to permit binding of the derivatives [192, 193]. These two points emphasise the power 
of in vivo selection from libraries of peptides, which provide enough structural diversity 
combined with similarity to their protein targets, producing diverse outcomes. 
1.4 TARGETING PSPF-SIGMA 54: PROJECT AIMS 
The PspF.E 54 interaction is a target for study for many reasons. As discussed, both 54 and 
the psp response are implicated to have roles in pathogenicity and bacterial resistance. 
Additionally, whilst RNAP is an existing target for antibiotics, the E 54 complex in particular 
has been under-targeted. Study of the 54 mechanism has the potential to provide 
information about all bacterial transcription as well as a host of 54 dependent gene products 
which have a wide range of activities. However, despite large amounts of work using 
classical genetic approaches, there are still aspects of the PspF. 54 interaction which are 
unclear, such as the number of Loop 1s interacting with 54 at the point of ATP hydrolysis. 
Furthermore, whilst gene knockout has revealed much about the network of 54 dependent 
genes and their roles, use of a WT system and a chemical genetic approach would allow 
many more experiments to be performed to examine the relationship between 54 and 
response to varying growth conditions. 
Existing active peptides against protein-DNA or protein-protein interactions in general, or 
RNAP specifically, confirm that peptides make good tools for a chemical genetic approach, 
and also have the potential to be antibiotics. What is the best way to target the PspF. 54 
interaction? Looking at the native interaction, it appears that the loop structures at the top of 
PspF, Loop1 and Loop 2, are key to the interaction, which peptides would be a natural 
choice to mimic. The aims of this project are therefore to probe the PspF. 54 interaction 
using peptides. 
Initially, the existing peptides Fragments 2 and 4, which were identified by a fragmentation 
approach [194] will be investigated. A key part of the approach will be to develop an 
appropriate assay to assess peptide activity, either through modification of an existing assay 
more commonly used to investigate mutant protein or promoter DNA, or by developing 
specific assays only suitable for use with peptides. 
Rational design of synthetic peptides might provide inhibitors for the interaction, however, to 
maximise the likelihood of finding a peptide inhibitor, a library based approach will be used. 
SICLOPPS is a well-established and versatile methodology which can be used to create 
cyclic peptides. However, if a peptide inhibitor is to be isolated, an appropriate screen will 
have to be developed and hits will need to be validated in vivo and in vitro. 
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2 MATERIALS AND METHODS 
This chapter describes the materials used and detailed methods for the experiments 
performed in this work. 
2.1 GENERAL MATERIALS AND METHODS 
This section describes general methods and materials used for all molecular biology 
performed, including kits used. For specific details about cloning performed, including the 
primers used see (2.2 Chapter Specific Methods) 
2.1.1 MEDIA 
MEDIUM COMPOSITION (L-1) 
LB (Luria Bertani Broth) 10 g peptone, 5 g yeast extract, 5 g NaCl 
LB agar 10 g peptone, 5 g yeast extract, 5 g NaCl, 15 g agar 
1x M9 Minimal Media 
1 X M9 salts, 2 mM MgSO4 100 M CaCl2, 0.01 % Cas 
amino acids where specified, specified carbon source. 
1x M9 Minimal Media agar As M9 minimal media, 15 agar, specified carbon source. 
5x Gutnick Minimal Media 
170 mM KH2PO4, 175 mM K2HPO4, 30 mM K2SO4, 2 mM 
MgSO4.7H2O 
1000x Trace Elements 
46 mM H3BO3, 5 mM FeSO4.7H2O, 8 mM Na2C4H4O6.2H2O 
(sodium tartrate), 0.15 mM CuCl2.2H2O, 0.15 mM ZnCl2, 
0.20 mM CoCl2.6H2O, 0.10 mM Na2MoO4.2H2O, 0.10 mM 
Na2SeO3, 1.30 mM H2SO4 
SOB 
20 g Tryptone, 5 g yeast extract, 10 mM NaCl, 2.5 mM KCl, 
10 mM MgCl2, 10 mM MgSO4, pH 7.5 
SOC SOB + 2 mM Glucose (filter sterilised) 
TA7 Top agar 10 g tryptone, 5 g salt, 7 g Difco agar 
Table 2.1 Media used in this study 
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2.1.2 GEL ELECTROPHORESIS AND BUFFERS 
2.1.2.1 GEL ELECTROPHORESIS COMPONENTS 
GEL/ COMPONENT COMPOSITION 
12.5% SDS Separating 
Gel 
4.2 mL 30% (w/v) Acrylamide 
2.5 mL Solution II 
3.3 mL d.H2O 
100 µL 10% (w/v) APS 
10 µL TEMED 
4.5% Stacking Gel 0.6 mL 30% (w/v) Acrylamide 
1.0 mL Solution III 
2.4 mL d.H2O 
40 µL 10% (w/v) APS 
4 µL TEMED  
Solution II 1.5 M Tris HCl pH 8.8, 0.3% SDS 
Solution III 0.5 M Tris HCl pH 6.8, 0.4% SDS 
4% Full-length 
Transcription Gel 
5 mL TBE 10X 
37 mL Sequencing system diluent (National Diagnostics) 
8 mL Sequencing system concentrate (National Diagnostics) 
500 µL 10% (w/v) APS 
40 µL TEMED 
20% Abortive Transcription 
Gel 
1.25 mL TBE 10X 
1.25 mL Sequencing system diluent (National Diagnostics) 
10 mL Sequencing system concentrate 
(National Diagnostics) 
250 µL 10% (w/v) APS 
10 µL TEMED 
Table 2.2 Components of gel electrophoresis systems 
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2.1.2.2 PROTEIN BUFFERS 
BUFFER COMPOSITION 
Cell Lysis Buffer 20 mM Tris HCl pH 8.0 
500 mM NaCl 
5% glycerol 
Chitin Buffer 20 mM Tris HCl pH 7.8 
1 mM DTT 
0.5 mM NaCl 
σ54 His Buffer A 20 mM Tris HCl pH 8.0 
250 mM NaCl 
5% glycerol 
σ54 His Buffer B 20 mM Tris HCl pH 8.0 
250 mM NaCl 
5% glycerol 
1 M imidazole 
σ54 Hep Buffer A 50 mM Tris HCl pH 8.0 
50 mM NaCl 
10 mM MgCl2 
5% glycerol 
0.1 mM EDTA 
1 mM DTT 
σ54 Hep Buffer B 50 mM Tris HCl pH 8.0 
1 M NaCl 
10 mM MgCl2 
5% glycerol 
0.1 mM EDTA 
1 mM DTT 
Table 2.3 Buffers for protein purification 
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2.1.2.3 ASSAY BUFFERS 
BUFFER ASSAY COMPOSITION 
10X STA buffer Transcription assays 
250mM Tris Acetate (pH 8.0) 
80mM Magnesium Acetate 
100mM KCl 
35% (w/v) PEG 8000 
Z Buffer 
-galactosidase activity assay 
(kinetic and classic) -
galactosidase activity assay 
(kinetic and classic) 
For 1 L: 
60 mM Na2HPO4 
40 mM NaH2PO4.2H2O 
10 mM KCl 
1 mM MgSO4.7H2O 
38 mM of 2-Mercaptoethanol was 
added per litre just before use. 
3 X Transcription 
Stop Dye 
 
Transcription assays
3 mg Xylene cyanol 
3 mg Bromophenol Blue 
0.8 mL EDTA (250 mM) 
10 mL deionised Formamide 
 
Table 2.4 Assorted Assay Buffers 
2.1.3 ANTIBIOTICS 
Antibiotic solutions were filter sterilised and used at the following concentrations for plasmid 
based selection and at half the stated concentration for chromosomal encoded drug 
selection. 
ANTIBIOTIC CONCENTRATION 
Ampicillin 100 µg/mL 
Chloramphenicol 25 µg/mL 
Kanamycin 50 µg/mL 
Tetracyclin 10 µg/mL 
Table 2.5 Antibiotics used in this study 
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2.1.4 KITS 
KIT SUPPLIER USE 
QIAprep Spin Miniprep Kit Qiagen Isolation of plasmid DNA. 
QIAGEN Plasmid Maxi Kit Qiagen Isolation of whole SICLOPPS libraries. 
QIAquick PCR Purification 
Kit 
Qiagen Purification of PCR products. 
GoTaq® DNA Polymerase Promega PCR 
Amersham ECL Western 
Blotting Detection Reagents 
GE Healthcare 
Detection of HRP conjugated 2º antibody 
for Western blotting. 
Modified Lowry Protein 
Assay Kit 
Thermo 
Scientific 
Protein quantification 
Table 2.6 Commercially available kits used in this study 
2.1.5 DYES AND CHEMICALS FOR MOLECULAR BIOLOGY APPLICATIONS 
DYE/ CHEMICAL SUPPLIER USE 
SYBR® Safe Invitrogen DNA gel stain 
6X DNA loading dye Fermentas DNA gel sample loading buffer 
2X Laemmli Sigma SDS-PAGE sample loading buffer 
IPTG Sigma Induction of protein expression from lac. 
Xgal Sigma 
Blue/ white screening/ demonstration of 
β-galactosidase activity. 
ONPG Sigma 
β-galactosidase activity assay 
substrate. 
Pgal Sigma 
Toxic lactose analogue for SICLOPPS 
library screens. 
Lysozyme from chicken egg 
white 
Sigma Bacterial cell lysis 
BugBuster® Protein Extraction 
Reagent 
Merck Bacterial cell lysis 
Table 2.7 Dyes and chemicals used in the molecular biology in this work 
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2.1.6 PLASMIDS, PRIMERS AND BACTERIAL STRAINS 
The sources and genotypes of E. coli strains used in this work are listed here. Plasmids and 
DNA primers (sourced from Operon) used are also described. 
2.1.6.1 BACTERIAL STRAINS 
STRAIN 
RELEVANT GENOTYPE OR 
DESCRIPTION 
REFERENCE/ 
SOURCE 
USAGE/ CHAPTER 
BL21(DE3) 
F-, dcm, ompT, hsdS(rB
- mB
--), 
galλ(DE3) 
Stratagene 
Expression strain/ 
Chapter 3 
ER2925cm dcm
- dam- NEB 
Cloning strain dam-
/dcm-/ Chapter 3 
JM109 
F´traD36 proA+B+ lacIq 
Δ(lacZ)M15/ Δ(lac-proAB) glnV44 
e14– gyrA96 recA1 
relA1 endA1 thi hsdR17 
NEB 
Cloning strain/ 
Chapter 3 
JW0742 ΔlacZ4787,  ΔgalE740 (kanR) 
[195], Keio 
collection 
Pgal sensitivity control 
and P1vir donor 
transduction strain, 
Chapter 4. 
LJR01 MVA27 himA kanR) This work 
-galactosidase 
assay, Chapter 3 
LJR03 MVA27 galE (kanR) This work 
Library selection strain 
intermediate 
LJR04 MVA27 galE This work 
Library selection 
strain, Chapters 4 and 
5 
LJR05 MVA27 galE, himA (kanR) This work 
Library selection 
strain, Chapters 4 and 
5 
LJR06 MVA27 rpoN (kanR) This work 
Pgal sensitivity control 
strain, Chapter 4 
MG1655 WT K-12 E. coli Lab collection 
WT K-12 strain, 
Chapters 3 and 5 
MG1655 
pspA 
MG1655 pspA [2] 
-galactosidase 
assay, Chapter 3 
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MVA27 
MG1655 pspA (pspA-
lac)(ampR) 
[2]/ Lab 
collection 
Chapter 3, 4, 5 
NVM1822 K-12 E. coli prototype 
[196]/ Lab 
collection 
WT K-12 strain, 
Chapter 5,  
NVM1822 
glnG  
K-12 E. coli prototype, glnG Lab collection glnG, Chapter 5 
 
2.1.6.2 PLASMIDS 
PLASMID ENCODES 
REFERENCE/ 
SOURCE 
USAGE/ 
CHAPTER  
pBAD18cm 
Multiple cloning site (MCS) under control of 
araC promoter, (CmR) 
[197] 3 
pBAD28 
MCS under control of araC promoter, (CmR, 
AmpR) 
[197] 3 
pET28b-
s54. 
pET28b encoding E. coli 54 (KanR)  3 
pGJ4 
PTAC expression vector harbouring gIV from f1 
phage (pIV filamentous phage protein) , (CmR) 
[2] 3 
pLJR1 PspF1-275 in pBAD28, (CmR, AmpR) This work 3 
pLJR2 MBP-F4 in pBAD28, (CmR, AmpR) This work 3 
pLJR3 MBP-F4 86A in pBAD28, (CmR, AmpR) This work 3 
pLJR5 MBP-F2 in pBAD28, (CmR, AmpR) This work 3 
pLJR6 PspF1-275 in pBAD18 (CmR) This work 3 
pLJR7 MBP-F4 in pBAD18, (CmR) This work 3 
pLJR8 F4 in pBAD28, (CmR, AmpR) This work 3 
pLJR9 MBP-F4 86A in pBAD28, (CmR, AmpR) This work 3 
pLJR10 F4 in pBAD18, (CmR) This work 3 
pPB1 pET28b encoding E. coli PspF1-275 WT (KanR) [1] 3 
pPB1 86A 
pET28b encoding E. coli PspF1-275 T86A 
(KanR) 
[1] 3 
pPB1 86S pET28b encoding E. coli PspF1-275 T86S [1] 3 
Table 2.8 Bacterial strains used in this work. 
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(KanR) 
pPB11 PspA1-68 in pBAD18cm, (CmR) [2] 3 
pPB3 MBP-F2 in pMAL C2, (AmpR) [194] 3 
pPB3 86A MBP-F2 86A in pMAL C2, (AmpR) [194] 3 
pPB3 86S MBP-F2 86S in pMAL C2, (AmpR) [194] 3 
pPB5 MBP-F4 in pMAL C2, (AmpR) [194] 3 
pPB5 86A MBP-F4 86A in pMAL C2, (AmpR) [194] 3 
pPB5 86S MBP-F4 86S in pMAL C2, (AmpR) [194] 3 
pSJI 
Fusion of pspAp promoter to lacZ reporter 
gene (TetR) 
[198] 3 
pCP20 
Encodes Flp recombinase for curing Kan 
resistance, (CmR, AmpR) 
[199] 4 
pGEM® T-
Easy 
Linear TA cloning shuttle vector, (AmpR) [200] 3 and 4 
pPB10 PspA in pBAD18cm, (CmR) [2] 3 and 4 
pARCBD SICLOPPS plasmid, (CmR) A. Tavassoli 4 and 5 
pJW0742 galE under IPTG inducible promoter, (CmR) 
[195, 201], 
Keio collection 
4 and 5 
pLib1 H1-
H91 
SICLOPPS plasmids encoding the Lib 1 
library hits 1 to 91, (CmR) 
This work 4 and 5 
pSGW H1 
SICLOPPS plasmids encoding the single 
SGW+5 hit, (CmR) 
This work 4 and 5 
Table 2.9 DNA plasmids used in this work. 
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2.1.6.3 DNA PRIMERS AND USAGE 
PRIMER SEQUENCE CHAPTER 
PspF1-275 Forward 
XbaI 
TCTAGAGGAGTGAAACGATGGCAGAATACAAAGATA
ATTTACTTGG 
3 
PspF1-275 Reverse 
Hind III 
TTTTAAGCTTTCATCACAGTGTTGGAAGCGAGGTGG 3 
PspF69 Forward 
XbaI 
TCTAGAGGAGTGAAACGAATGGAAAATCTGCTGGAT
TCCG 
3 
PspF69-102 
Fragment 2 
Reverse Hind III 
TTTTAAGCTTTCATCAACCGCCGTCGGCACG 3 
PspF69-93 Fragment 
4 Reverse Hind III 
TTTTAAGCTTTCATCATGGATGACGTTTTTGCGC 3 
MBP Forward XbaI 
TCTAGAGGAGTGAAACGATGAAAATCGAAGAAGGTA
AACTGG 
3 
pBAD Seq 
Forward 
ATGCCATAGCATTTTTATCC 3 
pBAD Seq 
Reverse 
GATTTAATCTGTATCAGG 3 
SGW+5 Forward 
GGAATTCGCCAATGGGGCGATCGCCCACAATAGCG
GGTGGNNSNNSNNSNNSNNSTGCTTAAGTTTTGGC 
4 
Lib 1 Forward 
GGAATTCGCCAATGGGGCGATCGCCCACAATTGCN
NSNNSGGGGCGTTTACCGGTGCGNNSNNSTGCTTAA
GTTTTGGC 
4 
Loop 1 Forward 
GGAATTCGCCAATGGGGCGATCGCCCACAAT 
TGCCACGAAGCGGGGGCGTTTACCGGTGCGCAAAA
ACGTCATTGCTTAAGTTTTGGC 
4 
Zipper GGAATTCGCCAATGGGGCGATCGCC  4 
CBDXbaI Reverse TCTAGATCATTGAAGCTGCCACAAGG 4 
CBDHindIII Reverse TTTTAAGCTTTCATTGAAGCTGCCACAAGG 4 
SICLOPPS Seq 
Forward 
GGGCGGATGGTCAGGTTAAGAATATATCC 5 
SICLOPPS Seq 
Reverse 
GGAAGCTCTGTCGTCCTGGTC 5 
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RpoN Forward 
(Pol 53) 
GGGGCATTTGATCGCCCACG 4 
KanR Reverse TGTAGGCTGGAGCTGCTTCG 4 
GalE Forward TTTTTGGTACCCCATAAGCCTAATGGAGCG 4 
GalE Reverse TTTGGTACCCGGGATTAAATTGCGTCATGG 4 
PspA Forward TTTTTGGTACCGCAGGACAATCCTGAACGC 4 
PspA Reverse TTTTGGTACCCGTTCGGACGCCGCC 4 
HimA Forward TTTTTCTAGATGTAGAGGCATTAAAAGAGCG 4 
HimA Reverse AAGCTTGACAGTGAAAAGAAAAAAGG 4 
Table 2.10 DNA primers used in this work. 
2.1.7 GENERATION OF BACTERIAL STRAINS 
P1 transduction was used to generate all strains novel to this work. This method uses the 
bacteriophage P1 to infect a donor strain carrying the desired mutation and relies on 
accidental packaging of bacterial DNA by the phage during the infection process. The 
method uses a mutant phage, P1vir, that is unable to form lysogens and so enters the lytic 
cycle upon infection; this ensures replication and cell lysis [202]. A lysate of many phage 
made from the donor strain may then be used to infect a recipient strain and in this process 
a small number of phage will transfer the bacterial DNA they are carrying onto the recipient 
chromosome. In order to select for recombination of the transferred DNA a genetic marker, 
such as an inserted antibiotic cassette, is required [202]. In this work, strains containing 
knockouts were created and isolated either by kanamycin or tetracycline selection. 
The Keio collection is a library of single-gene disruptions of all nonessential genes in E. coli 
K-12. Genes were replaced by a kanamycin cassette using the λ Red recombinase method 
reported by Datsenko and Wanner.[203] A flippase recombination enzyme (FLP) target 
(FRT) site is situated either side of the inserted antibiotic cassette allowing for later removal 
of KanR using the pCP20 plasmid [195]. 
2.1.7.1 P1VIR LYSATE GENERATION 
5 mL of LB containing appropriate antibiotic was inoculated from a single colony of the donor 
strain and grown overnight at 37 ˚C with shaking. To make the P1 lysate, 0.2 mL of the 
donor strain culture was added to 0.2 mL of an existing P1 lysate (from a laboratory 
collection) and the mixture was left at RT for 30 minutes without mixing. A growth medium 
mixture of 18.5 mL LB, 0.5 mL 40% glucose and 1 mL 0.1 M CaCl2 was then added and the 
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culture was grown at 37 ˚C with shaking at 200 rpm until cellular debris could be seen in the 
cultures (typically 6-7 hours). Any surviving bacteria were killed by vortexing after the 
addition of 2 mL chloroform. The lysate was then left at RT for 30 minutes before 
centrifugation at 16.1 rcf. The supernatant containing the P1 lysate was then removed and 
used to infect the recipient strain. 
2.1.7.2 P1VIR PHAGE TRANSDUCTION 
5 mL of LB containing appropriate antibiotic was inoculated from a single colony of the 
recipient strain and grown overnight at 37 ˚C with shaking. To 0.2 mL of this recipient strain 
was added 0.8 mL of P1 lysate (generated from the donor strain) and the mixture was 
incubated at 37 ˚C without shaking for 20 minutes. 1 mL of 1 M trisodium citrate was added 
and mixed by gently pipetting up and down. Recipient bacteria containing the target gene 
knockout were selected for by adding 3 mL melted TA7 top agar and pouring onto an LB 
agar plate containing appropriate antibiotic and grown overnight. Several colonies were then 
selected and re-streaked twice to eliminate any phage carry-over. 
2.1.7.3 CURING KANAMYCIN RESISTANCE 
Introduction of the galE and rpoN mutations by P1vir phage transduction resulted in the 
insertion of a kanamycin resistance cassette flanked by two flippase recognition targets 
(FRTs). It was therefore possible to cure the kanamycin resistance using the plasmid pCP20 
[199] which is a replication temperature sensitive AmpR, CmR plasmid. 
pCP20 (1 µL, 50 ng/ L) was transformed into CaCl2 competence cells (50 µL) of the kanR 
containing strain and the transformation plated onto LB agar containing ampicillin. The 
transformation was grown at 30 ˚C overnight to ensure plasmid replication; growth at 
temperatures of 37 ˚C or higher results in plasmid loss. Several colonies were picked from 
the transformation plate, re-streaked onto non-selective media and grown at 42 ˚C to ensure 
loss of pCP20. Single colonies from these re-streaks were then further streaked onto LB 
agar Kan and Cm to ensure loss of both the plasmid and the kanamycin cassette. 
2.1.8 DNA METHODS 
This section contains the general DNA methods used in this work. Whilst PCR setup for 
evaluation of created bacterial strains is included, for cloning PCR see (2.2 Chapter Specific 
Methods). 
2.1.8.1 PLASMID DNA PURIFICATION 
In the majority of this work plasmid DNA was isolated from 5 mL of overnight culture grown 
in LB in the presence of appropriate antibiotic and using a QIAprep Spin Miniprep Kit 
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(Qiagen) and following the manufacturer‟s protocol. DNA was eluted into 50 µL water. All 
sequencing data was collected using DNA purified in this way. 
Initial isolation of the C+5 and Lib1 SICLOPPS libraries was performed using a QIAGEN 
Plasmid Maxi Kit (Qiagen). The libraries were collected directly after transformation and 
growth on Cm25 LB agar plates by the addition of 2X 5 mL LB to each plate. A flame 
sterilised spreader was used to detach colonies from the solid media. The library containing 
LB fractions from multiple plates were pooled and DNA isolated following the manufacturer‟s 
protocol using the Plasmid Maxi Kit. DNA was eluted into 500 µL of water and quantified 
using a Nanodrop 1000 (Nanodrop). The plasmid DNA was then concentrated until dry and 
finally resuspended in enough water to give a final concentration of 100 ng/µL. 
2.1.8.2 COLONY PCR FOR ANALYSIS OF DELETED GENES 
To confirm the absence of genes deleted by P1 phage transduction colony PCR was 
performed using primers designed to anneal either side of the target gene. The reaction 
mixture was made up as for the typical cloning PCR reaction, but in place of template DNA a 
single colony was added to each tube by pipetting gently up and down. Gene deletion was 
confirmed by comparison with the parent strain by agarose gel electrophoresis (Section 
2.1.8.3 Agarose Gel Electrophoresis). 
2.1.8.3 AGAROSE GEL ELECTROPHORESIS 
Agarose gel electrophoresis was used to analyse and clean-up PCR reaction products. Gels 
were prepared by heating between 0.8 and 1.2% agarose (w/v) in either 30 or 80 mL 1X 
TBE buffer (National Diagnostics, 89 mM TrisBorate pH 8.3, 2 mM Na2EDTA) depending on 
the fragment size to be analysed or isolated. Before pouring, SYBR® Safe Green (Invitrogen) 
was added to a final dilution of 1:10,000. Gels were run in 1x TBE buffer at 80 V. 
2.1.8.4 PCR CLEAN-UP/ GEL EXTRACTION 
PCR products and DNA fragments were purified by excision from agarose gels and using a 
QIAquick PCR Purification Kit (Qiagen). DNA was eluted into a final volume of 30–50 µL of 
water. 
2.1.8.5 DNA SEQUENCING 
Sequences were obtained by mixing 7 µL of DNA with 3 µL of sequencing primer (10 µM) 
and were sequenced by the DNA Core Laboratory of MRC (Clinical Sciences Centre, 
Hammersmith Hospital, London), or by eurofins mwg operon, and were analysed using 
BioEdit Sequence Alignment Editor Version 7.0.9.0. 
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2.1.8.6  RESTRICTION DIGEST OF DNA 
DNA digests were typically performed in reaction sizes of 10 L or 20 L with Fermentas 
FastDigest ® or NEB endonucleases at 1/20 dilution to digest 350 ng or 700 ng of DNA 
respectively. Reactions were left for at least 30 minutes at 37 ºC before agarose gel 
purification. The manufacturer‟s protocol was followed for each type of enzyme. A typical 
reaction is shown in Table 2.11. 
REACTION COMPONENT VOLUME (µL) 
PCR product 7 
Xbal Fermentas FastDigest 0.5 
HindIII Fermentas FastDigest 0.5 
10x FastDigest Buffer 1 
H2O 1 
Total volume 10 L 
Table 2.11 A typical DNA digest reaction. 
2.1.8.7 LIGATION OF DNA 
Ligations were performed using NEB Quick T4 DNA Ligase. For general cloning a typical 
reaction is shown in Table 2.12. 
REACTION COMPONENT VOLUME (µL) 
Quick T4 DNA Ligase 1 
2x Quick Ligation Buffer 10 
Vector DNA (~50 ng) 2 
Insert DNA (~150 ng) 6 
H2O 1 
Total volume 20 mL 
Table 2.12 A typical DNA ligation reaction. 
2.1.9 PREPARATION OF COMPETENT CELLS 
2.1.9.1 CACL2 CHEMICALLY COMPETENT CELLS 
Chemically competent cells were prepared according the protocol given by Sambrook et al. 
[204] But briefly: working under sterile conditions, a single colony of the required strain was 
added to LB (5 ml) containing an antibiotic if appropriate, and the culture was shaken 
overnight (37°C, 220 rcf). Of this overnight culture, 200 µL was used to inoculate 100 mL LB 
containing an appropriate antibiotic, and the culture was shaken at 37°C, 220 rcf until an 
OD600 of 0.2 was reached. The cells were centrifuged (1.5 rcf, 4 °C, 10 min), resuspended in 
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50 mM CaCl2, 15 % glycerol (20 ml, autoclaved), left on ice for 20 minutes and then 
centrifuged again. The cells were resuspended again in 50 mM CaCl2, 15 % glycerol (1 ml, 
autoclaved), aliquoted and stored at -80°C. 
2.1.9.2 INOUE CHEMICALLY COMPETENT CELLS 
Inoue chemically competent cells were used for transformation of the ligated SICLOPPS 
libraries as they have increased competencies compared to those prepared by the CalCl2 
method, and their transformation is not inhibited by ligase, as electrocompetent cells are. 
Under standard laboratory conditions, the method outlined by Inoue et al. achieves 
transformation efficiencies of between 1 x108 and 3 x108 colonies/mg of plasmid DNA [205]. 
As before, a single colony of the required strain was added to LB (5 ml) containing an 
antibiotic if appropriate, and the culture was shaken overnight (37°C, 220 rcf). 250 mL of 
SOB media containing appropriate antibiotic was inoculated with 200 µL of the overnight 
culture. The culture was grown at 18 ºC with shaking at 220 rpm to an OD600 between 0.2–
0.4. The culture was transferred to two pre-chilled sterile centrifuge tubes and left on ice for 
10 minutes before centrifugation at 1.5 rcf for 10 minutes at 4 ºC. The supernatant was 
removed and each pellet was resuspended in 80 mL chilled TB buffer and left on ice for 10 
minutes. The resuspended cells were centrifuged again as before and then resuspended in 
20 mL ice-cold TB buffer containing 7% DMSO, aliquoted and stored at -80 ºC. 
Inoue competent cells of strains LJR04 and LJR05 were prepared using SOC media in place 
of SOB as initial attempts to make cells using the literature procedure yielded 
transformations with efficiencies only equivalent to those achieved using CaCl2 prepared 
cells. 
2.1.9.3  ELECTROCOMPETENT CELLS 
Electrocompetent cells were prepared by inoculating 200 mL LB with overnight culture grown 
from a single colony as before. Cells were cultured in the presence of antibiotic if appropriate 
at 37 ºC with shaking at 220 rpm to an OD600 between 0.5–0.7. The culture was transferred 
to 4 pre-chilled centrifuged tubes and spun down at 1.5 rcf for 10 minutes at 4 ºC. The 
supernatant was removed and the pellets resuspended in 50 mL chilled 10% glycerol 
(sterile). The cells were then centrifuged at 4 ºC and resuspended as before a further 2 
times before final resuspension of each pellet in 0.5 mL ice-cold 10% glycerol. Aliquots of 
100 µL were taken and stored at -80 ºC. 
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2.1.10 TRANSFORMATION OF E. COLI 
2.1.10.1 HEAT-SHOCK TRANSFORMATION 
Plasmid DNA, typically 2 µL of 50 ng/µL, was added to 80 µL of chemically competent cells, 
mixed gently and left on ice for 20 minutes. The cells were heat shocked at 37 ºC for 1 
minute, placed on ice for 5 minutes before the addition of 700 µL LB. The transformed cells 
were then allowed to recover at 37 ºC for 1 hour with gentle shaking before plating on LB 
agar containing appropriate antibiotic and growth at 37 ºC. Inoue chemically competent cells 
were also transformed using this protocol, but were recovered in SOC media for 1 hour in 
place of LB. 
2.1.10.2 ELECTROPORATION 
Plasmid DNA, typically 1-2 µL (50 ng/µL), was added to 100 µL of electrocompetent cells, 
mixed gently and the mixture transferred to a pre-chilled 0.2 cm electroporation cuvette 
(BioRad). Using a BioRad MicropulserTM, a pulse was applied to the cuvette which was 
appropriate for E. coli and the cuvette gap size. Immediately after the pulse was applied, 
900 µL of SOC medium was added to the cuvette and mixing was performed by gentle 
pipetting. The transformed mixture was transferred to a microcentrifuge tube and allowed to 
recover at 37 ºC for 1 hour with gentle shaking before plating on LB agar containing 
appropriate antibiotic and growth at 37 ºC. 
2.1.11 IN VITRO METHODS 
2.1.11.1 PURIFICATION OF RECOMBINANT PROTEINS 
This work utilised two recombinant proteins, purified from E. coli BL21(DE3) from vector 
pET28b+ encoding for either 54 or PspF1-275 with a thrombin cleavable, 6-His tag at the 
amino terminus. Both plasmids were transformed into CaCl2 chemically competent cells 
(CaCl2 Chemically Competent Cells) and transformed by heat shock (Heat-shock 
Transformation). 
2.1.11.2 PROTEIN OVER-EXPRESSION 
After initial transformation and working with sterilised tools, four colonies were picked from 
the transformation plate and each was spread onto one quarter of an LB agar plate 
containing appropriate antibiotic. The plate was left at 37°C for 7 hours. 25 mL LB broth 
supplemented with antibiotic was inoculated with a single colony from the re-streaked plate 
and was shaken overnight at 37 °C, 220 rcf. To 1 L of LB broth was added appropriate 
antibiotic and to this was added the overnight grown culture (20 mL). The mixture was 
shaken at 37 °C until the OD600 was measured as between 0.4 and0.6 (exponential phase). 
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The culture was placed in an ice-bath for 30 minutes with shaking in order to slow growth 
and cool the medium before induction. After 30 minutes IPTG (5 mL, 100 mM) was added 
and the culture was grown for 3 hours at 25 ˚C, 220 rcf before centrifugation (5000 rpm, 
15 mins, 4 °C). The supernatant was removed and the pellet resuspended in lysis buffer 
(10 mL). 
2.1.11.3 HIS-TAG PROTEIN PURIFICATION 
Purification was performed on both proteins using Ni-chelate affinity chromatography using a 
HiTrap™ Chelating HP column (GE Healthcare) charged with nickel chloride hexahydrate 
(20 mg/mL) and an AKTA (GE Healthcare) FPLC system. 
To the resuspended pellet was added half a tablet of protease inhibitor cocktail (Complete 
Protease Inhibitor Cocktail tablet, Roche Diagnostics GmbH) and the cells were allowed to 
thaw to RT in an ice-bath. The cells were then sonicated twice for 10 minutes (pulse rate 2 s, 
amplification 40%) and centrifuged (40 min, 16.1 rcf, 4°C). The supernatant was loaded on 
to the Ni HiTrap™ column using a loading supercoil (0.5 mL/min, 20 min). Once loaded, the 
supercoil was removed, the column washed with 100% His Buffer A (2 mL/min), and the 
flow-through collected. For 54 purification a 3% wash was performed of His Buffer B 
(2 mL/min) and the flow-through collected. For PspF1-275 purification a 7% His Buffer B 
(2 mL/min) was performed. A gradient (3-100% σ54/ 7-100% PspF1-275 Buffer B, 40 min, 
1 mL/min) was run and purified eluted protein was collected in 1 ml fractions and placed on 
ice. The fractions which contained purified protein were determined by SDS-PAGE. Purified 
protein was dialysed into storage buffer. 
2.1.11.4 HEPARIN PURIFICATION OF 54 
54 is a DNA binding protein which also forms complexes with RNAP. In order to purify 
recombinant 54 from E. coli RNAP, a second purification is required using a HiTrap™ 
Heparin HP (GE Healthcare) column. MgCl2 (10 mM final) was added to the His-tag purified 
and dialysed σ54 before loading (0.5 mL/min) onto 2 Hi-Trap 5 ml Heparin HP columns fitted 
together. The column was washed with 100% σ54 Hep Buffer A (1 mL/min) and the 
flow-through collected. A gradient of 0-100 % B was run over 60 minutes and the purified σ54 
was collected in 1 mL fractions. SDS-PAGE was used to determine fractions containing only 
pure σ54, and these were dialysed overnight into σ54 dialysis buffer. 
2.1.11.5 HIS-TAG CLEAVAGE 
His-tag cleavage and removal was performed using the Thrombin Cleavage Capture Kit 
(Novagen). To the dialysed and purified protein (approximately 6 mL) was added 10x 
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Thrombin Cleavage buffer (600 µL) which had warmed to RT. To this was added cleavage 
protein biotinylated thrombin (8 µL) at -20 °C and the mixture was stirred gently (RT, 4 
hours). 
Streptavidin agarose (300 µL) and Ni-NTA agarose (300 µL) were added to remove the 
cleaved His-tag and any un-cleaved protein. The protein mixture was shaken for 10 minutes, 
filtered and the protein dialysed overnight in Tris buffer (as above) before storage at -80°C. 
2.1.11.6 RECOMBINANT PROTEIN QUANTIFICATION 
The Folin-Lowry method was used for quantification of all proteins[206]. A BSA solution at a 
known concentration of 1 µg/mL was used to make a standard curve against which σ54 was 
compared. To make the Folin-Lowry „Fresh Mix‟ 2 % (w/v) Na2CO3 in 0.1 M NaOH (24.5 mL) 
was added to 2 % (w/v) NaK tartrate (250 µL) with mixing. To this was added 1 % (w/v) 
CuSO4.5H2O (250 µL). 
For a given protein a sample 5 µL and a 10 µL sample were taken and made up to 100 µL 
using d.H2O in triplicate and to each sample was added „Fresh Mix‟ (1 mL). After vortexing 
and incubation for 20 minutes at 37°C, a 1:1 mix of Folin-Ciocalteu‟s Phenol reagent 2N 
(100 µL) was added. The samples were vortexed again and incubated for 20 minutes at 
37 °C before absorption was measured at 750 nM. 
2.1.11.7 WESTERN BLOTTING 
Antibodies used and their appropriate dilutions are listed in Appendix B Antibodies for 
Western Blotting. Two SDS-PAGE gels were run; one for staining with Coomassie Blue to 
compare protein levels and one for the Western blot. The gel Western blotting was run with a 
Western marker (MagicMark™ XP Western Protein Standard (20-220 kDa)). After 
separation by SDS-PAGE the gel and eight Whatman paper filters (Merck) were equilibrated 
for 10 minutes in transblot buffer (10 mM Tris, 100 mM glycine, 10% (v/v) methanol). An 
Immun-Blot™ PVDF membrane was activated by soaking in methanol for 10 seconds, 
before being equilibrated in transblot buffer for 10 minutes. The protein was transferred 
using a Trans-Blot® SD Semi-Dry Transfer Cell (BIORAD) for 1 hour at 100-150 mA. Protein 
transfer was confirmed by staining the membrane for a few seconds in Ponceau S Staining 
solution (Sigma). The blocking, washing and incubation with primary and secondary 
antibodies were performed using a BenchPro™ 4100 Western Processing System 
(Invitrogen). Incubation periods were as follows: 
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STEP TIME (MINS) 
Blocking 5% (w/v) milk-powder in TBS 60 
Washing 2x in TBSTT 2x 10 
Washing 1x in TBS 10 
Incubation with primary antibody diluted in 5% (w/v) milk-powder in 
TBS 
60 
Washing 2x in TBSTT 2x 10 
Washing 1x in TBS 10 
Incubation with horseradish peroxidise (HRP) conjugated secondary 
antibody diluted in 5% (w/v) milk-powder in TBS 
60 
Washing 5x TBSTT 5x 10 
Table 2.13 Western blotting protocol using the BenchPro 4100 Western Processing System. TBS: 50 mM 
Tris HCl pH 7.5, 150 mM NaCl. TBSTT: TBS, 0.1% Tween 20 
Chemiluminescent detection of membrane-bound proteins was performed using an EZ-ECL 
kit (GeneFlow) according to the manufacturer‟s protocol. Western blots were imaged on a 
Western LAS-3000 Imaging machine (Fujifilm). 
2.1.12 -GALACTOSIDASE ACTIVITY ASSAYS 
-Galactosidase activity assays are used throughout this thesis to determine activity of the 
pspAp promoter fused to lacZ. The assay is based on the ability of lacZ gene product, -
galactosidase, to accept substrates other than its cellular target, lactose. When o-
nitrophenyl-β-galactoside (ONPG) is added to a lysed, buffered aliquot of cells, -
galactosidase in the solution will convert ONPG added to o-nitrophenol (ONP) and 
galactose. The reaction can be followed because at cellular pH ONP has a yellow colour, so 
accumulation of yellow can be timed and converted to the standard measure of activity, 
Miller Units, using Equation 2.1. This equation takes into account both cell number in a given 
sample size (OD600) and light scattering due to cellular debris after lysis which remains in the 
reaction (OD550). OD420 is measured to quantify ONP. 
In this thesis, both the standard end-point cuvette based and an alternative kinetic assay are 
used. In this general section only the cuvette-based assay protocol is detailed. For details of 
the alternative kinetic assay see 2.2.3.2 Kinetic Plate-Based -Galactosidase Assay. 
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2.1.12.1 CUVETTE-BASED ASSAY 
To 5 mL of LB containing the appropriate antibiotic(s) was added a single transformed 
colony, and the inoculated LB was shaken overnight at 37 °C (220 rcf). In the morning, a day 
culture of 5 mL of LB containing antibiotic was inoculated with 50 µL of the overnight culture, 
and was shaken at 37 °C until an OD600 of 0.2 was reached. If required, protein expression 
was induced by the addition of either IPTG (1 mM) or arabinose (0.02% w/v) was added to 
the culture, which was shaken for a further 3 hours at 37 °C (220 rcf). 
The day culture was placed on ice to stop cell growth and OD600 measured at a dilution such 
that the reading fell within the spectrophotometer linear range. For each culture the assay 
was performed in triplicate. To 200 µL of the day culture, was added 800 µL Z Buffer and 
50 µL chloroform, the sample was vortexed for 30 seconds and placed at 30 °C in a water 
bath. To each was added 200 µL of a solution of pre-warmed ONPG in Z Buffer (4 mg/mL) 
and the time of addition noted. When the solution had turned a pale yellow, Na2CO3 (500 µL, 
1 M) was added to stop the reaction and the time recorded. Measurements of OD420 and 
OD550 were made and the Miller Units calculated using the following equation [207]: 
, where 
OD420 = absorbance at 420 nm; OD550 = absorbance at 550 nm; OD600 = absorbance of 
day culture at 600 nm; t = time (minutes); v = volume of cells used (mL) 
Equation 2.1 Classic cuvette -galactosidase activity assay equation to calculate Miller Units. 
  
Figure 2.1 Conversion of o-nitrophenyl-β-galactoside (ONPG) to galactose and o-nitrophenol (ONP). 
Under cellular conditions o-nitrophenol is yellow and the activity of the -galactosidase enzyme can be 
measured by observing the time taken for a buffered lysis of cells to turn yellow after addition of ONPG. 
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2.2 CHAPTER SPECIFIC METHODS 
This section describes methods which are specific to individual chapters. 
2.2.1 CHAPTER 3: SYNTHETIC PEPTIDES AND DESIGN-LED APPROACHES 
2.2.1.1 SOLID PHASE PEPTIDE SYNTHESIS 
Automated solid phase peptide synthesis was performed using an Advanced ChemTech 
Apex 396 synthesiser or an Invatis ResPep LS automated synthesizer. Fully protected 
amino acids resins, coupling reagents and peptide synthesis grade DMF were purchased 
from Merck. 
Purification of the peptides was performed either by RP-HPLC or by LC-MS. The RP-HPLC 
was a Gilson Semi-preparative RP-HPLC , fitted with 306 pumps, a Gilson 155 UV/vis 
detector and an ACE 5 C18 column (250 x 21.2 mm) using a methanol gradient of 2 to 98% 
over 38 minutes. Analytical HPLC was performed on a Gilson Analytical HPLC system with 
322 pump, 234 Autoinjector, 155 UV/vis detector and an ACE 5 C18 column (250 x 4.6 mm). 
Both systems used HPLC-grade helium-degassed acetonitrile (VWR) supplemented with 
0.1% TFA. 
The LC-MS was a ESI Waters LC-MS fitted with Waters 2767 autosampler, Waters 515 
HPLC pump, Xbridge C18 column (Waters 4.6 mm x 100 mm analytical/ 19 mm x 100 mm 
preparative), Waters 3100 mass spectrometer with ESI and Waters 2998 Photodiode Array 
(200-600 nm). HPLC-grade methanol was degassed with helium and supplemented with 
0.1% formic acid. 
MALDI-TOF mass spectrometry was performed on a Micromass Autospec-Q spectrometer. 
ESI was performed on a Waters LC-MS. 
Peptides were freeze-dried on an Alpha 2-4 LD Plus freeze-dryer (Christ). 
2.2.1.2 LINEAR PEPTIDE SYNTHESIS 
Standard Fmoc-SPPS protocol was followed [208] but briefly: 
For the C-terminal free acid peptides, either pre-loaded Wang, or Rink amide resin 
(25 µM/well) was swelled in peptide synthesis grade DMF for 60 minutes before the first 
cycle. The N-terminal Fmoc group was removed with 20% (v/v) piperdine in DMF for 15 
minutes, with 2 further repetitions. Five equivalents of each side-chain fully protected amino 
acid were used and incoming amino acids were activated by the addition of HOBt/HBTU in 
situ (125 µmole, 250 µL) and DIPEA (125 µmole, 250 µL, 0.5 M). The resin was then 
washed in DMF (3x 1 ml). A typical cycle consisted of deprotection, DMF wash, in situ 
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coupling, DMF wash. After the final peptide coupling, the N-terminal Fmoc was cleaved 
using 20 % piperdine (v/v) in DMF. 
The beads were washed twice with DMF (2 mL), DCM (2 mL), methanol (2 mL) and diethyl 
ether (2 mL) and desiccated under vacuum for at least 12 hours. 
2.2.1.3 CLEAVAGE AND DEPROTECTION 
The peptides were cleaved from the beads and side-chain deprotected by shaking at RT for 
2 hours with 2 mL/well of deprotection solution (94% TFA, 2.5% d.H2O, 2.5% EDT and 1% 
TIS). 
The cleavage solution, containing the free peptide, was flushed into a tube and the beads 
washed with deprotection solution (1 mL). To the cleavage solution was added cold TBME 
(ca. 12 mL) and precipitation was induced with shaking. The mixture was then centrifuged 
(3500 rpm, -4 °C, 15 min). The supernatant was poured away and the pellet of precipitant 
resuspended in TBME and then centrifuged. This process was performed a total of 3 times, 
after which the peptides were desiccated under vacuum. 
The peptides were purified by preparative reverse phase HPLC using degassed methanol 
and water. Purity was then confirmed by analytical HPLC (2- 98% HPLC grade H2O: 
Acetonitrile over 40 minutes) and MALDI-TOF mass spectrometry. 
2.2.1.4 ON-BEAD ACETYLATION 
Peptides were synthesised on the automated synthesiser as described above (2.2.1.1 Solid 
Phase Peptide Synthesis). After removal from the synthesiser, the peptides were washed 
with DMF (2x 2 mL) and swelled by shaking in DMF (2 mL). After 30 minutes, 2 mL of 
acetylation solution (10% acetic anhydride, 20% DIPEA in DMF) was added and the mixture 
was shaken for a further hour. The beads were washed with DMF (2 mL), DCM (2 mL), 
methanol (2 mL) and diethyl ether (2 mL). After desiccation under vacuum overnight, the 
peptides were cleaved from the resin, deprotected and purified as described above (2.2.1.3 
Cleavage and Deprotection). 
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2.2.1.5 FRAGMENT 4 PEPTIDE CHARACTERISATION 
PEPTIDE RESIN MASS (MG) 
PERCENTAGE 
YIELD 
RT (MIN) 
MASS 
OBSERVED BY 
MALDI-TOF 
Fragment 4 N 
and C termini 
capped 
Rink 
Amide 
33.8 24 27.9 2781 (M+1) 
Fragment 4 
T86A N and C 
termini capped 
Rink 
Amide 
51.8 37.5 26.7 2751 (M+1) 
Loop 1 N and C 
termini capped 
Rink 
Amide 
31.8 25 24.3 1620 
Table 2.14 Characterisation data for the Fragment 4 peptides. For MALDI-TOF spectra of peptides see 
Appendix F. 
2.2.1.6 ON-BEAD PEPTIDE DANSYLATION 
Peptides were synthesised on the automated synthesiser as described above (2.2.1.1 Solid 
Phase Peptide Synthesis). After removal from the synthesiser, the peptides were shaken for 
1 hour at RT with 1 mL dansyl chloride solution (125 µmoles, 5 eqv/well) in DIPEA (0.5M, 
0.5 mL/well). The coupling mix was flushed away and replaced with a second 1 mL of 
coupling solution. The mixture was shaken for a further 1 hour at RT and then washed twice 
with DMF (2 mL), DCM (2 mL), methanol (2 mL) and diethyl ether (2 mL). After desiccation 
under vacuum overnight, the peptides were cleaved from the resin, deprotected and purified 
as described above (2.2.1.3 Cleavage and Deprotection). 
2.2.1.7 DANSYLATED PEPTIDE CHARACTERISATION 
PEPTIDE 
MASS 
(MG) 
PERCENTAGE 
YIELD 
RT 
(MIN) 
MASS OBSERVED BY MALDI-
TOF 
d-F469-93 2.8 4 30.6 2973 (M+1) 
d-F469-93 
T86A 
1.9 3 30.7 2943 (M+1) 
d-Loop 1 3.6 4 28.3 1855 
Table 2.15 Characterisation data for the dansylated peptides. For MALDI-TOF spectra of peptides see 
Appendix F. 
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2.2.1.8 DANSYL FLUORESCENCE INTENSITY BASED ASSAY 
The assay was performed in a SpectraMax M2e Microplate Reader (Molecular Devices). 
150 µL of 1 µM dansylated peptide in 54 buffer and 1X STA buffer was added to the cuvette 
and allowed equilibrate to the measurement temperature for 10 minutes. The emission 
spectrum was measure between 400 and 600 nm. 54 (100 µM) was added 1.5 µL at a time. 
The solution was mixed and allowed to equilibrate for 10 minutes after each addition. A total 
volume of 30 µL of 54 was added (17 µM final concentration). 
2.2.1.9 ISOTHERMAL TITRATION CALORIMETRY 
The peptides were lyophilised and accurately weighed before being dissolved directly into 
σ54 buffer. The ITC system was washed thoroughly with 4% Decon and then MilliQ H2O, 
after which the cell and syringe were thoroughly rinsed with 54 buffer. 1.5 mL of 54 
(100 µM) was loaded into the ITC cell, into which the loading syringe containing 280 µL of 
either Fragment 4 (1 mM) or buffer was placed. The experiment was conducted at 30°C. 100 
injections of 3.0620 µL of peptide were made with 300 seconds between each injection. The 
results were analysed using Origin7 software. 
2.2.1.10 TRANSCRIPTION ASSAYS 
2.2.1.10.1 FULL-LENGTH TRANSCRIPTION 
RNAP enzyme was purchased from Epicentre. RNAsin RNase inhibitor was purchased from 
Promega. 
Volumes and concentrations given are per reaction. Where appropriate, a master mix was 
constructed and aliquots taken for each reaction. 
E. coli RNA polymerase core enzyme (0.7µ L, 1.5 µM) was added to 54 (0.5 µL, 10 µM), 
dATP (0.5 µL, 100 µM), 5X STA Buffer – DTT (2 µL) and RNAsin (0.5 µL, 40 µM/µL). 
Enough dH2O was added to make the final reaction volume up to 10 µL, after elongation mix 
addition. Either MBP-fragment or synthetic peptides were added to the mixtures to give a 
final ratio PspF1-275: Fragment of 1:1, 1:2; 1:4 or 1:6. The reaction mix was incubated at 37°C 
for 5 minutes, supercoiled DNA (20 nM) was added, and the reaction mix incubated for a 
further 5 minutes. PspF1-275 (0.5 µL, 100 µM) was added and transcription was activated for 
5 minutes at 37°C. The elongation mixture (1 µL d.H2O or heparin at 1 mg/mL, 1 L of a 
nucleotide mixture at 20 mM ATP, GTP, CTP and 1 mM UTP and α-32P UTP) was added 
and the reaction was incubated at 37°C for 20 minutes, after which time the reaction was 
stopped by the addition of 4 µL of stop dye. The reaction mixture was boiled for 2 minutes 
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and run on a 4% sequencing gel in 1X TBE buffer. The gel was dried and visualised using a 
phosphorimager and analysed using Aida software. 
2.2.1.10.2 ABORTIVE TRANSCRIPTION 
Volumes and concentrations given are per reaction. Where appropriate, a master mix was 
constructed and aliquots taken for each reaction. 
E. coli RNA polymerase core enzyme (0.7µ L, 1.5 µM) was added to σ54 (0.5 µL, 10 µM), 
dATP (0.5 µL, 100 µM), 5X STA Buffer – DTT (2 µL) and RNAsin (0.5 µL, 40 µM/µL). 
Enough dH2O was added to make the final reaction volume up to 10 µL, after elongation mix 
addition. MBP-Fragment 4 (either 1.25 µL or 2.5 µL of a 20 µM stock, or 1.11 µL or 2.78 µL 
of a 90 µM stock) was added to give a ratio of MBP-Fragment 4 to PspF of 1:1, 1:2, 1:4 or 
1:10. The reaction mix was incubated at 37°C for 5 minutes, after which the nifH late melted 
DNA promoter probe (0.5 µL, 400 nM) was added. After a further 5 minutes of incubation at 
37°C, PspF (0.5 µL, 100 µM) was added and the mixture was incubated for a further 5 
minutes at 37°C. The elongation mixture (1 µL d.H2O or heparin at 1 mg/mL, αGTP 0.2 µL 
and UpG 0.4 µL, 1 mM) was added and the reaction was incubated at 37°C for 20 minutes, 
after which time the reaction was stopped by the addition of 4 µL of stop dye. 
The negative controls performed were Eσ54CC, EσF and EσF4, from which the PspF and 
dATP, the dATP, and the PspF were omitted respectively and volumes were made up with 
d.H2O. No MBP-Fragment 4 was added to any of the negative controls. The Eσ
54
OC positive 
control did not have any omissions, except that no MBP-Fragment 4 was added. A buffer 
control was also performed, to which σ54 buffer was added in place of MBP-Fragment 4. 
The reactions were run on a 20% DNA sequencing gel in 1X TBE buffer at 300 V for 25 
minutes. The gel was visualised using a phosphorimager and analysed using Aida software. 
2.2.1.11 INDUCTION OF PIV AND PSJI 
pSJI is a plasmid containing the reporter fusion pspAp-lacZ and pGJ4 contains the 
philamentous phage protein pIV. To measure the effect of the maltose binding protein (MBP) 
fused fragments, transformed cells containing the MBP-fusion, pSJI and pGJ4 subcultured 
from an overnight culture, grown to approximately OD600 0.1 and induced for 3 hours with 
1 mM IPTG. 
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2.2.1.12 FRAGMENT CLONING AND -GALACTOSIDASE ACTIVITY 
To clone the fragments into either pBAD18cm or pBAD28, constructs containing PspF1-
275/86A/86S or MBP-F4/86A/86S or MBP-F2/86A/86S were used as templates for PCR 
reactions. The primers and templates are shown in Table 2.16. 
DNA 
TEMPLATE 
FORWARD 
PRIMER 
REVERSE PRIMER 
TARGET INSERT (IN PBAD18-
CM AND PBAD 28) 
PspF1-275 
WT 
PspF1-275 Forward 
XbaI 
PspF1-275 Reverse Hind III PspF1-275 WT 
PspF1-275 
T86A 
PspF1-275 Forward 
XbaI 
PspF1-275 Reverse Hind III PspF1-275 T86A 
PspF1-275 
T86S 
PspF1-275 Forward 
XbaI 
PspF1-275 Reverse Hind III PspF1-275 T86S 
PspF1-275 
WT 
PspF69 Forward 
XbaI 
PspF69-102 Fragment 2 
Reverse Hind III 
PspF69-102 WT (Fragment 2) 
PspF1-275 
T86A 
PspF69 Forward 
XbaI 
PspF69-102 Fragment 2 
Reverse Hind III 
PspF69-102 T86A (Fragment 2) 
PspF1-275 
T86S 
PspF69 Forward 
XbaI 
PspF69-102 Fragment 2 
Reverse Hind III 
PspF69-102 T86S (Fragment 2) 
PspF1-275 
WT 
PspF69 Forward 
XbaI 
PspF69-93 Fragment 4 
Reverse Hind III 
PspF69-93 WT (Fragment 4) 
PspF1-275 
T86A 
PspF69 Forward 
XbaI 
PspF69-93 Fragment 4 
Reverse Hind III 
PspF69-93 T86A (Fragment 4) 
PspF1-275 
T86S 
PspF69 Forward 
XbaI 
PspF69-93 Fragment 4 
Reverse Hind III 
PspF69-93 T86S (Fragment 4) 
MBP-F4 
MBP Forward 
XbaI 
MBP Reverse XbaI MBP 
MBP-F4 F4 Forward XbaI F4 Reverse XbaI F4 
Table 2.16 DNA primers used in the subcloning of PspF Fragments 2 and 4 into pMBP. 
Initial attempts to ligate the PCR products into either pBAD18cm or pBAD28 after digestion 
with Xbal and HindIII were unsuccessful. To avoid problems with digestion of the PCR 
products, the shuttle vector pGem® T-Easy was used. PCR products with an expected 3‟-
terminal T residue in the sequence, when amplified by Taq polymerase, are created with 
adenine overhangs at the 3‟ ends [209, 210]. These can be combined with commercially 
available linearized vectors, such as pGEM® T-Easy, which have compatible thymidine 
overhangs at the 3‟ ends, to clone fragments into vectors without previous restriction digest 
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of PCR product or plasmid [200]. The resultant intermediate vectors were amplified in the 
strain ER2926cm which is dam-/dcm- to avoid sensitivity of the restriction enzyme XbaI to 
methylation at the GATC site. Once the fragments were digested (2.1.8.6 Restriction Digest 
of DNA) from the pGem vector, they were ligated using standard conditions (2.1.8.7 Ligation 
of DNA). 
2.2.2 CHAPTER 4: SICLOPPS I 
2.2.2.1 PCR FOR CLONING THE SICLOPPS LIBRARIES 
Cloning of the two libraries and one control peptide into the SICLOPPS vector required a 
higher than typical annealing step temperature due to primer length; higher than usual 
amounts of primers were also used. PCR reactions were performed using an Eppendorf 
Mastercycler personal and the programs and reaction components are given here: 
COMPONENT VOLUME (µL) FINAL CONCENTRATION 
5x Green GoTaq® Reaction Buffer 10 1x 
PCR Nucleotide Mix (10 mM) 1 200 µM 
Upstream primer (C+5, Lib1 or Loop1) 
(10 µM) 5 1 µM 
CBD downstream primer (10 µM) 5 1 µM 
GoTaq® DNA Polymerase (5 u/µL) 1 0.1 u/µL 
SICLOPPS-CBD plasmid 2 100 ng 
ddH2O 26 - 
Table 2.17 Components of the first SICLOPPS PCR reaction.  
 
COMPONENT VOLUME (µL) FINAL CONCENTRATION 
5x Green GoTaq® Reaction Buffer 10 1x 
PCR Nucleotide Mix (10 mM) 1 200 µM 
Zipper upstream primer (10 µM) 5 1 µM 
CBD downstream primer (10 µM) 5 1 µM 
GoTaq® DNA Polymerase (5 u/µL) 1 0.1 u/µL 
Purified PCR product of first SICLOPPS PCR 2 100 ng/reaction 
ddH2O 26 - 
Table 2.18 Components of the second SICLOPPS PCR reaction 
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PCR STEP TEMPERATURE DURATION 
Denaturation 94 ˚C 
5 minutes (first cycle) 
1 minute (subsequent cycles) 
Annealing 65 ˚C 
2 minutes (first cycle) 
1 minute (subsequent cycles) 
Extension 72 ˚C 
1.5 minutes (cycles 1-31/ 1-
26) 
10 minutes (cycle 32/ 27) 
Cycles 32/ 27  
Table 2.19 Conditions for the SICLOPPS PCR reactions. 
2.2.2.2 CIP TREATMENT OF DIGESTED PLASMID PARCBD 
In order to increase the ligation efficiency of the SICLOPPS libraries, the digested backbone 
pARCBD was treated with calf intestinal phosphatase (CIP). CIP treatment removes the 
phosphate groups from the 5‟ end of DNA and prevents re-circularisation of backbone DNA 
[204]. Digested pARCBD was incubated for 1 hour with 1 L of NEB CIP per 1 g of 
backbone DNA.  
2.2.2.3 DIALYSIS OF LIGATION MIXTURES 
To eliminate ligation buffer salts before electroporation, ligation mixtures were dialysed into 
water on Millipore MFTM membrane filters (0.025 M) for 30 minutes. 
2.2.2.4 CALCULATION OF TRANSFORMATION EFFICIENCY 
Calculation of transformation efficiency was key to ensuring that full coverage of the DNA 
library was achieved when creating both libraries. To calculate the transformation 
efficiencies, DNA concentrations of dialysed ligation mixtures were measured using a 
Nanodrop and a dilution of each transformation was plated onto selective LA medium. The 
number of colonies was then counted and the efficiency calculated using the equation: 
 
Equation 2.2 Calculation of transformation efficiency. 
2.2.2.5 COLLECTION OF THE SICLOPPS PLASMID LIBRARIES 
The SICLOPPS plasmid libraries were collected directly from the transformed ligation 
mixtures on LA plates. 5 transformed ligation reactions were collected for each library. To 
collect the libraries, 5 mL of LB was added to each plate, the colonies were resuspended 
using a sterile spreader and then pooled together. The plasmids were then purified using a 
Qiagen Maxiprep kit (see Table 2.6), as per the manufacturer‟s instructions. 
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2.2.2.6 ISOLATION OF PEPTIDE WITH CBD BEADS 
To isolate and visualise the splicing process, the three libraries were expressed and bound 
to CBD beads. The linear, pre-spliced form with CBD domain attached should bind to the 
beads where splicing will then occur. Visualisation of this sample by gel electrophoresis is 
then possible to identify the full length IC-peptide-IN and IN fragments. After expression in 
BL21(DE3) with 0.02% arabinose the cultures (200 mL) were spun down at 1.5 rcf. The cell 
pellet was resuspended in 8 mL Chitin buffer, a protease inhibitor table (Roche) added and 
the resuspension sonicated and centrifuged (as for 2.1.11.1 Purification of Recombinant 
Proteins). The column was prepared by adding 800 L of CBD beads (NEB, S6651S) to a 
column, draining away the ethanol suspension fluid and washing the beads with 2 x 5 mL 
Chitin buffer. The soluble fraction in Chitin buffer was added to the prepared column, 
incubated at RT for 10 minutes without flow, before the flowthrough was collected. The 
beads were incubated overnight at RT and then washed with 5 mL Chitin buffer to isolate 
spliced components.  
2.2.2.7 PEPCLEAN DESALTING 
Eluates from CBD bead incubation were desalted using Pierce Pepclean C18 Spin Columns, 
following the manufacturer‟s protocol. Briefly, the column resin was activated by addition of 
50 % MeOH (200 L), centrifugation at 1.5 rcf for 1 minute and repetition. The resin was 
equilibrated with 5 % ACN, 0.5 % TFA (200 L), centrifuged and the process repeated. To 
bind the sample, 150 L of CBD bead eluate was added to the resin, centrifuged and the 
flowthrough re-added to the resin. After centrifugation again, the resin was washed with 5 % 
ACN, 0.5 % TFA (200 L) twice with centrifugation between wash steps. Finally, the sample 
was eluted into 70 % ACN (20 L) by centrifugation, the flowthrough re-added to the column 
and the elution repeated once more. 
2.2.2.8 MINIMAL MEDIA PLATES 
Solid minimal media plates were made with M9 minimal salts plus a carbon source, antibiotic 
and for solid media selection, Pgal. To make the plates, 15 g of agar was sterilised in 40 mL 
of water. After sterilisation and whilst melted, 160 mL of 5X M9 salts were added (sterile) 
after which MgSO4 (2 mM) and CaCl2 (100 M), a carbon source, antibiotic to select for 
strain or plasmid and inducing agent (arabinose/ IPTG) were added. If the plate required 
Pgal, this was added directly to the agar plate, the minimal media mix (20 mL) was added to 
it and mixing was ensured by swirling. 
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2.2.2.9 SELECTION STRAIN GROWTH ON LA, LACTOSE AND GLUCOSE 
To test the sensitivity of strains to lactose, overnight cultures of either the strains or 
transformed strains were grown. In the morning, the overnights were subcultured at a 
dilution of 1/100 into LB medium and grown for 5 hours. Cultures were then centrifuged for 
10 minutes at 1.5 rcf, resuspended in the same volume of M9 minimal medium and the 
resuspension process repeated. The cultures were then normalised to an OD600 of 0.5 and 
10 L spotted onto plates. Plates were either - LA, M9 minimal medium plus 0.1-0.4% 
lactose, or 0.4% glucose as a sugar source. Samples were plated in replicate onto plates 
either with or without arabinose (0.02%), IPTG (0.5 mM) and chloramphenicol for plasmid 
selection. 
2.2.2.10 GROWTH CURVES WITH PGAL 
Growth curves were performed in either a SpectraMax M2e Microplate Reader (Molecular 
Devices) or a BMG FLUOstar Optima (BMG Labtech) using sterile, flat, clear-bottomed 96-
well plates with lid (Falcon). Overnight cultures were also grown in the 96-well format, but 
using sterile, deep-well plates (2.2 mL volume, Corning), sealed with Airpore Tape sheets 
(Qiagen). 
To test their sensitivity to Pgal, the selection strains and controls were grown in a 96-well 
plate format with the addition of Pgal to the media after 2 hours. Strains were grown 
overnight in LB plus appropriate antibiotic in deep-well 96 well plates (0.5 mL culture in 
2.2 mL total volume). In the morning, 10 L of overnight culture was added to 190 L LB 
plus antibiotic and induction agent if required. For the strain LJR06, glutamine (2 mg/mL) 
was added to all growth media to compensate for rpoN knockout. Cultures were grown at 
30 ºC for 2 hours with shaking at 200 rpm. After 2 hours, 10 L of Pgal solution was added 
to give the desired final concentration (for the concentration of the master solution for each 
final concentration see Table 2.20). To blanks and controls was added 10 L of sterile H2O. 
Growth of cultures was continued at 30 ºC, shaking at 200 rpm. 
FINAL PGAL CONCENTRATION (%) MASTER PGAL CONCENTRATION (%) 
0.05 1.05 
0.10 2.1 
0.20 4.2 
0.30 6.3 
0.40 8.4 
Table 2.20 Final and starting concentrations of Pgal for Pgal sensitivity growth curves. 
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2.2.2.11 SOLID MEDIA SCREEN 
2.2.2.11.1 MINIMAL MEDIA AND CARBON SOURCE GROWTH 
Plates were made as described in 2.2.2.8 Minimal Media Plates. Experiments to test the 
sensitivity of selection strains to Pgal on minimal media with varying carbon source were 
performed as described in 2.2.2.9 Selection Strain Growth on LA, Lactose and Glucose, 
except that Pgal was added to media to varying final concentrations. 
2.2.2.11.2 LIBRARY SCREENS 
Plates were made as described in 2.2.2.8 Minimal Media Plates. To screen the transformed 
library against a particular Pgal concentration, Inoue competent aliquots of the selection 
strain were transformed with the library DNA (1 L) and recovered in LB for 1 hour. An 
aliquot of transformation mixture was taken for calculation of transformation efficiency, which 
was performed as in 2.2.2.4 Calculation of Transformation Efficiency. For plating, the 
transformants were centrifuged at 1.5 rcf for 1 minute, the supernatant removed and the 
pellet carefully resuspended in M9 minimal media (100 L). The resuspension was plated 
and plates were grown at either 25 ºC or 37 ºC. 
2.2.2.12 LIQUID MEDIA SCREENS 
2.2.2.12.1 MULTI-ROUND SCREENS 
Multi-round liquid selections were performed at either high (0.02%) or low (0.002%) 
arabinose concentrations. The libraries were transformed as for the solid media screens 
(2.2.2.11.2 Library Screens) but were not resuspended in minimal media, and the 
transformation efficiency calculated (2.2.2.4 Calculation of Transformation Efficiency) to 
ensure theoretical library coverage. After transformation, the cultures were grown overnight 
in 20 mL volumes of LB plus chloramphenicol and arabinose. The following morning, they 
were sub-cultured (1/1000) into 20 mL LB, again containing chloramphenicol and arabinose. 
After 2 hours of growth at 37 ºC, 220 rpm, Pgal (0.05%) was added and selection was 
continued for 3 hours. OD600 readings were taken every hours using a plate reader using 
200 L volume and if appropriate dilutions of cultures were made in order to read in the 
linear range. 
After 5 hours of growth, the culture was centrifuged at 1.5 rcf for 10 minutes and the DNA 
isolated using a Qiagen Miniprep kit. For the next round of selection, the isolated DNA was 
transformed into fresh selection strain and the process repeated. 
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2.2.2.12.2 SINGLE ROUND SCREEN 
Single round selections were performed essentially as the multi-round screens (2.2.2.12.1 
Multi-Round Screens) but selection was not repeated over multiple rounds. The Pgal 
concentration used was also increased to 0.1%, in order to see a larger effect of Pgal 
toxicity. After the 3 hours of Pgal selection, instead of DNA isolation, the selections and 
controls were normalised to the same OD600 as the library selection culture (i.e. the culture 
containing either SGW+5 or Lib 1 in the presence of chloramphenicol, arabinose and Pgal) 
so that plated cultures would be comparable. 100 L aliquots of the selected day cultures 
were plated onto LB agar containing chloramphenicol and Xgal (80 g/mL) and arabinose, if 
the original cultures had been grown in its presence. Plates were placed at 37 ºC overnight. 
Selected hits were restreaked onto LB agar plus chloramphenicol, single colonies of which 
were used to inoculate overnight cultures for DNA isolation. 
2.2.3 CHAPTER 5: SCILOPPS II 
2.2.3.1 WORDCOUNT AND SEQUENCE ALIGNMENT 
The amino acid content of the Lib 1 liquid selection hit peptides was analysed using the 
online WordCount software (http://mobyle.pasteur.fr/cgi-bin/portal.py?#forms::wordcount), 
inputting the protein sequences and setting a word size of 1. The expected numbers present 
due to the GAFTGA motif were then removed from the raw data to produce the numbers 
found in the four randomised positions.  
Both DNA and protein sequences were aligned using the online Multalin software 
(http://multalin.toulouse.inra.fr/multalin/). Sequence alignment of PspF to 54-dependent 
activators was performed using NCBI Blast. 
2.2.3.2 KINETIC PLATE-BASED -GALACTOSIDASE ASSAY 
The principle behind the kinetic -galactosidase assay is essentially the same as for the 
traditional, cuvette based assay (2.1.12 -Galactosidase Activity Assays). The traditional -
galactosidase activity assay is performed on a relatively large-scale (1.7 mL total final 
volume) and the read-out is an end-point, measured in a cuvette. Whilst this method is 
robust, it does not allow for easy measurement of large numbers of samples in parallel. 
Thibodeau et al. reported the development of a kinetic 96-well plate version of the 
-galactosidase assay that gives results equivalent to the cuvette-based assay [211]. 
Equivalence is achieved through the calculation of three conversion factors which take into 
account the differences between absorbance measurements made in a plate and those in a 
cuvette and the addition of Na2CO3 in the cuvette assay which is not required in the kinetic 
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plate assay. Use of the plate-based assay not only allows measurement of multiple samples 
in parallel, but because it is kinetic results will always be taken when the enzyme activity is in 
its linear phase. 
2.2.3.2.1 CALCULATION OF THE CONVERSION FACTORS 
Conversion factor 1 (CF 1) converts the A420 measurements of ONP measured in a plate to 
those measured in a cuvette. To calculate CF 1 for a specific plate reader/ 
spectrophotometer pair, two times serial dilutions of ONP in Z-buffer (2 mg/ mL) were made 
up and the absorbance measured at 420 nm in both cuvette and plate reader. The values 
were plotted against one another and the gradient in the linear range is CF 1. 
Conversion factor 2 (CF 2) accounts for the difference in yellow colour seen due to the 
addition of Na2CO3 in the cuvette assay, but not in the plate assay. The plate assay does not 
require the addition of Na2CO3 to quench the reaction by raising the pH because it is a 
continuous kinetic assay and uses only the rate of reaction, V. To calculate CF 2, to 800 µL 
of each ONP serial dilution was added 333 µL Na2CO3 (1 M) and the absorbance was 
measured in a cuvette at 420 nm. These values were plotted against the OD420 values for 
ONP alone measured in a plate; the gradient of the slope is CF 2. 
Conversion factor 3 (CF 3) converts the OD600 measurement in a cuvette to that measured in 
a plate. The absorbance at 600 nm of two times serial dilutions of overnight bacterial 
cultures were measured in both cuvette and in plate and the values plotted against one 
another. The gradient of the slope is CF 3. 
2.2.3.2.2 PERFORMING THE ASSAY 
An overnight culture was prepared in 1 mL of LB containing appropriate antibiotic(s) in a 
sterile 96-well deep well plate (Corning, 2.2 mL). The plate was sealed with an Airpore Tape 
sheet (Qiagen) to seal each well and a sterile lid to minimise evaporation, and shaken 
overnight at 220 rpm at 37 ˚C. In the morning, 10 µL of overnight culture was transferred to a 
fresh deep-well plate containing 1 mL of LB antibiotic and sealed with an Airpore Tape 
sheet. The plates were shaken at 220 rpm at 37 ˚C to OD600 between 0.2 and 0.4. If 
required, the cultures were induced with either IPTG (1 mM), or L-arabinose (0.02% w/v) and 
grown for a further 3 hours. A final OD600 measurement was made by diluting the cultures to 
a final volume of 200 µL in a shallow, clear, flat-bottomed 96-well plate (Thermo Fisher 
Scientific). The measurement fell within the plate reader‟s linear range. A lysis mixture 
consisting of 10 µL 1x BugBuster® (BugBuster® 10x Protein Extraction Reagent, Novagen) in 
Z-buffer and 1 µL lysozyme at 4 u/µL (from chicken egg white, Sigma, 58100 u/mg) was 
prepared per 100 µL of cells to be lysed. In a shallow 96-well plate, 11 µL of lysis mixture 
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was added to 100 µL of cells (in triplicate for each subculture) and mixed by pipetting up and 
down gently. The lysing cells were left at 30 ˚C for 20 minutes to ensure complete lysis. 
15 µL of lysed cells were transferred to a fresh flat-bottomed, clear 96-well plate and to this 
was added 135 µL Z-buffer plus -mercaptoethanol (50 mM) and 30 µL ONPG (4 mg/mL in 
Z-buffer). Absorbance measurements at 420 nm were taken at 30 ˚C at 1 minute intervals for 
up to 45 minutes. Modified Miller Units were calculated using the following equation: 
, where, 
V = rate of the reaction (A420/min) A420 is absorbance at 420 nm; A600 = absorbance at 
600 nm; CF1 = conversion factor 1; CF2 = conversion factor 2; CF3 = conversion factor 3; 
cell lysate = relative volume of cell lysate used. 
Equation 2.3 Equation to calculate Modified Miller Units for -galactosidase activity in the kinetic, plate-
based assay. 
2.2.3.3 PLATE-BASED GROWTH CURVES 
Growth curves to test for escape from Pgal sensitivity were performed broadly as before 
(2.2.2.10 Growth Curves with Pgal), but in order to mimic the library selection, arabinose 
was added to the overnight cultures. This ensured that expressed peptide was present when 
Pgal was added. 
2.2.3.4 L-ARG GROWTH CURVES 
The growth of the L-arg cultures in 96-well plates was performed broadly as for previous 96-
well plate based growth experiments (2.2.2.10 Growth Curves with Pgal), but with several 
key differences. Cultures were grown overnight in rich media and in the presence of 
arabinose as before. However, in order to ensure no nitrogen-source carry-over, overnight, 
cultures were centrifuged for 10 minutes at 1.5 rcf and resuspended in the same volume of 
Gutnick minimal media without nitrogen source; this process was repeated a further two 
times. Subcultures for the day growths were then taken from these washed overnight 
cultures. Instead of M9 minimal media, the Gutnick recipe was followed simply because all 
previous work in the laboratory on ntrC strains had used this media. 
2.2.3.5 GROFIT ANALYSIS 
Analysis of the L-arg growth curves was performed using the add-on GroFit package[212] in 
the statistical analysis program R [213], which can be downloaded (http://www.r-
project.org/). 
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Data was imported into R from Microsoft Excel, where it was formatted into a numeric matrix 
of time versus OD600 and the standard GroFit workflow was executed (Run = grofit(time, 
data, FALSE)). This workflow applies the growth curve fitting to the matrix of time and data, 
but does not execute the dose-response curve fitting. The three replicates for each hit 
peptide or control were treated separately in GroFit and the output data averaged. Results 
were written into table form using the command “FileName <- summary (Run$gcFit)”. Data 
was exported back to Microsoft Excel for further analysis using the command “write.xls 
(Filename, C:/Filenameoutput.xls)” using the R package xlsReadWrite [214]. For an example 
command input workflow see Appendix 0 Table D.1 Sequences of Lib 1 hits from the single-
round liquid selection. 
E Example GroFit Input Commands. 
2.2.3.6 SOLID MEDIA GROWTH TESTS: ZONE OF INHIBITION AND HIT SPOTTING 
2.2.3.6.1 ZONE OF INHIBITION ASSAYS 
Zone of inhibition assays were performed on Gutnick minimal media plates containing 
chloramphenicol and 0.02% arabinose. To create a lawn of cells overnights of selected 
peptides and controls were normalised to an OD600 of 0.5/mL. 100 L of each culture was 
added to 3 mL of Gutnick T7 top agar and plated on top of the minimal media plates. Once 
the top agar had set, 1 L of either sterile H2O, 0.1%, 1% or 10% Pgal was spotted onto the 
plate. Plates were grown at 37 ºC. 
2.2.3.6.2 HIT SPOTTING 
Selected hits were spotted onto LB agar plates containing 1% Pgal (w/v). To make the 
plates, Pgal (2 mL, 10% (w/v)) was added to 18 mL of LB agar, also containing 0.02% 
arabinose and chloramphenicol. Control plates lacked Pgal to determine that a uniform 
number of cells was spotted, or contained Xgal (80 g/mL) in place of Pgal to determine lacZ 
activity. To perform the assay, overnight cultures of the selected hit peptides and controls 
were normalised to an OD600 of 0.5/mL. 10x serial dilutions of each were made and 2 L of 
each dilution was spotted onto 1% Pgal, Xgal or arabinose LB agar plates. 
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3 SYNTHETIC PEPTIDES AND DESIGN-LED APPROACHES 
This chapter describes approaches to investigating the interaction between 54 and PspF 
using linear synthetic peptides and linear peptides expressed as fusions to maltose binding 
protein (MBP). The interaction was investigated in vitro and in vivo, with the aim to develop 
an assay in which the interaction could be quantified. Firstly, the solid phase peptide 
synthesis (SPPS) of a potential positive control peptide, Fragment 4, was tackled. 
3.1 FRAGMENT 4 
As described in the Introduction (1.1.5 PspF Fragments 4 and 2), Fragment 4 (F4) is a 25 
amino acid peptide that contains the PspF Loop 1 sequence (Figure 3.1 B.). It was originally 
identified during a fragmentation approach as a fusion to maltose binding protein (MBP) 
which was able to interact with 54 bound to the S. meliloti early melted DNA probe [1]. As a 
fusion protein, F4 was demonstrated to be capable of forming a detectable interaction with 
54, and should therefore provide a positive control for the development of in vitro assays. 
Furthermore, if Fragment 4 is established as a positive control for either knockdown of the 
PspF1-275 interaction or for binding, further synthetic peptides can be investigated; possibly 
with conformational constraint introduced to make them more loop-like. 
This part of the project therefore has four broad aims. Firstly, to synthesise Fragment 4 by 
solid phase peptide synthesis (SPPS) and then to try to establish a facile in vitro assay 
which can be used to evaluate both its and other peptides‟ activities. Thirdly, to investigate 
the interaction in the existing in vitro transcription assays alongside the MBP-F4 fusion 
proteins and to try to characterise the strength of the interaction in vivo using isothermal 
titration calorimeter (ITC). Finally, this part of the work aims to characterise any inhibition of 
54 dependent activation of the pspAp promoter by the MBP-F4 fusions, with the ultimate 
aim of achieving inhibition with small synthetic peptides. In all cases, either the synthetic or 
cloned T86A mutant peptide, defective in target binding (1.1.4 Loop 1 and the GAFTGA 
Motif), should provide the negative control. 
3.1.1 INITIAL SYNTHESIS OF FRAGMENT 4 
Fragment 4 (Figure 3.1, B.) is a 25 amino acid, linear peptide and should be easily 
accessible through standard SPPS techniques. Initial syntheses of Fragment 4 used HBTU 
and DIPEA as coupling reagents and Fmoc protected amino acid monomers in a standard 
SPPS protocol. However, several attempts using this method failed, yielding major products 
which were approximately 96 and 233 daltons (Da) below the expected mass. As they do not 
appear to correspond directly to one or several missing amino acids it is difficult to be certain 
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which coupling stages were unsuccessful. Alternatively, the erroneous masses may be due 
to an incomplete deprotection in addition to missing amino acids, but it was not possible to 
account for these particular mass differences. 
The syntheses of two truncated versions of Fragment 4 were also attempted, PspF74-93 and 
PspF79-93. Previously, two other Loop 1-based peptides were successfully synthesised with 
sequences similar to the truncated Fragment 4s, however, as with the full length fragment, 
the major truncated products had masses 96 Da below the expected molecular weight. An 
additional consideration that given this peptide was to be utilised as a positive control for 
assay development, it should be easily available and in good yield. Therefore, an alternative 
approach was used. 
3.1.2 SYNTHESIS OF FRAGMENT 4 USING PSEUDOPROLINES 
Pseudoproline dipeptides are a backbone protecting group for use in peptide synthesis 
which can drastically enhance the successful yields of difficult or inaccessible sequences 
[215]. They consist of a proline-like oxazolidine derivation of either serine or threonine and a 
second, classically protected, amino acid of choice. The proline-like ring structure is acid 
labile, meaning that normal TFA deprotection conditions yield the unmodified serine and 
threonine (Figure 3.1, A.). 
Pseudoprolines are thought to reduce the propensity for self-association, on-bead 
aggregation and β-sheet formation by causing kinks in the chain due to the proline-like ring. 
Figure 3.1 Pseudoprolines and their use in the synthesis of PspF Fragment 4. A. Pseudoproline 
deprotection. The oxazolidine bonds in red on AA1-Gly- Ser(ψMe,Mepro)-AA4 are cleaved by TFA to reveal 
serine. B. The sequence of F4 is shown with the possible targets for pseudoproline replacements highlighted in 
blue. C. Fmoc-Asp(O
t
Bu)-Ser(ψMe,Mepro)-OH. D. Fmoc-Phe(O
t
Bu)-Thr(ψMe,Mepro)-OH. 
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Disruption of unwanted on-bead secondary structures results in increased solvation and 
coupling rates [215]. The sequence of Fragment 4 (Figure 3.1, B.) has one serine and one 
threonine present, meaning that two pseudoprolines could be introduced in the WT 
sequence, and one in the T86A sequence. The two pseudoprolines introduced replaced the 
aspartic acid and serine at positions 74 and 75 and the phenylalanine and threonine at 
positions 85 and 86, their structures are shown in Figure 3.1 C. and D. The pseudoprolines 
were incorporated into a standard Fmoc based solid phase peptide synthesis protocol and 
successfully yielded synthetic Fragment 4 for the first time. 
Figure 3.2 shows the RP-HPLC traces of purifications of Fragment 4 synthesised with and 
without pseudoprolines. Although the purifications were performed over slightly different 
timescales, it is clear that the synthesis with pseudoprolines gives a trace with significantly 
fewer peaks, in addition to giving Fragment 4 as the major product. The reduction in the 
number of peaks is most likely due to reduction in side product formation caused by 
incomplete coupling or deprotection steps during synthesis. 
3.1.3 CONCLUSIONS 
Initial syntheses of Fragment 4 were unsuccessful and produced products which were 
difficult to identify. However, the use of pseudoproline dipeptides allowed the chemical 
synthesis of Fragment 4 and Fragment 4 T86A for the first time. This suggests that the 
problems of the initial attempts related to on-bead aggregation leading to incomplete or low 
yielding coupling steps for difficult residues. Since this problem has now been overcome, all 
Fragment 4 mutants and derivatives should be available if required for testing. 
Figure 3.2 Overlaid RP-HPLC traces of purifications of Fragment 4 synthesised using standard amino 
acids (blue) and with FT and DS residues replaced by pseudoprolines (red). 
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3.2 DETECTING AN INTERACTION IN VITRO 
Several in vitro techniques have been extensively used to study the interaction of PspF and 
54, including gel filtration, full-length and abortive transcription assays and in trapping the 
PspF. 54 interaction using the ATP hydrolysis transition state analogue ADP.AlFx which 
captures PspF in a state just prior to ATP hydrolysis [216]. However, to routinely test 
peptides for interaction with 54, an assay is needed that is able to detect possibly weak 
interactions which might not withstand gel filtration or gel acrylamide based techniques. 
Furthermore, although the in vitro transcription assays are sensitive, it would be useful if 
radiolabelled nucleotides could be routinely avoided. 
3.2.1 TAGGING THE SYNTHETIC PEPTIDES WITH THE DANSYL ENVIRONMENTAL 
FLUOROPHORE 
Previously, the fragments were tagged in vivo as maltose binding protein (MBP) fusions [1, 
87]. This tag enabled the peptides to be visualised as they bound to 54 by the large shift in 
molecular weight, but also by immunoblotting. Furthermore the MBP tag allows purification 
of the peptides by column chromatography and ensures solubility [217]. However, MBP is a 
large tag, which may have a significant effect in altering the conditions around the binding 
interaction. It would therefore be optimal if a smaller tag could be used, which would provide 
real-time information about the binding interaction, if and when it occurs. 
The dansyl moiety is an environmental fluorophore when coupled to an amine, and has been 
used to study binding of peptides and proteins and protein folding extensively [218, 219]. 
Dansyl is affected by changes in the hydrophobicity of its environment; so that as binding 
into a hydrophobic pocket occurs, the emission spectrum of dansyl is altered. This 
fluorophore requires only the tagging of the peptide, so 54 can be left as WT, and should 
allow detection of interactions which have only a small mass change. In a hydrophilic 
environment, the dansyl group has a typical emission λMAX of 550 nm, but as the surrounding 
Figure 3.3 Dansyl chloride and tagging of synthetic peptides. A. The structure of dansyl chloride (5-
(dimethylamino)naphthalene-1-sulphonyl chloride)). B. Coupling of the dansyl group to the amino group of a 
peptide under basic conditions. 
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environment becomes more hydrophobic, the dipole moment alters the excited electronic 
state changing both the λMAX and peak intensity [220]. Dansyl chloride (Figure 3.3, A.) is the 
commercially available precursor, which is coupled to an amine under basic conditions in a 
facile reaction (Figure 3.3, B.) to become fluorescent [221]. Both F 4 and the F4 T86A 
variant were tagged with dansyl chloride in order to test for an interaction with σ54. 
3.2.2 PERFORMING THE ASSAY 
PEPTIDE SEQUENCE 
d-F4 d-NENLLDSELFHEAGAFTGAQKRHP 
d-F4 T86A d-NENLLDSELFHEAGAFAGAQKRHP 
d-Loop 1 d-GHEAGAFTGAQKRHPG 
Table 3.1 Sequences of peptides investigated using the dansyl-shift assay for binding to 
54
. 
As well as the dansylated Fragment 4 and its T86A mutant, a linear and dansylated version 
of Loop 1 was examined for interaction with 54; the sequence of each peptide is given in 
Table 3.1. In initial experiments the emission spectrum of 1 µM of dansylated F4 was 
measured at 25°C, before the addition of 54. After each addition, the emission spectrum 
was once again measured. As Figure 3.4, A. shows, the initial λmax of d-F4 was at 550 nm, 
and this remained unchanged with the addition of 1 M 54, however, the intensity of the 
fluorescence signal increases at least two-fold with the addition of 5 µM 54. Further 
increases in 54 concentration, up to 15 M, gave no further increase in the fluorescence 
intensity. There are small fluctuations within experimental error for these three 
concentrations but this phenomenon is most likely due to dilution effects or the introduction 
of glycerol via the 54 buffer system.  
Although there is a two-fold increase in fluorescence intensity, there is no alteration in the 
wavelength of λmax, which is usually associated with binding of dansylated peptides [219]. 
Since neither the buffer nor 54 alone gives increased fluorescence intensity, it appears that 
this change, albeit a seemingly modest one, is due to interaction between d-F4 and 54. To 
test whether the fluorescence intensity increase was peptide-dependent, d-F4 T86A was 
subjected to the same experimental procedure. If the peptide is binding as WT Loop 1 in 
PspF, mutation of T86 in the GAFTGA motif should be detrimental to peptide binding [87]. In 
WT PspF, mutation of T86 to alanine produces a protein defective for any currently 
detectable interaction with 54 and for activation of Eσ54CC in in vitro activity based assays [1, 
87]. It is therefore likely that if the interaction observed between F4 and 54 is specific, the 
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corresponding experiment with F4 T86A will either show no interaction, or it will be greatly 
reduced compared to the WT peptide. 
Figure 3.4, B. shows that as 54 is titrated into d-F4 T86A, there is no increase in 
fluorescence intensity. This data supports the conjecture that F4 is binding as WT PspF and 
that mutation of T86 to alanine abolishes that interaction. However, since the peptide 3-
dimensional structure is completely unknown, alteration of the sequence may also result in a 
grossly altered structure which is unable to bind. Using this assay alone, it would not be 
possible to distinguish between these two scenarios, but alternative approaches such as 
NMR could confirm the peptide structure. Finally, another peptide, Loop 1, which is a 
shortened version of d-F4, was submitted to the same assay. Figure 3.4, C. shows that Loop 
1 performs as d-F4 T86A, with no increase in fluorescence intensity as 54 is added. 
Although the increases in fluorescence intensity are modest, initial results in this assay are 
encouraging. It appears that there is a quantifiable signal which is relatable to presence and 
quantity of 54. However, the technique has several drawbacks with regards to this system in 
addition to the lack of decrease in the wavelength of λmax, repeats of the experiment at 25°C, 
however, revealed that the method suffered from reproducibility issues. In some cases, the 
previous pattern was repeated, but on other occasions no increase in λmax was observed 
using the same experimental protocol and materials as previously. Various aspects of the 
assay were investigated to see what might be the cause of the problem. It was conjectured 
that the samples had not always equilibrated when the spectrum was measured. The length 
of time after protein addition and before measurement was extended to ensure that all 
possible binding interactions had formed, but this did not have any effect on reliability or on 
the previously observed shift in λmax intensity or position. The concentration of the dansylated 
peptide was increased to try to see a larger shift, and finally the buffers were filtered using a 
45 µM cellulose membrane to exclude the possibility that particles were interfering with 
binding. The lack of reliability might be due to instability in 54, but this has not been 
observed over a similar time-frame for other in vitro assays involving the protein. None of the 
simple measures was able to improve the reliability of the assay, which makes this 
experimental system unsuitable for routinely studying the interactions between peptides and 
54. 
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Figure 3.4 Emission spectra of 1 M dansylated peptides with 
54
. The emission spectra of 
54
 alone and buffer plus 
H2O are shown in blue. A. Emission spectra of 1 µM d-F4 plus increasing concentration of 
54
. d-F4 alone has λmax at 
550 nm. As the concentration of σ
54
 increases, fluorescence intensity increases, but λmax does not change. B. Emission 
spectra of 1 µM d-F4 T86A plus increasing concentration of 
54
. In the presence of 
54
 there is no increase in the 
fluorescence intensity. C. d-Loop 1 behaves as the d-F4 T86A control, except that the peptide maximum fluorescence 
intensity is slightly higher. 
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3.2.3 CONCLUSIONS 
Although certain aspects of these data are very encouraging, there are also certain facets 
that are difficult to rationalise. One is the lack of change in position of λmax even when an 
increase in intensity is observed; the other is the unreliability of the assay. If it is assumed 
that the positive results do suggest that the peptide is binding, one possible explanation is 
that they are both linked to the position of the dansyl group in the bound complex. The 
peptides are N-terminally dansylated, but the binding determinant GAFTGA motif is located 
toward the peptide C-terminal. It could therefore be possible that when the peptide binds 54, 
the environment of the dansyl group is changed slightly, in that it is close to 54, but it is not 
located within a hydrophobic pocket itself. In this situation it could be that in certain 
orientations the dansyl group is in a partially hydrophobic environment, and that in some it is 
still solvent exposed. If this is the cause, changing the position of the dansyl group, e.g. 
tagging an amino acid side-chain closer to the GAFTGA motif, might improve the assay 
reliability. However, since other solution-based techniques are available, the most sensible 
option is to try an alternative method which would not require alteration of the peptide to see 
a consistent interaction. 
3.3 FULL-LENGTH AND ABORTIVE TRANSCRIPTION ASSAYS 
Binding of 54 with Fragment 4 has thus far only been observed by gel electrophoresis using 
radio-labelled DNA to give a ternary complex, whilst a binary complex of only PspF1-275 and 
54 is unable to survive. [87]. Using radiolabelled DNA increases sensitivity by allowing even 
small numbers of complexes to be quantified, but an activity-based assay might be a more 
robust and sensitive measure of interaction between Fragment 4 and 54. One possible 
appropriate assay is an in vitro transcription assay, which is a basic measure of the number 
of open complexes able formed by E 54 in the presence of promoter DNA and PspF1-275. 
Figure 3.5 shows the basic outline of in vitro abortive and full-length transcription activity 
assays which have been modified to try to measure the inhibitory effect of MBP-Fragment 4. 
In the standard protocol, E 54 is allowed to form a complex with promoter DNA, before 
addition of PspF1-275. If PspF1-275 is able to remodel E
54 as it hydrolyses ATP, the promoter 
DNA will be melted and addition of an elongation mix, which contains radiolabelled 
nucleotide, will result in formation of a labelled RNA transcript. The principle difference 
between abortive and full-length assays is the length of transcript produced by E 54OC. For 
abortive assays, the elongation mix contains only a limited number of nucleotides able to 
form a short transcript on the promoter DNA. In full-length assays, a full complement of 
NTPs are available so that WT formed open complexes are able to produce longer 
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transcripts. Since the produced transcripts are radiolabelled, gel electrophoresis enables 
quantification of the separated bands, which is a direct measure of E 54RPOC activity. 
To test the inhibitory effects of MBP-Fragment 4, a complex between Eσ54 and varying 
concentrations of fragment was allowed to form before promoter DNA was added. 
Concentrations of inhibitory fragment were relative to the concentration of PspF1-275 at 5 M 
(PspF: MBP-Fragment ratios of 1:1, 1:2, 1:4 and 1:6). After 5 minutes, PspF1-275 was added 
and the mixture left for a further 5 minutes to form the open complex before the elongation 
mixture containing 32P-labelled- and unlabelled-nucleotide triphosphate was added. After 20 
minutes the reactions were stopped and run on a sequencing gel. 
The MBP-fusion and synthetic fragments were also tested to see if they could form a trapped 
complex with the transition state analogue ADP.AlFx. ADP.AlFX has a planar conformation 
that mimics the transition state of ATP hydrolysis [222]. It has been used extensively with 
PspF1-275 [43, 74, 84, 223] where it allows the formation of a „trapped‟ complex between 
PspF and 54, that can be visualised by native gel electrophoresis. 
Figure 3.5 Cartoon showing basic protocol of a full-length or abortive transcription assay. The MBP-
Fragment is first allowed to equilibrate with E
54
 before the DNA is added. The E
54
.MBP-Fragment is competed 
out with PspF1-275, before the elongation mix is added. Only ATP hydrolysis by PspF1-275 bound to E
54
 results in 
remodelling of promoter DNA. Radiolabelled nucleotide in the elongation mix results in labelled RNA which can 
be visualised and quantified on a sequencing gel. Competition for E
54
 by MBP-F4 should result in reduced open 
complex and therefore RNA product. All steps are performed at 37°C. 
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In this experiment, the fragments were incubated with 54 in the presence of ADP.AlFx, with 
a trapped complex observable as a separate band to 54 alone by native gel electrophoresis. 
They were also tested for the ability to activate full-length transcription in the absence of 
PspF1-275, and as expected, no trapped complexes or transcripts were observed (Figure 3.6 
lane E 54CC) 
3.3.1 FULL-LENGTH TRANSCRIPTION INHIBITION BY MBP-FRAGMENT 4 
Full length transcription was performed with increasing ratios of MBP-Fragment 4 to PspF1-
275 and using supercoiled DNA as a template. As shown in Figure 3.6 B., the number of full-
length transcripts appears to decrease with increasing ratio of MBP-Fragment 4 to PspF1-275. 
The gel (Figure 3.6 A.) also clearly shows a reduction in the number of transcripts. This 
suggests that MBP-Fragment 4 is capable of making an interaction with 54 and is not 
entirely competed out by PspF1-275. Testing whether the abortive product is also diminished 
by the presence of MBP-Fragment 4 should confirm these results. 
Figure 3.6 Full length transcription competition assay with MBP-F4 and MBP-F2. E
54
OC represents 
unchallenged activation by PspF alone. E
54
CC represents no activator (PspF1-275) addition. Ratios given 
are for PspF:MBP-Fragment A. Full length transcripts from MBP-F4 inhibition assay. B. Quantification of the 
MBP-F4 gel spots. The amount of full-length transcript decreases with increasing amount of MBP-F4. C. Full-
length transcripts from MBP-F2 inhibition assay. D. Quantification of gel spots for MBP-F2. Increasing amounts of 
MBP-F2 do not decrease the amount of full-length transcript relative to E
54
OC. MBP-F2 T86A also fails to inhibit 
transcription. 
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The alternative, slightly longer PspF fragment, MBP-F2 and its T86A mutant were also 
tested for inhibition of full-length transcription. MBP-F2 was previously shown not to be able 
to form the same stable complex with 54, but was able to inhibit PspF1-275 oligomerisation 
and PspF1-275 dependent 
54.DNA isomerisation [87]. In this assay, no effect of MBP-F2 was 
visible (Figure 3.6 A. and B.) which is unexpected. However, ability of the fragment to effect 
both PspF1-275 oligomerisation and DNA isomerisation can be explained by considering the 
order of addition. In this assay, PspF is added as a hexamer and this oligomer is able to 
compete out MBP-F2 which is unable to form the same stable complex with 54. The MBP-
F2 and MBP-F2 T86A data do demonstrate that the trend seen in the MBP-F4 case is not 
due to non-specific MBP binding. The MBP-F4 and MBP-F2 fusion proteins used in this 
assay were purified by Dr Patricia Burrows. 
3.3.2 ABORTIVE TRANSCRIPTION INHIBITION BY MBP- AND SYNTHETIC- 
FRAGMENT 4 
Abortive assays were performed with both MBP- and synthetic- F4 (un-tagged) in order to 
see if there was any difference in the activity, and to rule out the possibility that the MBP-
fusion itself might contribute to the binding of Fragment 4 to 54 by exclusion of solvent from 
the protein-protein interface. As before the PspF was challenged in ratios of PspF: Fragment 
Figure 3.7 Inhibition of abortive transcription on the early melted DNA probe by MBP-F4 and synthetic F4. 
E
54
OC represents uninhibited activation by PspF alone. Ratios given are for PspF:Fragment. 
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of 1:1, 1:2, 1:4 and 1:6). In both cases, the fragments were incubated with E 54 for 5 minutes 
before the addition of PspF1-275, and a nifH late-melted promoter probe was used (see 
Appendix A Transcription Assay). This probe has a base mismatch which causes it to be 
partially stably opened, which in turn may promote stability of a Fragment.E 54.promoter 
complex. However, the results (shown in Figure 3.7) appear inconclusive, despite apparent 
differences between the MBP-fusion and synthetic Fragment 4s. For MBP-F4 (in red) there 
is a decrease in the incorporation of 32P-labelled nucleotide relative to E 54 activated by 
PspF, but some decrease is also observable for the MBP-F4 T86A suggesting that the 
integrity of the GAFTGA motif is not required for inhibition, despite its requirement for 
successful 54-dependent activation [87]. 
The level of abortive product is higher for all the synthetic F4 ratios (blue), and does not 
appear significantly different from the uninhibited sample. In this case, the synthetic F4 T86A 
behaves almost identically to both unchallenged E 54, and to synthetic F4. This may indicate 
that binding of F4 to 54 is aided by the presence of MBP, either by influencing conformation, 
or by excluding solvent from the protein-protein interface. 
3.3.3 CONCLUSIONS 
As expected, the fragments cannot trap 54 in the presence of ADP.AlFx or activate full-
length or abortive transcription. Full-length and abortive transcription assays indicate that 
MBP-F4 is an inhibitor of the PspF1-275-
54 interaction, but results are not conclusive in the 
case of synthetic F4. 
The full-length transcription results fit well with the existing data on MBP –F4 and –F2. A 
lowering in the amount of transcript was observed in the presence of MBP-F4 but not MBP-
F2. Although MBP-F2 has previously been shown to inhibit nucleotide-dependent PspF1-275  
oligomerisation and subsequently full-length transcription, the activity was dependent on the 
order of addition. Only pre-incubation of MBP-F2 with PspF1-275 resulted in inhibition of 
transcription; and these affects were drastically reduced for the mutants T86A and T86S 
[194]. In these previous experiments, MBP-F4 was unable to inhibit PspF1-275 oligomerisation 
and was not explored for its ability to inhibit transcription. However, in these experiments, 
both full-length and abortive transcription assays, a decrease in the number of transcripts 
was seen in the presence of MBP-F4. In the abortive assay, the MBP-F4 T86A mutant also 
shows a small decrease in the number of transcripts, suggesting that the integrity of the 
GAFTGA T86 may not be critical to the binding of the fragment to E 54CC in order to prevent 
binding of PspF1-275. 
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The effect of synthetic F4 and F4T86A was also examined in the abortive assay. In this 
case, the synthetic peptide F4 does not perform as well as the MBP-bound equivalent, 
although some small drop in transcripts is seen. This difference could be attributable to 
conformational differences between synthetic peptide and the fused version due the 
presence of MBP. This highlights one drawback of fused-peptide selection: the activities not 
always entirely retained when synthetic versions are tested  
In order to determine if synthetic F4 is binding to 54 and to characterise the fragment- 54 
interaction strength, an alternative method should be used to determine the Kd. Once the 
dissociation constant is known, further transcription assays could be performed, in which the 
concentration of the peptide present is of a level known to cause an effect. Once the basis of 
the assay is established, various promoter probes could be investigated, to see if they have 
an effect on fragment – 54 complex stability. 
3.4 ISOTHERMAL TITRATION CALORIMETRY SHOWS BINDING OF F4 TO 
54
 
Isothermal titration Calorimetry (ITC) is a thermodynamic technique that directly measures 
the heat change associated with binding events. The technique can allow accurate 
determination of binding constants (KB), reaction stoichiometry (n), enthalpy (ΔH), entropy 
(ΔS) and can elucidate the interaction mechanism. Although other solution phase binding 
methods are available, such as surface plasmon resonance, ITC is experimentally simple to 
set up and optimise. A single ITC experiment is performed by titrating the ligand into a 
solution of its binding partner, measuring the heat change associated with each injection, 
and plotting successive heats against the ligand/ binding partner ratio to plot a binding curve. 
Because it measures the strength of an interaction directly and in solution, ITC may be an 
ideal method for studying the F4. 54 interaction. Since Fragment 4, the initial ligand, 
consists only of a small fraction of PspF and is completely unconstrained, it can be assumed 
that the interaction will be weaker than that between 54 and PspF. Because ITC is also 
suitable for studying weak interactions, it is a good technique to begin studying the 
interaction with, since ligand and protein concentrations can be increased to optimise the 
signal to noise ratio. 
3.4.1 PLANNING AND ANALYSIS 
Both Fragment 4 and 54 were buffered using phosphate buffer; which was chosen because 
it has a low heat of ionisation (ΔHion = 0.9 kcal/mol), compared to the Tris buffer usually used 
for σ54 (ΔHion = 11.4 kcal/mol) [224]. 
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Cryo EM data suggest that more than one PspF1-275 loop 1 interacts with 
54 [3], but the 
exact number and nature of the binding sites is uncertain. It may be that all binding sites are 
equal and that loop1 has equal affinity for all. However, it is also likely that the binding of the 
first loop 1 has a positive allosteric effect on subsequent binding interactions; meaning that 
not all binding affinities are equal. Initial ITC data (Figure 3.8) were fitted to a „One Sites‟ 
model which represents all binding sites being equal. The data suggest that there is a 
binding interaction between Fragment 4 and 54, with an approximate Kd of 10 µM and a 
stoichiometry of 2.29. In this experiment, 54 was present at 100 µM and the heat change 
observed was small. Future follow-up experiments will require the concentrations of both 
protein and ligand to be increased so that a larger signal to noise ratio is achieved. Despite 
the small signal size, the binding curve is well-defined, and should be open to optimisation. 
The main disadvantage with ITC is the amount of material required for one experiment. 
Since the Fragment 4. 54 binding interaction is relatively weak a high concentration of 54 is 
required, with each experiment using approximately 8 mg of protein and 1 mg of peptide. If 
subsequent experiments confirm the peptide. 54 interaction, it would be interesting to see 
the effect of the presence of E 54 or promoter DNA on binding. However, the amount of 
material required might make this prohibitively expensive. 
A general problem with using small, untagged peptides is that accurate determination of 
concentration is difficult. Although the peptides are thoroughly lyophilised before use, 
comparison of mass-determined concentrations with tag-absorption determined 
concentrations (e.g. dansyl tagged peptides) suggests that the peptides still contain a 
significant mass of water. Since we need to know the concentrations accurately to produce a 
binding curve and determine Kd, we can assume that our binding constants contain an error 
and that specifically the stoichiometry measurement of 2.29 may be incorrect. One way of 
reducing this would be to use a dansyl-tagged peptide, as the concentration of this may be 
determined accurately using the dansyl molar absorbtivity coefficient (εDansyl = 4300 M
-1cm-1) 
at 330 nm. 
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3.5 DETECTING THE EFFECTS OF INTERACTION IN VIVO 
Previously, interactions between the MBP-fusions of Fragments 2 and 4, and the mutations 
thereof, were assayed in vitro and analysed by gel electrophoresis [1, 87]. In this work, a 
more biochemical approach has been used to try and study the interaction using synthetic 
Fragment 4 in vitro. However, it was decided to also try to observe the interaction in vivo, 
Figure 3.8 Binding curve derived from ITC experiment. A one sites model has been used to fit the data to a 
binding curve which gives a stoichiometry of 2.29 and Kd
obs
 of 10 µM. The data has not been corrected for heats of 
dilution. 
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since long-term plans include introduction of the synthetic peptides into the cell to monitor 
their effects. Future work may also include the screening of a peptide library in vivo, so it is 
important to demonstrate that disruption of the interaction is discernible above that of the 
cell‟s background. 
3.5.1 THE -GALACTOSIDASE ASSAY 
The enzyme -galactosidase is encoded by the lacZ gene of the lac operon in E. coli and 
functions to cleave lactose to glucose and galactose for use as carbon and energy sources. 
The colourless lactose analogue, o-nitrophenyl-β-D-galactoside (ONPG) is also a substrate 
for the enzyme, and when cleaved yields galactoside and o-nitrophenol, which has a yellow 
colour at cellular pH. The production of o-nitrophenol, and by extension, the yellow colour, 
per unit time in a reaction is proportional to the amount of enzyme present. This can be used 
as an output of a promoter‟s activity, where the promoter of interest is fused to the lacZ gene 
[225]. 
3.5.1.1 INITIAL METHODOLOGY 
A fusion of the pspA promoter to the reporter gene lacZ should allow a read out that 
correlates -galactosidase activity to 54-dependent transcriptional activation. Since the 
transcription assay showed that the MBP-fragments are unable to activate transcription, the 
only possible read-out is a knock-down (i.e. inhibition) of transcription. Therefore, a 
„stressed‟ system in which transcription is continuously „on‟ will have to be used. There are 
two ways of achieving a state in which psp is permanently in an „on‟ state: through the use of 
a ∆pspA strain, or expression of the pIV filamentous protein (1.1.2.1 The PSP Response). 
The pMBP-c2: parallel plasmid, which the fragments have been cloned into, is derived from 
the MBP pMAL-c2 backbone plasmid, which has ampicillin resistance [226]. An ideal cell 
strain would have a chromosomal lacZ fusion, but unfortunately, existing suitable cell strains 
also have ampicillin selection, so they are incompatible for use with the MBP-fusions. In 
order to avoid selecting for two conditions with one marker, it was decided to use the pSJ1 
Figure 3.9 Hydrolysis of o-nitrophenyl-β-D-galactoside to galactoside and o-nitrophenol, which is 
yellow at cellular pH. 
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plasmid (TetR), which contains a pspAp-lacZ fusion, either in a ΔpspA strain, or with the 
addition of the pIV secretin protein on an additional plasmid. 
3.5.1.2 USING THE FILAMENTOUS PHAGE PIV TO INDUCE THE PSP RESPONSE 
Initially, work focused on using the pIV secretin in order to stress the system and activate 
transcription of the psp operon. This involved a triple transformation in WT E. coli strain 
MG1655, completed in stages. -galactosidase assays were performed for all fragments 
which had been transformed with pSJ1 and pGJ4, which is a plasmid harbouring the 
filamentous phage protein pIV, and for the fragments transformed with the pSJ1 reporter 
construct only. 
The observed β-galactosidase activity for strains containing both the pSJI reporter construct 
and pGJ4 plasmids, or pSJI alone is similarly high at around 1800 Miller Units (Figure 3.10 
MG1655) and it appears that induction of pIV does not increase the -galactosidase activity 
from the reporter under these conditions. In cultures containing any MBP-fragment fusion the 
baseline -galactosidase activity is much reduced (Figure 3.10 – pIV, blue columns) and 
activity is increased approximately threefold with the addition of pIV (Figure 3.10 + pIV, red 
Figure 3.10 Graph showing difference in β-galactosidase activity using pIV to induce stress in MG1655 
containing the pspAp-lacZ reporter construct PSJ1. Data are given for MG1655 containing the reporter 
construct and fusion fragments alone (in blue) and with the addition and induction of pIV (in red). The levels of β-
galactosidase activity are high with and without the pIV plasmid. The presence of pIV does increase -
galactosidase activity, but levels are low relative to the strain lacking any MBP-fragment. Differences between -
galactosidase activity levels between the fragments are not large. 
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columns). Since there is no observable difference between the activities of the WT MBP-F4 
and F2 and the mutants (T86A/ T86S) it is likely that the reduction in -galactosidase activity 
is attributable to the extra strain placed on the cell by expression of the MBP-fragment 
fusions, and the requirements of maintaining an extra plasmid under continuous selection 
conditions. Expression of the MBP-fusions was confirmed by SDS-PAGE (not shown) and 
confirmed approximately equal expression by Coomassie staining. However, in either the 
presence or absence of pIV, expression of any of the MBP-fusions does not appear to 
reduce -galactosidase activity.  
It was decided to amend the system to ease the competition between plasmids for 
replication and expression; the pIV plasmid was excluded and a strain used which is 
naturally in an „on‟ state.  
3.5.1.3 USING A ΔPSPA STRAIN 
The strain K-12 MG1655 ΔpspA does not contain a chromosomally encoded PspA; meaning 
that PspF activated transcription is continuously on (1.1.2.1 The PSP Response). As before, 
the chromosomal lacZ fusion was not used because of overlapping antibiotic resistance with 
the pMBP-fragment plasmids. Therefore, MG1655 ΔpspA was transformed first with pSJ1, 
and then with the MBP-fragment fusion plasmids. Initial attempts to transform the MBP-F2, -
F286A and -F286S were unsuccessful, so it was decided to test the system using MBP-F4, -
F486A and –F486S before pursuing the other fusions. 
Figure 3.11 shows the results of three separate repeats of the -galactosidase activity 
assay, each of which is in turn performed in triplicate. One problem with the assay in its 
current set-up is the induction of the native lac operon by the presence of IPTG used to 
induce protein expression of the MBP-fragment fusions. Addition of the pSJ1 reporter 
plasmid does not give a significant increase in -galactosidase activity over this background 
activity. 
In one instance (Figure 3.11, Experiment 3) expression of MBP-F4 appears to nearly abolish 
-galactosidase activity whilst expression of the other fusions or no fusion give high -
galactosidase activity. However, this experiment alone seems difficult to rely upon, since 
background lacZ activity should be unaffected by the fragment and should have some 
residual level. Repeats of the assay give varying results, with some knockdown when MBP-
F4 is expressed, but not for the other fragment controls. It is likely that for Experiments 1 and 
2, where a small knockdown in the presence of MBP-F4 is observable, that the full effect of 
the fragment may be masked by the native lac activity. Because IPTG is not metabolised by 
E. coli, its concentration remains constant and there should be a constant activity from the 
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native lac operon, so any knockdown should be from the 54-dependent activation of pspAp-
lacZ. 
Another source of variation in the results might be due to the use of the pspAp-lacZ reporter 
construct pSJ1. Although SDS-PAGE confirmed that protein expression levels were similar, 
it is still not possible to say how many copies of the pSJI plasmid are present in each culture. 
Differences in pSJ1 copy number may cause differences between transformants carrying the 
same plasmids, and could be responsible for the variation in basal level of -galactosidase 
activity from pspAp-lacZ (Figure 3.11 pSJ1 +IPTG). 
To solve these issues, a better experimental set-up would use a chromosomal pspAp-lacZ 
fusion, and introduce only the MBP-fragment by plasmid. Although expression levels 
between proteins may differ slightly, this can be checked and should be within a closer range 
if only one plasmid is being expressed. In order to use the existing strains containing a 
chromosomal fusion, the fragments must be sub-cloned into a different vector. 
  
Figure 3.11 Graph showing differences in β-galactosidase activity between cultures of strain MG1655 
ΔpspA containing MBP-Fragments. However, the results are inconsistent, and this may be due to differences 
in copy number of the pSJI lacZ fusion plasmid. 
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3.5.1.4 SUBCLONING THE FRAGMENTS INTO PBAD 
The pMBP-fragment vectors have an ampicillin resistance gene which makes them 
unsuitable for use with the E. coli strains with chromosomal lacZ fusions currently available 
in our lab, since they also have an ampicillin marker. This led to the use of a second vector 
which carried the pspAp-lacZ fusion in order to perform β-galactosidase assays, and a third 
vector was added when a ΔpspA strain was not used in order to activate the psp response. 
These approaches had several problems which were inherent in the experimental design, 
and in order to eliminate them it was decided to sub-clone the fragments into a vector 
system that would allow the use of a strain with chromosomal lacZ fusion. 
One problem with the previous experimental set up was that the use of multiple plasmids 
increases the chances of variation in copy numbers of plasmids between experiments. This 
would lead to variations in results between technical repeats of the same day culture and to 
uncertainty about the cause of variations between different samples. 
The pBAD vectors are a family of plasmids that allow genes to be placed under the control of 
an arabinose-dependent promoter, PBAD, which allows tight regulation of its associated 
genes as well as modulation of expression levels and the possibility of repression by glucose 
[197]. Furthermore, the PBAD promoter has fast induction times and can result in high 
expression levels [197]. Both the lack of leaky expression and the capacity for modulation of 
induction are useful properties for the study of fragment inhibition. It is desirable to avoid any 
expression in the negative controls, since we may not wish to use high levels of expression 
in the „on‟ states in order to avoid unwanted side effects caused by over-expression. If an 
effect due to the fragments is seen it will be desirable to observe whether the effect 
increases with fragment expression levels. For these reasons, pBAD was chosen as a 
suitable expression system for the study of the fragments in vivo, and the array of vectors 
available meant that a suitable marker could be chosen. 
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3.5.1.4.1 THE FRAGMENTS IN PBAD28 
The pBAD vector pBAD28, which has both chloramphenicol and ampicillin resistance, was 
chosen as the initial target vector for the subcloning. Primers were designed to include a 
suitable restriction site at either end of the PCR amplified product and Shine-Dalgarno 
sequence, in addition to the start of the template strand and complement of the non-template 
strand. The Shine-Dalgarno sequence, which codes for the ribosomal binding site [227] is 
not included in pBAD28 [197] and must be cloned in to ensure translation occurs. Existing 
constructs containing PspF1-275 or MBP-Fragments plus mutants, were used as DNA 
templates for PCR reactions; the resulting products were digested with XbaI and HindIII 
endonucleases and ligated into pBAD28. 
The fragments alone, F4/ 86A, were also cloned into pBAD28, in addition to the MBP fusions 
of the fragments, in order to try to see any effect of the MBP tag. Due to the small size of the 
fragments alone, the MBP tag is still required to be able to visualize and quantify the protein 
expression levels (see Figure 3.12, B. lower panel). PspF1-275 was also cloned in to pBAD28, 
to compare behaviour of PspF with that of the fragments. Expression of PspF1-275 should not 
alter the -galactosidase level, but provides a control which examines the effect of general 
protein expression on the assay. 
Cloning the fragments into pBAD, allows the use of the reporter strain MVA27. MVA27 lacks 
the PspF negative regulator PspA, and contains a chromosomal fusion of the pspAp 
promoter to lacZ. Therefore, whilst -galactosidase activity is constitutively „on‟, activity 
should come from the lacZ fusion and not background induction of the native lac operon by 
IPTG. 
3.5.1.4.1.1 VARYING THE INDUCTION TIME 
Figure 3.12, A. shows the results of -galactosidase activity assays expressing the 
fragments from pBAD28, with induction at varying times. Cultures were either induced for 
1 hour after reaching an OD600 of 0.4, overnight at the start of culture growth (12-14 hours 
total growth) or for 4 hours with induction at the point of subculture from an uninduced 
overnight culture. When cultures are induced at an OD600 of 0.4, the expression of MBP-F4 
does not decrease -galactosidase activity. Equally, expression of F4 and MBP alone gives 
-galactosidase activities close to that of the vector pBAD28 alone. Expression of PspA 
however, reduces the -galactosidase activity from approximately 2000 units to around 400. 
That this control has the expected activity supports the proposal that the pspAp-lacZ fusion 
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is suitable reporter for native psp gene regulation despite the unexpected results for the 
fragments. 
To maximise the possible effects of expression of the fragments, cultures which were 
induced overnight were assayed (12-14 hours growth, 37 ºC). In general, the overall amount 
of -galactosidase is reduced, except for the culture expressing PspA. In this case it appears 
that extended over-expression of PspA relieves its inhibitory effect, which can probably be 
attributed to a likely change in the aggregation state beyond the active form needed for 
repression of PspF as it is overexpressed. 
However, neither overnight expression of MBP-F4 or F4 gives detectible inhibition of the 
pspAp promoter. To further test the effects of induction time, the cultures were assayed after 
induction at the start of the day culture (4 hours total growth, 37 ºC). This approach 
reinstates the inhibitory effect of PspA whilst giving the maximum -galactosidase activity 
levels. In general this seems to increase the error values between replicates, but does not 
expose any changes in -galactosidase level due to expression of F4. 
For the fusions with MBP tags, it was possible to verify that protein expression was occurring 
by performing Western blots. Figure 3.12, B. shows that colonies containing MBP and MBP-
F4 express a detectable amount of fusion protein in the presence of arabinose, but that no 
leaky expression is perceivable in its absence. 
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3.5.1.4.1.2 USING AN ALTERNATIVE REPORTER STRAIN 
In assays where the -galactosidase activity is very high, such as those in the pspA 
reporter strain MVA27, it might be possible that a lack of sensitivity masks the effect of either 
F4 or MBP-F4. Therefore, a derivation of the reporter strain was made which lacks the gene 
Figure 3.12 -Galactosidase activity assays in pBAD vectors expressing MBP-F4 and controls and 
determination of expression. A. Expression of MBP-F4 fusion and controls in -galactosidase reporter strain 
MVA27. Depending on the time of induction, activity levels are varied, but do not conclusively show knockdown 
by expression of MBP-F4. B. Expression of MBP-F4 from pBAD18 is detectable by 12.5% SDS PAGE and 
Western blot and is not leaky. Recomb. MBP-F4 is purified MBP-F4. C. Newly created reporter strain LJR01 has 
a knockout of himA which results in reduced -galactosidase activity. Performing -galactosidase assays in this 
strain reduces the experimental errors. D. Expression of the fragment from alternative pBAD vector pBAD18 
does not show knockdown in -galactosidase activity dependent on expression of MBP-F4. 
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himA. himA encodes for the  subunit of the integration host factor (IHF) which is involved in 
the DNA bending required for PspF to contact 54 (1.1.1 70 and 54 Dependent Transcription 
Initiation) [228, 229]. Removal of himA does not eliminate PspF activation of 54, but should 
reduce the quantity of -galactosidase activity from the pspA-lacZ fusion. The new reporter 
strain was made using a P1vir transduction and was confirmed by -galactosidase activity 
assay and colony PCR using primers designed to anneal 50 bps either side of the himA 
position. 
Figure 3.12, C. shows the activity of the himA strain, LJR01, which is much reduced 
compared to the parental reporter strain MVA27. To test the effect of MBP-F4, the pBAD28 
vectors containing the fusions were transformed and assayed following the standard 
experimental procedure, with induction at an OD600 of 0.4. Figure 3.12, C. shows the results 
of the key fusions MBP and MBP-F4, and shows that no difference is demonstrable between 
either of those and the control PspF1-275. However, what is clear, is that reduction in -
galactosidase activity level by removal of himA has greatly reduced the errors previously 
seen between replicates, and has increased the reliability of the assay. 
3.5.1.4.2 AN ALTERNATIVE PBAD: PBAD18 
Finally, to test the effects of plasmid copy number, the fragments were also cloned into the 
alternative pBAD vector, pBAD18 which has a slightly higher copy number than pBAD28 
[197]. The subcloned fragments were again tested in the LJR01 reporter strain and the 
results are shown in Figure 3.12, D. In this case, expression of PspA is again able to vastly 
reduce -galactosidase activity level, but expression of MBP-F4 also slightly reduces the 
level compared to the pBAD18 and MBP alone controls. Although the difference is only 
small, this result mirrors the results of the pBAD28 constructs in LJR01 and suggests 
expression of MBP-F4 does have some effect but that the experimental setup needs further 
refinement in order to amplify the effect. 
3.5.1.5 CONCLUSIONS 
Initially, the methodology chosen to investigate the activity of F4 and MBP-F4 in vivo was 
sub-optimal. The reporter strain had a native lac operon which was induced by IPTG, and 
the fusions were in a construct that was incompatible with existing pspAp-lacZ reporter 
fusion and the whole system required activation by induction of pIV. When the system was 
slightly altered to incorporate a pspA strain, only 2 plasmids were required and some 
reduction in -galactosidase activity was seen with expression of MBP-F4. However, there 
was large variability between experimental repeats. 
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Subcloning the fragments into pBAD28 allowed the use of the reporter strain MVA27, which 
has a chromosomal fusion of the pspAp promoter to lacZ. However, despite performing the 
assay under 3 different induction conditions, it was not possible to find consistent results in 
which MBP-F4 knocked-down -galactosidase activity. To reduce the high level of -
galactosidase activity, a second reporter strain which also had a knockout of himA was 
created and this gave a lower -galactosidase baseline and lower experimental errors 
between replicates. Additionally, a small decrease in -galactosidase activity in the presence 
of MBP-F4 was observed. Finally, subcloning the fragments into an alternative pBAD vector, 
pBAD18, produced -galactosidase activity for MBP-F4 which was slightly reduced 
compared to MBP and the backbone alone. 
3.6 CONCLUSIONS 
3.6.1 SUMMARY 
Previous in vitro data suggest that MBP-F4 binds to 54 [1]. Building on this, synthesis of F4 
was successful, despite initial problems with side-product formation. In order to verify binding 
of F4 to 54, it was decided to develop an in vitro assay. Initial focus was on a fluorescence-
based assay using the environmental fluorophore dansyl, tagged onto the peptide. In this 
assay, a clear shift in the maximal fluorescence intensity on binding of F4, but not control F4 
T86A, was seen, but not the expected shift in max wavelength. This suggests that F4 is 
binding to 54, as expected, but that the environmental change around the dansyl moiety is 
not large enough to give a very clear signal. 
In full-length transcription assays, knockdown of transcript numbers was seen with 
increasing ratio of PspF1-275: MBP-F4, and whilst this was also seen in abortive assays, 
synthetic F4 failed to have any effect. However, the scope of in vitro transcription assays is 
very wide, with varying promoter probes which mimic different stages of formation of the 
initiation complex. It may therefore still be a suitable assay for peptide activity analysis for 
other synthetic peptides, either designed or library selected.  
Only a few very initial experiments have been conducted using ITC to probe the F4- 54 
interaction, but the results seem promising. It appears that an interaction can be detected 
between F4 and 54, suggesting that the MBP fusion is not entirely responsible for the 
previous observations. The interaction is not a strong one, with a Kd of approximately 10 µM. 
This can be rationalised as follows: although loop 1 is quite flexible, there are definite 
interactions at the base of the Loop 1 stem with helix 3, and the loop‟s global position is 
determined by the nucleotide hydrolysis state of ATP (or ADP +Pi) in the ATPase catalytic 
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site. There must be some functional state, and so structure, defined by the rest of the AAA 
domain of PspF which is key to Loop 1 action. In the synthetic peptide, no structure is 
defined by permanent covalent interactions, meaning that the loop is comparatively near to 
being completely flexible. Constraining the loop in a conformation required for binding would 
be of entropic benefit to the binding thermodynamics, thus lowering the Kd. In later studies, it 
would be interesting to examine the effect of introducing covalent crosslink in the loop, such 
as a disulfide bridge, or creating a circular version of F4. Finally, the effect of the fusion 
proteins on transcription from the pspAp promoter was also examined in vivo using a -
galactosidase activity assay. Despite optimising both the experimental set-up and examining 
assay conditions, it was not possible to establish a clear knockdown of -galactosidase 
activity by induction of either F4 or MBP-F4. 
3.6.2 ROUTES TO PURSUE 
This chapter has detailed several approaches to studying the MBP-F4/F4. 54 interaction 
which aimed to establish both in vitro and in vivo assays to study peptide interactions with 
54. The initial work using in vitro transcription assays, preliminary ITC data and a dansyl-
based binding assay show that if a peptide or peptide fusion is capable of binding to 54, it is 
possible to examine this in vitro.  
However, the original selection of F4 was based on a simple fragmentation approach [1], 
which did nothing to optimise either peptide binding to 54, or peptide stability in vivo. The 
addition of the MBP tag, whilst useful for quantification and detection of expression is also 
likely to alter peptide activity. Since the in vitro binding with synthetic F4 imply that a peptide 
alone is able to interact with 54, it might be best to focus on finding a peptide able to bind 
54 strongly, before pursuing further follow-up in vitro and in vivo assays with F4. 
If an optimum peptide binder for 54 is to be found, several aspects of peptide characteristics 
should be considered. Constraining peptide structure can have a number of benefits. It (i) 
reduces the degree of freedom and when constrained in a binding conformation, (ii) 
decreases the associated entropy compared to the unconstrained, linear version [230]. 
Additionally, (iii) cyclisation can also increase peptide bioavailability in vivo. Creation of a 
library of synthetic peptides, based on the Loop 1 structure, should identify a peptide which 
has increased binding affinity for 54 compared to PspF. A number of methodologies exist for 
creation of cyclic peptides, such as disulfide bond formation, native chemical ligation click 
chemistry or metathesis [112, 231-234]. Each method has associated benefits, for example, 
disulfide bond formation is simple and straightforward, but the product is likely to be unstable 
in vivo, and it remains to be seen how this approach could be applied to the creation of a 
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library easily. Head-to-tail cyclisation, however, should give optimal in vivo stability, and 
technology exists to couple this to peptide library creation; application and exploration of this 
will be discussed in the next 2 chapters. 
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4 SICLOPPS I: LIBRARY DESIGN AND SCREEN 
DEVELOPMENT 
In this chapter, the creation of two cyclic peptide libraries, one random and the other 
containing the targeting GAFTGA motif, as well as a control peptide based on PspF Loop 1 
via the SICLOPPS technology (1.1.2.3.6 Split-Intein Mediated Circular Ligation of Peptides 
and Proteins (SICLOPPS)) is discussed. Further, two selection strains were created and the 
selection strategy, conditions and limitations were explored. 
4.1  DEVELOPING AN IN VIVO AND LIBRARY-BASED STRATEGY 
Up to this point a key challenge in this project has been how to make and screen large 
enough numbers of peptides in order to identify a strong binder for 54, or a good inhibitor for 
the PspF. 54 interaction. Previously, work has focused on rational design of peptides and 
either cloning or synthetic creation of individual peptides. Whilst it is desirable to screen as 
many peptides as possible, it is also desirable to create a screen that is as close to the 
target native system as possible. Previous in vitro assays have used both tagged and 
untagged peptides (3.2 Detecting an Interaction in vitro), but have only ever included 54 and 
PspF, not the promoter DNA, RNAP or other cellular components that could influence 
peptide activity. Although the in vivo assays did target PspF.E 54 as a promoter bound 
complex (3.5 Detecting the Effects of Interaction in vivo), they only investigated small 
numbers of unique peptides and these were MBP tagged. In order to progress in this project, 
three key questions were addressed: (i) how can large numbers of peptides be screened 
with minimal synthetic work? (ii) How can the interactions be studied in vivo? And (iii) how 
can the native system as closely as possible be studied? 
SICLOPPS (1.1.2.3.6 Split-Intein Mediated Circular Ligation of Peptides and Proteins 
(SICLOPPS)) is a genetic technology that allows large libraries of cyclic peptides to be 
encoded at the DNA level and to be expressed and cyclised in bacteria in vivo. By coupling 
the plasmid-borne SICLOPPS technique with a suitable selection system, it is possible to 
identify cyclic peptides that disrupt a specific protein-protein interaction (PPI) [5, 149, 150, 
153]. The SICLOPPS technology itself is well-established, and whilst it has been frequently 
used in conjunction with a bacterial-reverse two hybrid system (RTH), for application to the 
PspF- 54 system this is not readily possible. The difficulty in using the RTH screen is due to 
the requirement for PspF1-275 hexamer formation for 
54 interaction [46], and the required 
orientation between PspF and 54. These two aspects make it unlikely that an interaction 
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between a PspF monomer and 54 as fusion proteins in a RTH system will reflect the native 
interaction, if any occurred at all. 
The SICLOPPS technology is appealing for several reasons with regard to the PspF- 54 
interaction. The peptides produced are cyclic, produced in vivo and large library sizes can be 
achieved relatively easily. Since PspF has a key loop structure (Loop 1) which is central to 
interaction with 54, a cyclic peptide could be expected to be more likely to bind to 54 than a 
linear version, since constraint to achieve a Loop 1-like conformation would lower the 
entropic cost of binding to the system compared to the unchallenged interaction [235, 236]. 
Additionally, the cyclical nature of the isolated peptide lends additional biostability compared 
to linear equivalents, as there are no termini available for attack by exopeptidases [237]. 
Finally, production of a large and diverse library of peptides in vivo is ideal if an appropriate 
and rigorous screen can be developed. It avoids problems associated with delivery of 
synthetic peptides into E. coli for in vivo testing and allows targeting of the whole system. 
4.2 Designing the Libraries 
SICLOPPS allows an almost free rein with respect to library design, with the only 
requirement being the inclusion of a nucleophilic cysteine or serine at position 1 and with 
ring sizes down to four amino acids reported as accessible [160]. Since the PspF- 54 
interaction contains a loop that it might be desirable to mimic (Loop 1), the loop size and 
amino acid composition should be considered when designing a library of potential inhibitors. 
4.2.1 THE BASIS FOR LIBRARY DESIGN 
It was decided to clone two separate libraries into the SICLOPPS plasmid: one containing 
five random amino acids and one containing four random positions flanking the GAFTGA 
motif, shown to be critical for creation of a meaningful interaction between 54 and PspF 
(1.1.4 Loop 1 and the GAFTGA Motif). Additionally, a peptide based on the sequence of 
PspF Loop 1 was designed. Since the sequence and mass of this peptide would be known, it 
would provide a useful control that the cloning and expression techniques were functional. 
The structure of peptide „Loop 1‟ is shown in Table 4.1; it contains the critical GAFTGA motif 
and immediately surrounding residues. In PspF, the two histidine residues are thought to 
form the basis of the loop [42]. Since the linear synthetic peptide and fusion protein MBP-F4 
have some in vitro activity (3.2 Detecting an Interaction in vitro and 3.3 Full-Length and 
Abortive Transcription Assays), this cyclic version of Loop 1 may display some in vivo 
activity. However, because the two libraries contain a more diverse set of sequences and will 
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undergo selection for survival for activity against the PspF- 54 interaction, it is unlikely that 
any observed Loop 1 activity will be as high as actively selected hits.. 
Two libraries, Library 1 (Lib 1) and SGW+5 will be cloned into the SICLOPPS backbone 
(plasmid pARCBD) shown in Table 4.1. Library 1 (Lib 1) contains four random positions 
flanking the conserved GAFTGA motif giving a library size of 160,000 (Table 4.1) at the 
peptide level and 1,048,576 members at the DNA level. Although this is a modest library 
size, it is hoped that other factors in the design will increase the likelihood of finding an 
effective inhibitor. Each library member will contain the GAFTGA motif and should be a 
similar ring size to PspF Loop 1, as well as having a degree of diversity in the positions 
flanking the GAFTGA sequence. 
SGW+5 is a larger library with 3,200,000 members at peptide level (Table 4.1) and 
33,554,432 at the DNA level from 5 randomised positions. This library should provide 
diversity and size to identify inhibitors completely unrelated to the structure of PspF Loop 1, 
or hits may contain some commonality with the native loop. 
PEPTIDE SEQUENCE 
pARCBD plasmid [SGGYLPPL] cyclo 
Loop 1 [CHEAGAFTGAQKRH]cyclo 
Lib 1 [CXXGAFTGAXX]cyclo 
SGW+5 [SGWXXXXX]cyclo 
Table 4.1 Naming expected spliced peptide sequences of the designed SICLOPPS peptide libraries and 
Loop 1 peptide. X denotes and randomised amino acid position. pARCBD is the backbone plasmid containing 
the IC and IN genes in SICLOPPS orientation with the CBD fusion. Loop 1 contains a single peptide whereas Lib 
1 and SGW+5 encode for 160,000 and 3,200,000 peptides respectively. 
4.2.2 LIBRARY CREATION, CONFIRMATION OF PEPTIDE PRODUCTION AND 
DIVERSITY 
To create the libraries, random and conserved sections of the desired sequence are 
incorporated into a synthetic forward DNA primer for a PCR reaction. The forward primer 
(sequences for the library primers and control peptide given in 2.1.6.3 DNA Primers and 
Usage) is designed such that it anneals to the 3‟ end of the IC and the 5‟ end of IN with the 
library in between. The reverse primer anneals to the 3‟ end of a chitin binding domain 
(CBD) tag at the 3‟ end of IN (Figure 4.1, A.). Randomised positions are introduced using the 
degenerate nucleotide codon NNS, where N can be A, T, G or C, but S can only be G or C. 
This effectively generates a reduced genetic code (for codon chart see Appendix C Codon 
Chart for SICLOPPS) containing just 32 codons that still represent all 20 natural amino acids 
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and only the amber stop codon, whilst ochre and opal stop codons are eliminated. The first 
PCR serves to introduce the library sequence, but after this initial step base pair mismatches 
in the amplified DNA are common [5]. A second PCR reaction uses a „zipper‟ primer, which 
anneals to the 3‟ end of IC and the CBD reverse primer again, to ensure that the two 
amplified DNA strands are correctly annealed (Figure 4.1, A.). 
The outcome of the two PCR reactions is shown in Figure 4.1 B., and C. The first reaction 
uses the SICLOPPS plasmid pARCBD, which contains the IC and IN inteins with a short DNA 
sequence in between, as a template and the library forward primers. The three DNA bands 
were gel extracted and then provided the DNA templates for the second PCR (Figure 4.1, 
B.). After gel extraction, the PCR products and pARCBD backbone were digested with BglI 
and Xbal and ligated in several ratios of insert: backbone. However, transformation of these 
initial ligation mixtures with both JM109 and DH5  electrocompetent E. coli cells resulted in 
either no, or few transformants, whilst the plasmid control was transformed with high 
efficiency (~108 colonies/ g DNA). It was considered that the problem might lie with 
inefficient ligation of DNA. Initially, treatment of the backbone with CIP, preventing re-
circularisation of the pARCBD backbone [204], was used to try to increase ligation efficiency. 
Additionally, it was thought that the presence of active ligase can inhibit transformation [238] 
so the ligation mixtures were heat inactivated by heating for 5 minutes at 65 ºC before 
transformation. Both of these measures however, failed to increase the numbers of colonies 
found on the transformation plates. 
In order to test whether the restriction digest of the backbone pARCBD was effective, the 
plasmid was individually digested with each restriction enzyme singly and with both. 
Transformation of these reactions without ligation gave only a few background colonies and 
successful digestion was also evident by agarose gel electrophoresis (not shown). Singly 
digested and ligated reactions of pARCBD were transformed with efficiencies between 
(2.3 x105 and 4.8 x105) and although improved compared to earlier attempts, this would not 
be sufficient to have confidence in library coverage. pARCBD was also doubly digested and 
ligated, and this gave even fewer transformants. An additional consideration was the 
sensitivity of Xbal to dam methylation when the recognition sequence is flanked by GA at the 
5‟ end or TC at the 3‟ end giving the dam methylase recognition sequence GATC, the 
methylation of which decreases XbaI restriction [239, 240]. GATC is found at the 3‟ end of 
the CBD domain, however pARCBD prepared from both JM109 and the dam- ER2925cm 
strains (ER2925cm has overlapping resistance with pARCBD; to prepare the plasmid from 
ER2925cm cells, chloramphenicol concentration was increased to 100 g/mL) showed equal 
amounts of product after restriction by Xbal. 
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Digestion of pARCBD with XbaI was successful and reactions run on agarose gel show no 
sign of uncut vector. Despite this ligations gave sub-optimal numbers of transformants, 
suggesting that a problem remains with either ligation or transformation reactions. 
Additionally, it was not possible to directly follow the digest of the DNA PCR fragments, due 
to the small change in fragment size. To investigate further whether the problem lay with the 
digest of PCR fragments, a test ligation and transformation was performed with the TA 
Figure 4.1 Cloning the SICLOPPS plasmids. A. Outline of the SICLOPPS cloning strategy. Two PCR 
reactions are required to introduce a library into the backbone pARCBD. The first PCR introduces the library, but 
some of the product may contain base pair mismatches. The second PCR uses a universal „zipper‟ primer to 
give correctly paired product, which can be digested and ligated in to the pARCBD backbone to give the library. 
Adapted from [5] B. First SICLOPPS PCR with library specific forward primers. The gel extracted bands are 
used as templates in C. the second SICLOPPS PCR, with the zipper primer in all reactions. 
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shuttle cloning vector pGEM® T-Easy (Promega). PCR products with an expected 3‟-terminal 
T residue in the sequence, when amplified by Taq polymerase, are created with adenine 
overhangs at the 3‟ ends [209, 210]. These can be combined with commercially available 
linearized vectors, such as pGEM® T-Easy, which have compatible thymidine overhangs at 
the 3‟ ends, to clone fragments into vectors without previous restriction digest of PCR 
product or plasmid [200]. Purified PCR product of the SGW+5 library was ligated with 
pGEM® T-Easy and transformed with electrocompetent DH5  with an efficiency of 4.8 x108, 
which is sufficient for library coverage and much higher than previous attempts. Since 
successful digestion of the backbone is confirmed by agarose gel, this result suggests that 
the PCR fragments are not being fully digested by either BglI or Xbal. Although the SGW+5 
library was successfully cloned into pGEM® T-Easy with good library coverage, further 
manipulation involving plasmid amplification, purification and digest, followed by ligation into 
the correct vector mean that this approach would not give complete confidence that library 
coverage had been maximised. 
Initially, the libraries were amplified using a reverse CBD primer with an Xbal restriction site 
at its 3‟ end. However, since complete restriction of the PCR product fragments could not be 
confirmed, the reverse primer was altered to contain a HindIII restriction site, to see if 
alteration of the 3‟ end of the PCR product would affect ligation efficiency. As a result of this, 
transformation efficiencies were immediately increased, to between 1 x104 and 1 x105 
cfu/ g DNA. Although electroporation typically provides the highest transformation 
efficiencies, it was judged that lab conditions using „lab-made‟ electrocompetent cells might 
be less than ideal, with each batch having an associated variation in efficiency. This variation 
in efficiency could therefore be the final contributing factor in the observed low 
transformation efficiencies. 
Several factors have been found to influence the transformability of chemically competent E. 
coli strains with plasmid DNA, including the length of exposure to CaCl2 [241], the presence 
of multiple cations in the transformation buffer [242], treatment with DMSO [243] and the 
growth phase when cells are harvested for preparation [244]. The Inoue method [205], 
incorporates both multiple cations and DMSO in its transformation buffer and cells are 
harvested in the early exponential phase, but the protocol additionally stipulates that cells be 
grown at 18 °C, rather than the traditional 37 °C. It has been speculated that this altered 
temperature influences the composition or characteristics of the bacterial cell membrane, 
creating one which is more easily transformed [204], but this has not been fully investigated. 
However, Inoue cells do give typically higher transformation efficiencies than other 
chemically competent cells (between 1 x108 and 3 x108). Moreover, the protocol has fewer 
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time-critical steps and gives a higher level of reproducibility, as well as being unaffected by 
the presence of DNA ligase or ligase buffer. 
Once Inoue cells were used, the same range of ligation reactions were performed and all 
saw increased efficiencies, with the highest achieving 2.7 x108 cfu/ g ligated DNA. Ligation 
reactions with the highest efficiency for each library were performed 5 times and the repeats 
pooled to form the library DNA, theoretically with many-fold coverage. 
4.2.3 ASSESSING THE LIBRARIES 
To assess the success of the library cloning, cyclisation of the Loop 1 peptide inteins and 
mass spec analysis of the resulting peptide was performed. Additionally, sequencing of 
random clones of each library was performed to examine their diversity. 
The expression of pARCBD, SGW+5, Lib 1 and the Loop 1 control peptide was tested with 
visualisation of intein splicing by binding the soluble cell fraction, after cell disruption by 
sonication and centrifugation, to a column containing chitin binding domain beads. Figure 4.2 
Figure 4.2 Examining splicing and detection of the cyclic peptide Loop 1. A. A 15% SDS gel showing the 
whole cell and soluble fractions of expressed Loop 1 culture as well as the flowthrough (FT) and eluate from 
binding to CBD beads. Only bands corresponding to the expected masses of IC-peptide-IN are seen in the CBD 
eluate lane. B. LC-MS traces of flowthrough and eluate fractions of Loop 1 expression after treatment with 
PepClean C18 desalting spin columns. The desalted flowthrough (FT) has multiple peaks in the UV but only one 
is present for the CBD eluate fraction. In both flowthrough and eluate the M/3
+3
 for Loop 1 can be detected, 
corresponding to the peak in the UV trace. 
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A shows at 15% SDS gel with whole cell, soluble fraction, flowthrough and bead fractions for 
the Loop 1 peptide. Treatment of both libraries and the pARCBD backbone gave the same 
results (data not shown). The eluate and flowthrough fractions from the peptides were 
desalted using PepClean mini C18 spin columns (Pierce) and samples were analysed by 
LC-MS. Figure 4.2 B shows the cropped LC-MS traces of flowthrough (FT) and eluate. In 
both runs, the M/3+3 (M/Z = 495) for expected mass of Loop 1 (1495 cyclic) is detectable in 
the ESI+ and corresponds to the retention time of peaks in both UV spectra. The clear 
difference between runs is the purity of sample; for the flowthrough, at least 4 peaks are 
visible, but these are reduced to a single sharp peak after incubation on the CBD beads 
overnight. Treatment of the samples with PepClean columns removes all but relatively small 
peptides, either from soluble cell fraction, or the cyclic peptide product of splicing from the 
CBD bead fraction. 
When the ESI+ data for the single UV visible peak in the CBD eluate fraction are examined, 
several ionisation peaks at 495, 497, 498, 499 500 are present (spectrum not shown), 
corresponding to the M/3 value for the cyclic Loop 1 peptide. The samples were also run 
using MALDI-TOF, but no peak was visible for either fraction, probably due to limited 
ionisation of the cyclic peptide. In addition to confirmation of peptide identity by DNA 
sequencing, the Loop 1 peptide can be confirmed as expressed and cyclised to the correct 
product and furthermore, the combination of CBD bead purification and LC-MS analysis is 
shown to be sufficient for peptide characterisation. 
Although it is not possible to submit a whole library to DNA sequencing so that full library 
diversity is certain, it would be helpful if library variety could be confirmed. To this end, 10 
individual members of each library were sequenced as well as the Loop 1 control to confirm 
correct cloning. The results (see 5.1.1.2 SGW+5: 1 Hit Wonder?), were 10 unique individuals 
for each library and with both libraries in place, development and execution of an appropriate 
screen for the PspF- 54 interaction could then be investigated. 
4.3 PEPTIDE SELECTION: TARGETING THE PSPF-
54 
INTERACTION 
4.3.1 REQUIREMENTS OF THE SELECTION SYSTEM 
Selection of peptides in vivo is intended to increase the likelihood of isolating cyclic peptides 
capable of perturbing the native system and excluding peptides which bind or are active 
against other cellular components. It is therefore desirable that the selection strain reflects 
as closely as is possible the WT system, meaning that a bacterial reverse-two hybrid (RTH) 
system would not be appropriate. Although the RTH has been successfully used in the past 
(1.1.2.3.6 Split-Intein Mediated Circular Ligation of Peptides and Proteins (SICLOPPS)), it 
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was thought that it would not allow for a WT-like interaction between 54 and PspF in terms 
of orientation. If however, the PspF-PspF homohexamer were the target of peptide inhibition, 
the bacterial RTH system would be an appropriate selection method, with the additional 
benefit of a well-established existing selection protocol. 
In the in vivo study of the psp response, the reporter gene lacZ, encoding -galactosidase, 
has frequently been used as a fusion to the pspA promoter. Usually, lacZ is used as a 
reporter enzyme with chromogenic substrate such as Xgal or ONPG, and the activity of the 
enzyme is monitored by an associated colour change. However, in order to screen large 
libraries, a simple colour change would not be appropriate as individuals with lowered -
galactosidase activity would be hard to visualise. Ideally, the peptide libraries could be 
screened in a positive selection system, in which knockdown of the pspA promoter results in 
growth whilst peptides unable to have a negative effect are contained cells which die. 
Fortunately, lacZ activity can be made toxic, as detailed below. 
4.3.1.1 E. COLI MUTANTS LACKING UDP-GALACTOSE-4-EPIMERASE ARE SENSITIVE 
TO GALACTOSE 
The lacZ gene produces the enzyme -galactosidase, which in WT metabolism hydrolyses 
the disaccharide sugar lactose and other b-galactosides to produce -D-galactose [245]. -
D-galactose is then processed to -D-galactose via the enzyme galactose mutarose, and 
enters the Leloir pathway (Figure 4.3), which is responsible for the metabolism of galactose 
to the cell‟s preferred energy source, glucose [246]. 
The Leloir pathway is wholly responsible for metabolism of galactose, and in addition to 
galactose mutarose, is made up of three enzymes: galactose kinase (GalK), galactose-1-
phosphate uridylytransferase (GalT) and UDP-galactose-4-epimerase (GalE) [246, 247] All 
four enzymes are contained in one operon in E. coli, known as the gal operon [246]. After 
conversion to -D-galactose, GalK utilises one molecule of ATP to produce galactose-1-
phosphate. Galactose-1-phosphate is then converted to UDP-galactose, with the concurrent 
transformation of co-factor UDP-glucose to glucose-1-phosphate by GalT. The final enzyme, 
GalE, converts UDP-galactose to UDP-glucose, with inversion at the sugar C4. The reaction 
is a reversible oxidation-reduction reaction which is non-stereospecific with respect to the 
hexopyranosyl substrates and utilises an NAD+ group, bound tightly to each enzyme subunit 
(2 per dimer) [246, 248, 249]. 
123 
 
Although the enzymes of the galactose operon are usually non-essential genes, deletion of 
galE results in E. coli cells unable to survive on galactose. Half a century ago, Fukasawa 
and Nikaido observed mutants of Salmonella lacking GalE, which underwent severe cell 
lysis when galactose was added to the culture medium [250, 251]. Galactose, at 
concentrations between 0.1 and 0.002% was added to cells during their exponential growth 
phase, and between 20 and 60 minutes later bacteriolysis was seen, measured by a drop in 
OD600 [250]. Cell lysis was only observed when galactose was added to growing cells and 
growth in hypertonic medium had a protective effect. Instead of lysing, the cells converted to 
fragile, spherical bodies known as spheroplasts. Finally, crude analysis of the mutant cell 
walls revealed an altered sugar composition. These three observations hint that loss of GalE 
results in compromised bacterial cell walls, which are osmotically fragile in normal growth 
medium and have an altered composition. It was later observed that mutation of galE is 
enough to cause deficiencies in the lipopolysaccharides (LPS), found in the outer membrane 
of gram negative bacteria [252]. The LPS, also known as lipoglycans, contained shorter 
chain lengths in galE mutants than those of galE+ strains, which may alter the structural 
integrity of the E. coli cell. Lastly, mutation of GalT or GalK produces cells which are not 
Figure 4.3 The Leloir Pathway of Galactose Metabolism. The pathway consists of four enzymes (named in 
blue) that are responsible for the conversion of -D-galactose to Glucose-1-phophate via UDP-Glucose in E. coli. 
UDP-Galactose-4-epimerase (GalE) is responsible for the conversion of UDP-Galactose to UDP-Glucose. 
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lysed by addition of galactose, but go into bacteriostasis [252, 253], which suggests that the 
toxicity is due to accumulation of UDP-galactose. 
This toxicity was observed by direct addition of galactose to culture medium. However, in 
cells where -galactosidase activity is induced or constitutive, addition of a galactose 
precursor would lead to production of galactose and cell lysis. An additional advantage of the 
use of galE strains is the potential for increased transformability. In several pathogenic 
E. coli, galE mutants were shown to have increased transformability compared to their 
parental galE+ strains [252] which is thought to be an indirect effect which results in 
formation of altered an altered LPS in the outer membrane. 
4.3.1.2 PHENYL-BETA-D-GALACTOSIDE IS A LACTOSE ANALOGUE TOXIC TO CELLS 
LACKING GALE 
Phenyl- -D-galactoside (Pgal) is a commercially available lactose analogue that is also a 
source of galactose when in the presence of the enzyme -galactosidase. As shown in 
Figure 4.4, as with other lactose analogues, -galactosidase accepts Pgal as a substrate 
and hydrolyses it to galactose and phenol. As a result lacZ+, galE strains are unable to 
grow in the presence of lactose or its analogue Pgal [254]. 
Selection based on galE strains, either with lactose or Pgal, has been widely used to 
identify mutants of lacI and lacZ [254-261]. These techniques include genetic mapping of the 
lac operon [254, 255, 259], selection of lacZ- plasmids [256, 261], mutation studies in 
transgenic mice [258, 260] and identification of spontaneous stationary phase mutants [257]. 
Thus far however, Pgal has yet to be used as a positive selection tool in which lacZ is a 
reporter enzyme for promoter activity. Accordingly, it is likely that the existing selection 
protocols will require extensive modification in order for Pgal to be a suitable selection tool. 
Previous types of selection has shown that strains exhibiting the highest level of -
galactosidase activity are more effectively killed by the presence of Pgal, and those with 
lower activity surviving to a greater degree [261]. Since the basis of Pgal toxicity is 
Figure 4.4 Structure and hydrolysis of Phenyl- -D-galactoside (Pgal). Pgal is hydrolysed by -galactosidase 
to galactose and phenol. 
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generation of galactose, the more commonly used lactose analogues ONPG and Xgal 
should also be toxic to strains lacking galE; however, generation of a coloured product in 
cultures could interfere with OD600 measurement. Although the selection is not expected to 
be linear in its toxicity, this observation suggests that complete knockdown of -
galactosidase activity that is, no promoter activity, would not be required for survival. This is 
a key requirement of the selection, since it is unlikely that many if any initially screened for 
peptides will be both efficacious and bountiful enough to completely prevent transcription 
from the pspAp promoter. 
4.3.2 CREATION AND ANALYSIS OF THE SELECTION STRAIN 
4.3.2.1 THE SELECTION STRAIN AND CONTROLS 
All strain manipulations were performed using P1vir transductions (2.1.7 Generation of 
Bacterial Strains). In order for -galactosidase activity to cause toxicity in the presence of 
Pgal, the pspAp-LacZ fusion must be actively transcribed. This can either be achieved by 
inducing the psp response, for example by induction of the phage protein pIV from a 
plasmid, or by making PspF constitutively active by removal of PspA. In addition to its 
effector function in the cell PspA is the negative regulator of PspF (1.1.2 Phage Shock 
Protein F and the PSP Response) and its deletion means that PspF is free to activate 
transcription from the pspA promoter continuously. MVA27 is a WT E. coli strain with a 
deletion of pspA and a lacZ fusion to the pspA promoter ( pspAp-lacZ) and as a result has a 
high -galactosidase activity. This strain was used as the starting parental strain to make two 
galE mutants. 
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The first selection strain, LJR04, is MVA27, but with deletion of galE, and was made by P1vir 
transduction, selection by kanamycin marker and then curing the kanamycin resistance 
[199]. The pspAp-lacZ activity is unaffected by loss of galE (Figure 4.5, D). A second strain 
was made using LJR04 as the parental strain with a deletion of himA, the -subunit of the 
IHF. Loss of himA creates a strain which still has constitutive -galactosidase activity, but it 
is not as high as that of LJR04 (Figure 4.5, D). With its lower -galactosidase activity this 
strain should be less affected by Pgal and may provide a wider dynamic range to the 
Figure 4.5 Characterisation of the selection and control strains created by P1vir transduction. A. 
Confirmation that the selection strain LJR04 has deletions of pspA and galE. The WT strain is MG1655, MVA27 
is pspA, and LJR04 is MVA27 galE. B. Confirmation that the secondary selection strain LJR05 has deletions 
of pspA, galE and himA. LJR05 is LJR04 himA. F&R indicates forward and reverse primers. C. Confirmation 
that the control strain LJR06 has deletions of pspA, galE and rpoN. LJR06 is LJR04 rpoN, kanR. D. -
galactosidase activity of the selection and control strains. Strain LJR04 is unaffected by deletion of galE, LJR05 
has reduced -galactosidase activity due to loss of himA and LJR06 has no activity due to loss of rpoN. 
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selection process. Figure 4.5, A and B, show the results of colony PCR experiments to 
confirm the loss of galE and himA in A, LJR04, and B, LJR05. A control strains was also 
created from LJR04, in which the gene for 54, rpoN, is also knocked out (LJR06). Because 
of the strict requirement for activation of pspAp-lacZ by 54, deletion of rpoN results in a 
strain with virtually no -galactosidase activity under these conditions (Figure 4.5, D). 
The donor strain, from which the galE P1vir were made, JW0742, came from the Keio 
collection [195] and provides a control for the dependence of Pgal toxicity on the activity of 
-galactosidase. JW0742 lacks galE, but it is also lacZ- and should be unaffected by Pgal. 
4.3.2.2 LIBRARY EXPRESSION IN LIQUID AND SOLID MEDIA 
To examine the expression of both libraries and control peptides in the selection strain 
LJR04, Western blots were performed with an anti-CBD antibody (NEB). Liquid cultures 
were grown, varying amounts of arabinose added and the libraries/ control peptide induced 
for 3 hours at 37 ºC; the results are shown in Figure 4.6. Detection of bands corresponding 
to IC-peptide-IN-CBD and peptide-IN-CBD can be seen at 0.02 and 0.2% arabinose. The 
upper IC-peptide-IN-CBD band can be seen for all samples, although is very feint for the 
SGW+5 library. 
Figure 4.6 Detection of expression by CBD tag of both libraries and control peptides in LJR04, liquid 
culture. Both libraries are expressed and are able to splice in the selection strain LJR04. In all cases expression 
can be detected at 0.002% arabinose. Expression was performed at 37 ºC for 3 hours; samples were run on 18% 
SDS gels. 
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Protein expression can vary considerably with media conditions, which therefore includes 
differences between solid and liquid media growth. To investigate this, the SGW+5 library 
was transformed and grown on LA plates with varying arabinose concentration, overnight at 
37 ºC. Figure 4.6 shows the resulting SDS gel and Western blot; it appears that expression 
of SGW+5 is poorer on solid media than in liquid with no observable band at 0.002% 
arabinose, despite the longer growth period. This could be because of a lack of recovery 
time between transformation and plating, although growth of transformed SGW+5 on 
arabinose-LA plates gave confluent lawns of cells, suggesting growth itself is unaffected. 
4.3.2.3 THE SELECTION STRAINS ARE SENSITIVE TO PGAL 
4.3.2.3.1 GROWTH ON LACTOSE 
Initially, the ability of the strains to grow on LA, glucose and lactose was tested. As shown in 
Figure 4.8, A., the strain LJR04 grows well on LA and 0.4% glucose but is unable to grow 
when 0.1% lactose is the sugar source. LJR04 pAska GalE contains a plasmid bearing the 
enzyme GalE, and expression from this vector allows strong growth on 0.1% lactose and 
good growth on up to 0.4% lactose. Strain LJR05 behaves as LJR04, except when 
transformed with pAska GalE and in the absence of inducing agent (IPTG). In this case 
LJR04 pAska GalE is unable to survive on 0.1% lactose, but LJR05, with its lower -
galactosidase activity, is able to grow due to the leaky expression from pAska GalE (Figure 
4.8, B.). This highlights the rate-limiting nature of -galactosidase activity in galactose 
Figure 4.7 Detection of expression by CBD tag of library SGW+5 on solid media. Arabinose was present at 
increasing concentrations for SGW+5 on solid media. Detection of the inteins by CBD tag is only possible at 
0.02% arabinose. Cultures were grown for 14 hours at 37 ºC; samples were run on 18% SDS gels. 
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toxicity; if it is only moderately high, leaky plasmid expression of GalE is sufficient to rescue 
growth. 
4.3.2.3.2 LIQUID MEDIA GROWTH 
To test the toxicity of Pgal in liquid medium, selection strain LJR05 was grown in increasing 
concentrations of Pgal in a 96 well plate format. LJR05 has the lower constitutive -
galactosidase activity of the two strains (Figure 4.5, D.) and its growth in Pgal represents the 
lower level of Pgal toxicity in liquid media. Additionally, the effect of plasmid, PspA and GalE 
expression was assayed and the results are shown in Figure 4.9. In these experiments, a 
single culture was grown of each type and then split at the time of Pgal addition at 3 hours, 
in order to ensure identical growth up to that point. 
Figure 4.9, A. shows that addition of Pgal at 0.05% causes a drop in OD600 and higher 
levels of Pgal cause increasing drops. As discussed earlier (4.3.1.2 Phenyl-Beta-D-
Galactoside is a Lactose Analogue Toxic to Cells Lacking GalE) Pgal toxicity causes cell 
lysis with associated drop in OD600. Although it is difficult to be certain what portion of the 
OD600 is due to live, viable cells, decreased OD600 in correlation with increasing Pgal 
concentration must relate to increased culture lysis. 
  
Figure 4.8 Lactose sensitivity of LJR04 and rescue by leaky or full expression of GalE. A. LJR04 grows 
well on LA and glucose plates, but fails to grow when lactose is the sugar source. Expression of GalE rescues 
growth. B. Leaky expression of GalE from pAska GalE is high enough to rescue growth on lactose. 
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As might be expected and a critical aspect with regards to selection of the SICLOPPS 
plasmid, expression of a plasmid alters the extent of Pgal toxicity. Figure 4.9, B. shows the 
growth of LJR05 in Pgal and equivalents growths expressing the control plasmid pBAD18. 
Although pBAD18 is an empty plasmid vector, the cellular loading imposed through usage of 
cellular resources for plasmid replication, and transcription and translation of the essential 
chloramphenicol acetyltransferase, will reduce their availability for transcription from the 
pspA promoter, and translation of the expressed -galactosidase mRNA. This effect is so 
marked that at 0.05% Pgal added at 3 hours, growth of the culture expressing pBAD18 is 
unaffected. However, unless the culture enters stationary phase it is likely that the toxicity is 
merely delayed, rather than eliminated altogether. When higher levels of Pgal are added 
(0.4% shown) however, the OD600 is seen to drop, although not as soon as for the culture 
without plasmid expression. 
At 0.05% Pgal, expression of PspA appears to prevent cell lysis (Figure 4.9, C.) However, 
direct comparison of PspA expression to pBAD18 expression reveals that PspA does not 
appear to rescue culture growth from Pgal toxicity (Figure 4.9, B. and C.). If there are 
differences in culture death between PspA and pBAD18 cultures, they are small enough that 
it cannot be confidently attributed to PspA dependent knockdown of the pspA promoter. This 
result is not unexpected since expression of PspA from a plasmid can be considered very 
different from WT expression of PspA in response to activation of the psp response which 
also leads to pspBC expression. Overexpression of PspA to high levels causes aggregation 
of the protein product past relatively low concentrations when isolated in vitro. It is therefore 
conceivable that overexpression to give in vivo concentrations which are beyond normal 
tolerances will not give the WT product, but some inactive aggregate. Therefore PspA 
expression is not the best model positive control for full inhibition of the high, constitutively 
active -galactosidase activity from the pspA promoter. Finally, Figure 4.9, D. shows that 
expression of the GalE enzyme completely abolishes the toxicity of Pgal, even at 0.4%, 
demonstrating the requirement of the galE knockout for selection strain function. 
Furthermore, although processing of Pgal by -galactosidase releases phenol as well as 
galactose and this might be expected to contribute to toxicity, the results in Figure 4.9, D. 
show this is not the case. Cultures expressing UDP-galactose grow equally well in the 
presence of 0.4% Pgal as they do in its absence, even with continuous -galactosidase 
activity. 
131 
 
These experiments demonstrate that Pgal is toxic in liquid media and additionally, the lysis 
response is linear with increasing Pgal concentration. That plasmid expression relieves Pgal 
toxicity slightly will need to be kept in mind during the design of subsequent selection assays 
with regard to the Pgal concentration and selection time after addition. 
Figure 4.9 Liquid media growth of LJR05 plus Pgal. Growth is of selection strain LJR05 either alone, or 
expressing indicated plasmid. Pgal was added at 180 minutes. A. Pgal is toxic to LJR05 at a concentration of 
0.05%, with toxicity increasing with Pgal concentration. B. Expression of control plasmid pBAD18 decreases 
the toxic effect of Pgal. C. Expression of PspA does not clearly rescue growth above the level of plasmid 
rescue. D. Expression of GalE completely abolishes Pgal toxicity. 
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4.3.2.3.3 SOLID MEDIA GROWTH 
Initially, mock transformations and day cultures were either plated or spotted onto LB agar 
containing increasing concentrations of Pgal. However, in both cases, the selection seen in 
liquid media was not evident in the solid media tests. Mock transformations of LJR04 plated 
onto 0.3% Pgal plates gave large numbers of background colonies too numerous to count 
that would clearly undermine selection. Moreover, drop spotting of 2 L of 0.5 OD600 
normalised day culture gave many single colonies on Pgal, although selection is evident 
when compared to the minus Pgal spot (Figure 4.10). Since Pgal has been previously 
reported for selection on minimal media at concentrations as low as 0.05% [256, 260] 
sensitivity of the selection strain on 0.4% glucose was tested. A significant amount of escape 
was also seen when glucose was the available sugar source, although addition of Pgal was 
selective enough to produce single colonies from spotting 2 L of 0.5 OD600 culture (Figure 
4.10).  
To see whether glucose might be suitable for the library screens, a selection test was 
performed on minimal media with 0.1% glucose as the sugar source and 0.1% Pgal for 
selection. Day cultures of LJR04 containing either plasmid pBAD18 or pPB10 (for PspA) 
were normalised to 0.5 OD600 and 90 L of the pBAD18 culture was mixed with 10 L of the 
pPB10 culture and the mixed cells spread on the test selection plate. Although PspA 
expression was not able to rescue growth in liquid media containing Pgal above 0.05%, 
selection of PspA containing colonies on solid media would increase confidence in the 
selection process on solid media. Also, since solid media selection appears to be less 
vigorous, PspA expression may well be more effective in growth rescue on solid media. After 
growth at 25 ºC for 3 days, the Pgal containing plate had far fewer colonies than the control 
–Pgal plate, and there were larger size differences between the approximately 50 colonies. 
Six „large‟ and six „small‟ colonies were picked from the plus Pgal plate and were restreaked 
onto another plus Pgal plate. All restreaked colonies grew, with originally larger colonies 
having more growth after 1 day at 25 ºC. To see if any of the colonies picked contained 
PspA, Western blots were performed, but only the PspA control had detectable PspA. Whilst 
PspA may not be an entirely reliable positive control for selection, it appears that the 
background levels of growth on glucose minimal media do not give sufficient selection over 
the background. Although the media must provide some sugar source for cellular growth, it 
should not allow such vigorous growth that Pgal toxicity is escaped. 
These data emphasise the importance of the sugar source in selection and although some 
selection is achieved through the use of LB agar and minimal media plus glucose, both 
carbon sources do not give enough confidence in the selection levels achieved. Finally, 
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glycerol was investigated as a possible sugar source. E. coli growth rate on glycerol is 
slower than on the preferred carbon source, glucose, and it is therefore conceivable that this 
slower growth will increase Pgal toxicity. The original investigation of galE strains in 
galactose identified that the toxicity was dependent on the active growth of cell cultures [250] 
since extended growth time will increase the time available for -galactosidase activity 
before a toxic level of UDP-galactose is accumulated. Substantiating this, drop spotting 
normalised cultures of LJR04 gave the lowest numbers of colonies when Pgal was present 
(Figure 4.10) compared to LB agar and glucose. 
To further assess the expected background on glycerol after transformation, mock 
transformed and recovered cultures of LJR04 were plated onto 0.4% glycerol plates plus 0.1, 
0.2 or 0.3% Pgal. Whilst the control platings onto glycerol without Pgal gave highly dense, 
near confluent lawns of cells, only 36, 20 and 21 colonies were found on plates containing 
Pgal. Glycerol then is seemingly one useful carbon source for good growth whilst providing a 
clear Pgal selection. 
4.3.2.4 THE TIME OF PGAL ADDITION IS IMPORTANT 
That the addition of Pgal after 3 hours growth is toxic to the selection strains is clear (Figure 
4.9), however, is the timing of this addition critical? In the original foundation work by 
Fukasawa and Nikaido, they noted that addition of galactose to galE strains of Salmonella 
was toxic only if cells were growing [250]. Where cells were prevented from growing by 
suspension in a buffered medium, no lysis was observed when galactose was added. 
Figure 4.10 The sugar source affects the toxicity of Pgal towards selection strain LJR04 on solid media. 
On both LB agar and minimal media with glucose, Pgal has lowered toxicity. When the only sugar available is 
glycerol, Pgal has maximal toxicity whilst growth is supported in its absence. 
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Additionally, when histidine-requiring mutants were grown until histidine was exhausted they 
entered stationary phase and addition of galactose was non-toxic. However, if histidine was 
then added, the culture entered a second period of growth, which was followed by cell lysis 
[250]. It follows that if lysis is caused by incorporation of the UDP-Galactose into cell walls at 
too high a concentration, if no new cell walls are being created, i.e. if cells are stationary, 
then the precursor to UDP-Galactose will lose its toxicity. 
To further characterise the effect of Pgal addition on the selection strains and to test how 
critical the time of addition was, the selection strain LJR04 ( pspA, galE) was grown in a 
96-well plate and 0.1% Pgal added at varying times and the results are shown in Figure 
4.11. When Pgal was added at 30 or 60 minutes, before cultures had left the lag phase, 
growth appears to be retarded until around 200 minutes, when the cultures begin to grow. As 
expected, the presence of Pgal is toxic to the cultures and delays growth, but, since the 
selection strain has a high -galactosidase activity level, it can be assumed that after a 
certain amount of time the Pgal in solution will be exhausted. Cell lysis releases the -
galactosidase contained within the selection strain, where it has easier access to the 
supplemented Pgal, compared to living cells that must transport Pgal into the cells before it 
can be hydrolysed. 
Figure 4.11 also shows however, that addition of Pgal at 90, 120 and 180 minutes has an 
equivalent effect. In all of these cases, the cultures have left lag phase and are at varying 
Figure 4.11 Addition of 0.1% Pgal to selection strain LJR04 at varying times. If Pgal is added too early (30 
or 60 minutes) the culture does not grow until close to 200 minutes, when Pgal is likely to be depleted. If Pgal is 
added too late (240 minutes) it has little effect. Addition of Pgal between these times leads to a predictable 
response. 
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stages of exponential growth when the Pgal is added. The result is that after 3 and a half 
hours‟ growth the OD600 of each culture is reduced, indicating that cell lysis has occurred. 
Interestingly, it does not appear to matter when the Pgal is added between 90 and 180 
minutes, as cell lysis and therefore death occur concurrently in all three instances. When 
Pgal is added at 240 minutes however, the addition appears to have little impact on the 
culture growth. This cannot be due to a lack of cell growth, since the culture has clearly not 
reached stationary phase, but is likely due to the high level of -galactosidase enzyme 
produced by this cell strain. 
4.3.2.5 PGAL TOXICITY IS RPON, LACZ AND GALE DEPENDENT 
Addition of a plasmid bearing the enzyme GalE was earlier shown to nullify the toxic effect of 
Pgal, it still was important to characterise the toxicity as being dependent on 54-dependent 
activation of the pspAp-lacZ fusion as well as the lack of GalE. The specificity of Pgal toxicity 
was examined by comparison of growth curves in the presence and absence of Pgal of 
several control strains as well as selection strain LJR04. Strain JW0742 is the parental Keio 
collection strain from which the galE deletion was taken. In addition, it lacks lacZ, so the 
unaffected growth in the presence of Pgal demonstrates the dependence of the toxicity on 
lacZ (Figure 4.12). MVA27 is identical to LJR04, except it retains galE and is consequently 
Figure 4.12 Insensitivity of the control strains to Pgal compared to selection strain LJR04. Strains JW0742 
( lacZ, galE), MVA27 (galE
+
) and LJR06 ( rpoN, galE) are insensitive to Pgal added at 2 hours, whilst 
selection strain LJR04 dies in its presence. 
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also immune to the effects of Pgal. Finally, LJR06 is also identical to the selection strain, but 
has a deletion of the gene for 54, rpoN, without which no specific transcription is possible 
from the pspAp-lacZ promoter. Pgal toxicity is therefore dependent on lacZ, rpoN-dependent 
transcription and the galE deletion. 
4.4 SCREENING THE LIBRARIES 
Pgal has been demonstrated as toxic to the selection strains in both liquid and solid media 
and so selection for activity against the PspF. 54 interaction could be possible in either 
format. Previously, reported SICLOPPS screens have been based on reverse two hybrid 
selection on solid media. As previously discussed (4.3.1 Requirements of the Selection 
System), a bacterial reverse two hybrid system would not be appropriate to screen for 
inhibitors of the PspF. 54 interaction. Instead, Pgal and a selection strain containing a 
knockout of galE will be used for positive selection to make the pspA promoter fusion to lacZ 
toxic when on. Pgal has been used for positive selection previously for genetic mutants [257, 
258, 260-262], so finding appropriate conditions for a screen involving a small peptide 
inhibitor might prove difficult and time consuming. Since there is a precedent for using both 
Pgal and SICLOPPS in solid media selection conditions it was decided to initially try and 
perform the selection on agar plates. As well as being the standard for SICLOPPS selection, 
a solid media screen enables an easy physical isolation of individual clones, ready for further 
characterisation. If screens were performed in liquid media, individual clone activity would 
not be discernible during the screen, and a separate method for isolation of individuals would 
have to be found. 
4.4.1 SOLID MEDIA SCREENS 
Figure 4.13 Outline of solid media selection with Pgal. The library is transformed into the selection strain and 
after recovery plated onto Pgal and arabinose containing minimal media. Surviving colonies which grown on the 
selection media should contain a peptide which is able to knockdown the pspA promoter. The peptide is identified 
by DNA sequencing of the plasmid recovered from the surviving colony. 
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The general outline of the solid media screen is shown in Figure 4.13. The library is 
transformed into the selection strain, and allowed to recover as in a standard transformation 
protocol. The transformed cells are then plated onto minimal glycerol containing media 
plates containing arabinose to induce cyclic peptide formation and Pgal to select for peptides 
able to knockdown transcription at the pspA promoter. Colonies able to grow on the Pgal 
containing medium should contain peptides active against PspF. 54 which can be identified 
by sequencing the plasmid DNA contained in the surviving colony. 
The previous work to choose optimal sugar source revealed that the media composition, as 
well as Pgal concentration can greatly affect the severity of selection. Although test 
experiments can aid selection design, it is still necessary to examine the selection system by 
performing the screens themselves. 
4.4.1.1 INITIAL SCREENS: GLYCEROL AND HIGH ARABINOSE 
At the outset, it was conjectured that the screen would produce the most initial hits if peptide 
expression would be set to the highest possible level with an arabinose concentration of 
0.02%. This is a reasonably high arabinose level and was shown to produce the highest 
detectable level of library expression (Figure 4.6). Maximal expression should mean that less 
active peptides are produced in large enough quantities to produce a discernible effect. The 
screen was repeated several times with both SGW+5 and Lib 1 libraries to assess its 
reproducibility. The control strains and plasmids gave good growth on glycerol and glycerol 
plus Pgal (for plasmid pAska GalE, and MVA27 and JW0742). However, the controls where 
the library plasmids were plated onto varying Pgal without arabinose gave relatively high 
variability between screen repeats in terms of numbers of background colonies. 
When the libraries or control plasmid pARCBD were expressed on glycerol without Pgal, 
instead of the expected near confluent lawn, in all cases the numbers of colonies were much 
lower than those expected and required. IPTG induced expression of pAska GalE was 
unaffected by glycerol, giving the expected lawn of cells, whilst only between 10 and 30 
colonies grew on the non-selective arabinose platings of pARCBD, Lib 1 and SGW+5. 
When Pgal was added, between 0.05 and 0.3%, no colonies grew on any plate. 
Furthermore, in the absence of arabinose but with Pgal, there was a large degree of 
variation between the pARCBD and SGW+5 plates. For the highest confidence in the 
screening process, the numbers of escapees should be consistent; otherwise there is the 
potential to possibly only select background colonies as false positives. 
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This initial round of screening demonstrated that there is a degree of variability in the basic 
Pgal toxicity level. This could be due to differences in the cells after recovery from the 
transformation, but it is unclear how these differences could be eliminated. Additionally, 
there is arabinose-dependent toxicity. Whilst the IPTG induced plasmid pAska GalE is 
unaffected by growth on glycerol, the combination of glycerol and 0.02% arabinose reduces 
the transformation efficiency of the library plasmids to single figures. In order to have library 
coverage at the start of the selection process, this toxicity from expression will have to be 
eliminated. 
4.4.1.2 ARABINOSE CONCENTRATION AFFECTS PGAL TOXICITY 
To confirm the arabinose toxicity effect, day cultures of LJR04 expressing pARCBD, 
normalised to 0.5 OD600, were plated on three types of solid media with or without Pgal, 
mimicking the Pgal toxicity test for the strain alone described in Figure 4.10. The results in 
Figure 4.14 show that whilst the cultures grow equally well on all sugars in the absence of 
Pgal, when Pgal is present growth is severely inhibited. Even on LB agar, which previously 
allowed escape from Pgal toxicity (4.3.2.3.3 Solid Media Growth); only a weak outline and 
thin lawn of cells are visible within the spot. When glucose is the sugar source, four single 
colonies were able to grow, fewer than in the absence of arabinose and on glycerol no 
colonies were able to form at all. 
Figure 4.14 Plasmid expression affects Pgal toxicity. The selection strain LJR04 expressing control plasmid 
pARCBD with arabinose at 0.02% is sensitive to 0.3% Pgal even on LB agar. 
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This data confirms that high arabinose concentration increases Pgal toxicity, and underlines 
the importance of finding the correct balance of conditions in terms of both arabinose and 
Pgal toxicity, for optimal screening of the libraries. 
4.4.1.3 GLYCEROL AND LOW ARABINOSE 
4.4.1.3.1 SGW+5 
To avoid arabinose toxicity, the concentration was reduced to 2 x10-4%. Although intein, and 
therefore peptide expression is not detectable by Western blot at this level (Figure 4.6 and 
Figure 4.7) using low expression may facilitate the selection of strongly active peptides. At 
this level of arabinose though, the control platings of transformed library onto plates plus 
arabinose but without Pgal gave near confluent lawns, meaning there can be confidence that 
library coverage is being achieved. 
In the library selections, plating of pARCBD in LJR04 onto 0.4% glycerol plus between 0.25 
and 0.4% Pgal gave no colonies. At 0.25% Pgal, 85 were colonies formed from the SGW+5 
transformed library, 1 colony at 0.3%, 130 colonies at 0.35% and no colonies at 0.4%. 
Although the response was not linear, the 130 colonies were isolated and both respotted 
and restreaked onto 0.4% glycerol plus 0.35% Pgal either with or without arabinose and 
whilst the control pARCBD failed to grow on Pgal, the respotted/ restreaked hits grew in an 
arabinose independent manner. 
Since there was no arabinose dependence in the growth of these initial hits, and the 
inconsistency in growth between pARCBD and the libraries without arabinose on Pgal it was 
decided to pursue screen characterisation before following up on these hits. So that there 
can be reasonable confidence that the initial hits contain several potential genuine hits, it is 
important that the screens are reproducible and reliable before investing effort in developing 
the follow-up screening methods. 
4.4.1.3.2 LIBRARY 1 
The same screen conditions were utilised to screen the Lib 1 library. Again the control 
plating to assess transformation growth in the absence of Pgal gave a near confluent lawn. 
The pARCBD control on Pgal, as for the SGW+5 library gave no colonies, whilst the Lib 1 
library produced only 5 colonies at the lowest Pgal concentration tested, 0.1%. 
4.4.1.4 BLUE/ WHITE SCREENING PLUS PGAL 
To try to overcome the difficulties encountered using minimal media, a slightly altered solid 
media selection was trialled. Instead of selecting solely with Pgal and on a limited sugar 
source, a combination of a blue/ white screen and Pgal positive selection was used on LB 
140 
 
agar. Initially, the blue/ white approach was not deemed desirable because of the inability to 
screen the full library size in this manner. Plating hundreds of thousands or millions of 
colonies onto a single or several plates and visualising each one to pick white colonies 
would be labour intensive. However, combining Pgal with Xgal could reduce the total number 
of colonies to be screened by positive selection leaving fewer for analysis by blue/ white 
selection. 
The Lib 1 library and control plasmid were transformed, split and plated onto five Xgal, 0.3% 
Pgal plates with arabinose at 0.02%. Whilst the pARCBD control produced 16 blue colonies, 
the Lib 1 transformed library gave 26 single colonies, 24 blue and 2 white. Although it is 
encouraging to see more colonies on the plus Pgal, plus arabinose plate, the differences 
between the two are not large and the total numbers of surviving colonies also seem very 
small. Ideally, to go forward with hits from a selection, larger numbers should be found, to 
increase the likelihood that after further screening genuine hits remain. As well as this, 
although 8 of the colonies from the Lib 1 library plates had altered morphology (flatter, with 
raised rim) all but two of the total were blue. To be confident that the selection contains 
genuine hits, colonies grown on arabinose should have at least some -galactosidase 
knockdown. 
4.4.1.5 SELECTION ON LB AGAR PLUS PGAL 
Since LB agar plus 0.3% Pgal was shown have significantly higher selectivity in the 
presence of arabinose (Figure 4.14), selection of the Lib 1 library was attempted on rich 
media. Plating of a mock transformation of LJR04 pARCBD onto Xgal, LB agar plus 0.3% 
Pgal to investigate the basal level of escape gave a very thin and blue lawn of cells (akin to 
the thin layer of cells seen in Figure 4.14). This escape from Pgal toxicity could be the result 
of fast metabolism of glucose in the rich medium and resulting quick initial growth. The 
thinness of the cell growth can be rationalised by introducing the Pgal toxicity, which appears 
to catch up with the cells and causes either cell death or bacteriostasis. Expression of the 
Lib 1 library in the presence of Xgal but no Pgal, gave near confluent growth as expected, 
and some visible single colonies were pale blue or white suggesting peptide mediated -
galactosidase knockdown. 
When Pgal was added in the presence of 0.02% arabinose, a single blue colony formed on 
the pARCBD control plate, with approximately 200 forming on the Lib 1 plate. Furthermore, 
15 of these were either light blue or white. These hits were picked and restreaked onto Xgal/ 
Xgal, arabinose/ Xgal, Pgal or Xgal, Pgal, arabinose plates but were all successfully 
restreaked on the Pgal plates in an arabinose independent manner. Furthermore, the 
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restreaks were equally blue plus/ minus arabinose which does suggest that the initial white/ 
light blueness is not attributable to mutation of the selection strain in the presence of Pgal. 
From this result, it is clear that simple restreaks are not appropriate for characterising an 
initial hit further. The quantity of cells that are plated in a restreak may not demonstrate Pgal 
toxicity or escape effectively. Additionally, although Xgal is a useful way to characterise -
galactosidase activity, it must compete as a substrate with Pgal and may then decrease Pgal 
toxicity further. Finally, it is unclear what -galactosidase level is required to produce a blue 
colour which might mask small differences in -galactosidase activity. Given that once again 
only a small number of potential initial hits have been isolated from this type of solid screen, 
it seems sensible to further develop the screening methodology. The primary screen should 
isolate a larger number of initial hits, in the expectation that this will make finding a genuine 
hit after secondary screen more likely. 
4.4.1.6 CAN LOOP 1 RESCUE GROWTH ON SOLID MEDIA? 
The Loop 1 peptide was cloned to provide a control peptide to assess cyclisation, isolation 
and expression by CBD beads and LC-MS. However, since it potentially has a similar 
structure to PspF Loop 1, it was tested to see if it has any activity against the pspAp-lacZ 
fusion. Day cultures of both selection strains expressing Loop 1 were normalised and plated 
onto 0.4% glycerol plates containing 0.05% Pgal. In neither case was the expression of 
Loop1 able to rescue growth over the pARCBD controls. In both cases, around 20 colonies 
were able to form on Loop 1 and pARCBD platings.  
4.4.1.7 CONCLUSIONS 
Despite development of optimal conditions for a solid media based positive screen on 
minimal media plus either glucose or glycerol as a sugar, it appears that the solid media 
base does not completely eliminate background hits. Additionally, there is relatively large 
variation between individual screens which reduces the level of confidence in the hits found. 
Regardless of these results, the previous success of Pgal on solid media [260, 261] 
suggests that a solid media screen should be possible, but that the ideal conditions have so 
far eluded characterisation. Further worthy possible avenues of investigation are higher Pgal 
levels combined with either rich media, or glucose, giving fast growth coupled with high 
toxicity levels. The toxicity associated with arabinose concentration could still have some 
influence and since it is not possible to detect plasmid expression at the lowest arabinose 
level, it could be worth increasing the arabinose concentration but decreasing Pgal 
concentration to balance the toxicity. Unfortunately due to time constraints, this avenue was 
not pursued further. 
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4.4.2 LIQUID MEDIA SCREENS 
The screening of the libraries on solid media suffered from variability between screens which 
led to doubts about the integrity of the screen and reliability of the results. It was therefore 
decided to explore alternative screening methods, with the possibility of visualising in some 
way the positive selection process. As part of the initial process of verifying the toxicity of 
Pgal to the selection strain liquid growth tests were performed, which demonstrated cell 
death after the addition of Pgal in liquid media (4.3.2.3 The Selection Strains are Sensitive 
to Pgal). These liquid growth assays gave consistent results with small experimental errors 
and the culture death could be graphed before and after addition of Pgal at a specific time 
point. Furthermore, liquid selection allows the experiments to be performed in rich media, 
which increases growth rates and decreases the experimental times. Growth of the libraries 
in liquid media, with the addition of Pgal, could therefore provide a traceable form of 
selection, with the controls already shown to be robust and reliable. Figure 4.15 shows two 
possible types of liquid selection, multi-round and single round plus plating onto Xgal. This 
section details the usage of both of these two types of selection. 
  
Figure 4.15 Outline of liquid selection with Pgal. The library is transformed into the selection strain and 
peptide expression induced with arabinose. Cultures are grown in rich liquid media supplemented with Pgal 
over either one or multiple rounds. Only cells containing peptides able to knockdown the pspA promoter are 
able to escape death. 
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4.4.2.1 DETERMINATION OF SCREEN CONDITIONS 
Initially, the libraries were transformed by electroporation, recovered in a small volume of 
SOC media for 1 hour, after which the culture volume was increased to 20 mL LB containing 
0.02% arabinose. Electroporation was chosen as the transformation method because of its 
high efficiency, but also its speed; chemically competent cells require incubation with the 
plasmid DNA before heat shock, which would increase the experimental set up time. The 
cultures were grown for a further two hours at 37 ºC before the addition of either 0.01% or 
0.05% Pgal; however, for all cultures expressing a plasmid, even in the absence of Pgal, 
growth was not detectable for at least 6 hours (data not shown). Since control cultures of the 
parent strain MVA27 (galE+) and the selection strain (LJR04) were able to grow during this 
time frame the arabinose concentration was lowered to 0.002%. However, even at low 
arabinose concentration, cultures appeared unable to exit lag phase during the first seven 
hours of growth (data not shown). It was therefore a concern that during this time period the 
Pgal present would be exhausted, and any outgrowth observed would not be due to positive 
selection of either library. 
In order to reduce the arabinose toxicity, it was decided to alter the assay protocol. Instead 
of performing the selections in one day, cells were transformed, allowed to recover, and then 
grown overnight in the presence of arabinose, but with no selection other than antibiotic. It 
was reasoned that sub-culturing the following morning would start the selection process with 
readily growing cells in a nevertheless clean selection strain that also contained expressed 
peptide. If selection were started at this point, the cells would have the best chance of 
survival, but death after Pgal addition would also be much clearer. 
It was found that recovery and expression overnight did provide cultures that were able to 
grow normally before Pgal addition (see Figure 4.16 A. and Figure 4.17 A.), whether the 
arabinose concentration was high or low. However, it can also be seen that the difference in 
growth between cultures of the selection strain LJR04 carrying plasmid pSGW+5 in the 
presence or absence of arabinose is not large after 3 hours of selection. It was therefore 
decided to try to enrich for plasmids encouraging survival by performing multiple rounds of 
selection. 
4.4.2.2 MULTI-ROUND LIQUID SCREEN TRIAL 
Theoretically, performing multiple rounds of positive selection should enrich the population 
with plasmids which express peptides able to promote cells survival. After Pgal is added to a 
culture, cells bearing plasmids unable to support survival will die due to cell lysis. This cell 
lysis will release the plasmid into the culture medium where it should remain, even after the 
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centrifugation step of DNA plasmid preparation, thus it will not be purified and will not be 
carried forward into the next round of selection. At the end of each selection round, only 
plasmids from whole, living cells should be purified and these isolated plasmids are taken 
into further rounds of selection (Figure 4.15). 
4.4.2.2.1 LOW ARABINOSE CONCENTRATION 
In the first instance, the selection was performed with a low arabinose concentration of 
2 x 10-3 %. The selection strain was transformed, recovered and grown overnight with 
arabinose and antibiotic selection, but no Pgal. The following morning, the overnights were 
sub-cultured and grown for a further 2 hours with arabinose and antibiotic selection. This 
ensures that cultures are growing normally before addition of Pgal, so that any cell death is 
attributable to genuine selection. Additionally, when Pgal toxicity against the selection strain 
was tested (4.3.2.4, The Time of Pgal Addition is Important, Figure 4.11), it was observed 
that if Pgal was added to cultures too early, no growth is observed. After 2 hours of growth, 
0.1 % Pgal was added and selection was performed for 3 hours, after which the plasmid 
DNA from each culture was purified for use in the next selection round. 
Figure 4.16 shows the results of liquid selection over 4 rounds with low levels of arabinose 
present. The data is presented in column graphs, with each bar representing the OD600 
reading at a time point and the numerical figure given above the data-set for each culture 
denoting the final OD600 after 3 hours of Pgal selection. Figure 4.16, A shows the growth 
after 1 round of selection. The strain MVA27 is identical to the selection strain, except it 
retains the gene for UDP-Galactose-4-epimerase and its growth is therefore unaffected by 
the addition of Pgal. pAska GalE is an IPTG inducible plasmid bearing the gene for UDP-
Galactose-4-epimerase, expression of GalE in the selection strain (pAska GalE +Pgal, 
IPTG), also eliminates Pgal toxicity towards the selection strain LJR04. However, addition of 
Pgal to the selection strain (LJR04 + Pgal) results in a plateauing of OD600, whereas growth 
of the culture without Pgal addition is uninhibited (LJR04). 
Using this method of transforming and recovering overnight, coupled with low arabinose 
levels, results in normal culture growth for strains expressing a plasmid (pARCBD + ara and 
SGW+5 + ara). Addition of Pgal (pARCBD + Pgal and SGW+ Pgal) results in toxicity 
equivalent to that displayed by the strain LJR04 alone, indicating that at this low level 
arabinose does not confer resistance to Pgal. After one round of grow out however, there is 
no apparent difference between cultures expressing the SGW+5 library versus the pARCBD 
control when Pgal is added (pARCBD + Pgal, ara and SGW+5 + Pgal, ara). 
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Figure 4.16, B shows the final OD600 of the four key cultures for assessing multi-round 
selection over the four rounds. If there were positive selection of plasmids contributing to 
survival, an increase in the final OD600 of the strain expressing the library might be 
expected. Conversely, no increase in final OD600 of either the strain expressing the control 
pARCBD, or strains not expressing plasmids would be expected. From these results, after 4 
rounds of selection, no overall increase in survival of the strain expressing SGW+5 (SGW+5 
+ Pgal, ara) is seen. For the culture SGW+5 in the absence of arabinose, the marginal 
increase in final OD600 in Round 2 also highlights that there is some naturally occurring 
degree of variability in selection between rounds which cannot be attributed to selection. It is 
therefore critical that the increase in OD600 be large enough relative to the controls to be 
considered a reliable indication of positive selection. 
4.4.2.2.2 HIGH ARABINOSE CONCENTRATION 
In order to detect an effect of the presence of the library over the pARCBD control, the 
concentration of arabinose was increased to 0.02%. Although this amount was previously 
toxic in liquid screens, using the modified protocol of overnight recovery eliminates the 
arabinose toxicity effect (Figure 4.17, A). Figure 4.17, C shows the growth of the selection 
strain containing control plasmid pARCBD in the presence of Pgal and either with or without 
Figure 4.16 Results of multi-round liquid selection with low arabinose level. Growth represents cultures of 
strain LJR04 plus the indicated plasmid unless stated otherwise. Numbers above columns are the final OD600 
readings after 3 hours of Pgal selection; Pgal was added after two hours of growth. A. Results of the first round of 
liquid selection with low arabinose. This level of arabinose is not toxic to cell growth. B. Final OD600 of selected 
cultures over four rounds of selection. There does not appear to be an increase in survival by the pSGW+5 culture 
with arabinose, over that of the pARCBD control. 
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arabinose, over the four selection rounds. Comparison of the growth of the +/- arabinose 
cultures indicates that the presence of arabinose does slightly increase the survival of the 
cultures in the presence of Pgal. Figure 4.17, C also demonstrates that there is a natural 
variation in growth levels between cultures expressing the same plasmid over several 
repeats; for example, in Round 3 both cultures +/- arabinose grow less well than in the 
previous two rounds. Because the cell toxicity of Pgal is linked to the growth stage when it is 
added to the culture (4.3.2.4 The Time of Pgal Addition is Important), variation in growth will 
inevitably lead to some variability in the selection, so it is important to compare the cultures 
to the controls within the particular selection round. 
As for the low arabinose selection, the controls respond to Pgal as expected (Figure 4.17, 
A.). As an interesting aside, the strain containing pAska but in the absence of IPTG (data not 
shown) is equally unaffected by Pgal as is its equivalent plus IPTG. Cell survival is 
presumably due to leaky expression from the promoter, but a Western blot to confirm this 
was not performed. This was also observed on the minimal media solid agar plates, so it 
does not seem to be dependent on the range of carbon sources available, which would be 
far greater in the rich media liquid screen. 
Figure 4.17, A shows the selection results after 1 round. Although the margins are very 
small, the culture expressing the library (SGW+5 + Pgal, ara) appears to survive to a slightly 
greater degree compared to its arabinose minus equivalent. This is despite the cultures 
having near identical optical densities when the Pgal was added. Conversely, there is no 
difference between the cultures bearing pARCBD with or without arabinose. As for the 
previous selection, the final OD600 of the cultures over the four rounds were plotted and the 
results are shown in Figure 4.17, B. In this case, an increase in survival for the expressed 
SGW+5 culture (SGW+5 + Pgal, ara) compared to the culture with no arabinose (SGW+5 + 
Pgal) was observed, but it is uncertain whether this is attributable only to the presence of 
arabinose. Since the pARCBD controls also show this effect, albeit on a smaller scale, and 
due to the natural variations in selection pressure, it is clear that further rounds of selection 
would need to be performed for certainty. These initial results show that multi-round 
selection could be a promising route for Pgal-based selection. The method produces a 
graphical representation of what is potentially positive selection as it occurs and so it should 
produce a measurable output as cell growth over the controls. However, whilst after four 
rounds of selection there are hints that selection is occurring, it is unclear how many rounds 
would be required to produce a clear and significant result. 
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The variation in growth and subsequent variation in the extent of death induced by addition 
of Pgal in cultures in Figure 4.17, C, also demonstrates that there is variation in how this 
selection assay might be performed. In Rounds 2 to 4, the addition of Pgal at 2 hours is 
followed by a decrease in OD600 by 4 hours and a partial recovery by 5 hours. Whilst this 
case selection was continued to 5 hours of experiment time, the point of plasmid collection 
could be important in determining the success or speed of selection over a number of 
Figure 4.17 Results of multi-round liquid selection with high arabinose level. Growth represents cultures of 
LJR04 plus the indicated plasmid unless stated otherwise. Numbers above columns are the final OD600 
readings after 5 hours of selection. Pgal was added after two hours of growth. A. Results of the first round of 
liquid selection with low arabinose. This level of arabinose is not toxic to cell growth. B. Final OD600 of selected 
cultures over four rounds of selection. An increase in survival by the pSGW+5 culture with arabinose, over that of 
the pARCBD control was not observed. C. Growth of cultures containing the plasmid pARCBD in Pgal, either 
with or without arabinose.  These controls indicate that selection may be slightly too long, but that addition of 
arabinose does not confer a protective effect. 
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rounds. Additionally, the time of Pgal addition, as well as the partially explored arabinose 
and Pgal levels could cause significant differences in the extent and success of the 
selection. Unfortunately the scope and time-frame of this project did not enable full 
investigation of all possible protocols, but the goal to show that Pgal is a valid selection tool 
in the first instance. 
4.4.2.3 SINGLE-ROUND SCREEN WITH PLATING 
A significant increase in the survival of cultures expressing the SGW+5 library over those 
either not expressing the library or expressing the control plasmid was not seen after four 
rounds of selection. However, it was judged that the necessary extra steps not directly 
related to the positive selection, such as plasmid purification, could result in the loss of 
potential hits. With this in mind, and with the lack of clear advantage conferred by a multi-
round approach, it was decided to attempt a single round of active selection with Pgal, with 
further selection by plating onto Xgal, arabinose solid media (see Figure 4.15). Cells 
containing hit peptide should survive one round of selection and should form white or light 
blue colonies when plated on Xgal, arabinose medium compared to the starting strain; these 
colonies will be selected for further investigation. 
The experiment is therefore performed as follows: the libraries and controls are transformed, 
recovered and grown overnight either with or without arabinose as before. The next morning, 
the overnight cultures are sub-cultured into fresh media with or without arabinose and grown 
for 2 hours before Pgal addition. As before, observed growth before Pgal addition is critical 
to culture growth or death being attributable to positive selection after Pgal is added. After 3 
hours of selection, the OD600 of each culture was normalised to that of the expressed 
selected library. The normalised culture was plated onto Xgal, arabinose LA plates and 
single colonies with either a light blue or white phenotype were selected. The typical 
workflow, in this case for Library 1, is shown in Figure 4.18, C. 
4.4.2.3.1 LIBRARY 1 
The results of the single round screen of Library 1 with 0.1% Pgal (Lib 1) are shown in 
Figure 4.18, A and B. Alongside the library selection, equivalent cultures and selection was 
performed for the selection strain plus PspA (plasmid pPB10). As shown in Figure 4.18, A, 
addition of Pgal causes cell death which is observable by a drop or plateauing of OD600. 
Similarly to the results of the multi-round screen and as expected, there are no large 
differences between control plasmid pARCBD and the cultures containing Lib 1. 
Furthermore, expression of PspA, as previously observed (Figure 4.9), is not sufficient to 
rescue growth but may be useful as a comparison in the plating on Xgal. 
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Plating a normalised culture onto Xgal, arabinose plates (Figure 4.18, B.) immediately 
reveals that although OD600 is an approximate way to gauge the extent of cell death, there 
are substantial differences between the viability of cells in cultures of the same OD600. This 
means that the OD600 underestimates the toxicity of Pgal, but also means that small 
differences in the number of viable cells will not be evident through measurement of OD600 
alone. The cultures of pARCBD, PspA and Lib 1 grown with arabinose only formed near 
Figure 4.18 Single round liquid selection with Library 1. Growth represents cultures of LJR04 plus the 
indicated plasmid. A. Culture growth with +/- arabinose and Pgal as indicated. PspA is expressed from plasmid 
pPB10. B. After 5 hours of day culture, a portion of normalised growth was plated onto Xgal, arabinose medium. 
All arabinose only cultures have significantly denser growth compared to those containing Pgal. White or light blue 
colonies from Lib 1 + ara, Pgal were selected for further investigation. C. Workflow of the single round selection. 
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confluent lawns when plated whereas all the cultures exposed to Pgal were single colonies 
at a much lower density. In all cultures exposed to Pgal only, some white colonies, 
presumably due to strain mutation, are visible, but qualitatively not as many as were found in 
the Lib 1 selection plus arabinose plate. When plated onto Xgal, the culture expressing PspA 
produces colonies which have a blue centre and white perimeter, ostensibly due to a -
galactosidase level which is reduced, but not abolished. Encouragingly, similar colonies 
were found on the Lib 1 selected culture plate, but not on the pARCBD control. From the Lib 
1 selection plate, a total of 91 colonies, white, light blue, or with blue centre were picked for 
further study. Results of the subsequent investigation are detailed in Chapter 5 SICLOPPS 
II: Hit Peptide Confirmation And Analysis. 
4.4.2.3.2 SGW+5 
The same experimental procedure was used to screen the SGW+5 library and the results 
are shown in Figure 4.19. As before there were only small differences in the final OD600s 
achieved by the cultures expressing the library plus Pgal and those without arabinose. 
However, although OD600 is an approximate guide to cell lysis, it does not completely reflect 
the numbers of viable cells remaining in the culture. Plating of the normalised SGW+5 
Figure 4.19 Single round liquid selection of SGW+5. Growth represents cultures of LJR04 plus the indicated 
plasmid. A. Culture growth with +/- arabinose and Pgal as indicated. PspA is expressed from plasmid pPB10. B. 
After 5 hours of day culture, a portion of normalised growth was plated onto Xgal, arabinose medium. Colonies 
observed are either „blue‟, „light blue‟ or „white‟. All colonies were selected for further investigation. 
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culture which underwent Pgal selection whilst expressing the library gave colonies with 3 
clear types of phenotype on Xgal plates. Figure 4.19, B. shows some colonies which are 
deep blue, some which are a lighter blue and many which are white. Because there were 
only 51 surviving colonies after plating a portion of the selected library, all the colonies were 
selected for further investigation. Results of the subsequent investigation are detailed in 
Chapter 5 SICLOPPS II: Hit Peptide Confirmation And Analysis. 
4.4.2.4 CONCLUSIONS 
Although the SICLOPPS technology has been previously applied to diverse protein-protein 
interactions (PPIs), when employing the technique in a novel situation some care needs to 
be taken. Design and cloning of the libraries themselves, although potentially problematic if a 
library creation has never been undertaken before, is relatively straightforward and requires 
only the following of a specific protocol [5]. In cases, such as that of PspF- 54, where the PPI 
under investigation is not a simple homo-dimerisation, design of a selection strategy and 
strain is the more difficult task. 
In its WT form the PspF- 54 interaction involves the homo-hexameric PspF bound to the 
DNA UAS and 54 in complex with the core RNAP, all bound to promoter DNA. The 
complexity and multi-meric nature of this system makes a chemical genetic approach 
attractive, but also makes designing an appropriate clean and efficient screen difficult. Since 
the chosen target was specifically the point of contact between PspF and 54, a bacterial 
reverse two hybrid system, akin to those previously used with SICLOPPS, would not have 
been appropriate. It was therefore necessary to target the promoter-bound complex and to 
achieve a positive selection system using an additive toxic to cell survival when the psp 
promoter was activated. 
Initially, two libraries were designed, one which contained five randomised residues, and 
another comprising of four random residues and the GAFTGA motif, shown to be critical for 
achieving a meaningful interaction between PspF and 54 (link to Introduction). Both libraries 
were cloned as per the published protocol [5], were found to produce cyclic peptides and 
were assessed for diversity by random selection of ten clones. A control peptide, based on 
the structure of PspF Loop 1 was also cloned, tested for cyclisation, was isolated and the 
peptide identity was confirmed by LC-MS analysis. 
Two selection strains were created, both lacking the PspF negative regulatory protein PspA 
[54-56], and GalE, a key enzyme in the Leloir pathway of galactose metabolism (see 4.3.1.1 
E. coli Mutants Lacking UDP-Galactose-4-Epimerase are Sensitive to Galactose), and 
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having a fusion of the pspA promoter to reporter gene lacZ. The second selection strain also 
lacked the IHF subunit HimA, deletion of which reduces the transcription at the psp promoter 
by reducing the DNA bending required by PspF in order to make interaction with 54 [30, 31]. 
Growth tests in liquid media showed that the addition of Pgal to both strains was toxic, with 
the effect being more pronounced as the Pgal concentration was increased. 
The first types of selection attempted were based on solid media with glycerol as a sugar 
source. Initial work showed that sugar source makes critical differences in the extent of Pgal 
toxicity, and the initial screens also demonstrated that arabinose concentration was crucial in 
the selection efficacy. Repetition of the screens at the non-toxic low arabinose level revealed 
some variability in the basic level of Pgal toxicity to the strains not expressing a plasmid and 
few or no survivors when the libraries were expressed. To encourage hit growth, LB agar 
was trialled as a growth medium and although with peptide expression good selection was 
achieved, there was still variability between screens and between survival of transformants 
not expressing a plasmid. 
To create a selection system which could be followed via and OD600 readout, liquid 
selection was investigated. Initially it was clear that the requirement for expression makes 
transformation and selection on the same day toxic. Instead, transformed cells must be 
recovered overnight with selection. It could be that this reduces the likelihood of finding a 
very potent inhibitor, since cells are given time to accumulate peptide before selection takes 
place. Further tweaking of this form of selection could be required, but this will not be known 
until the results from one form of this selection are fully explored. Allowing the cultures to 
recover overnight eliminated the toxic effect of arabinose, but the arabinose concentration 
had to be increased for any potential effect to be observed. At high arabinose concentration 
levels, it appears that the SGW+5 library did confer some increased survival, albeit only by a 
small amount. It was decided however, not to pursue this type of selection since it was 
unclear whether the selection was genuine, or due to natural fluctuation in culture growth. It 
is also unclear how many rounds of selection will be required before a clear difference can 
be seen. However, this type of selection system is potentially the most useful type of 
selection, since if working correctly its efficacy should be able to be visualised round by 
round. After validation of Pgal as a selection tool, and development of secondary selection 
systems it would be beneficial to re-visit multi-round selection. 
After even one round of selection however, some differences in growth were seen in cultures 
expressing a library, versus those bearing the control or in the absence of arabinose. Since 
Xgal and Pgal were shown to compete for -galactosidase, they could not be used 
153 
 
concurrently for selection purposes. However, single round selection followed by plating a 
portion of the selected culture on an Xgal plate was used to isolate single colonies having a 
lacZ knockdown phenotype, i.e. white or light blue colonies. This protocol was used to 
isolate initial hit peptides from both the SGW+5 and Lib 1 libraries for further testing, the 
results of which will be discussed in the next chapter. 
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5 SICLOPPS II: HIT PEPTIDE CONFIRMATION AND 
ANALYSIS 
This chapter covers the work done to follow-up on the results of the liquid-based selection 
screen (4.4.2.3 Single-Round Screen with Plating). The main aim of this part of the project 
was to establish a method for determining which hits were worthwhile pursuing, leading 
ultimately to in vitro characterisation and validation. Included therefore is hit peptide 
composition and sequence analysis, selection for further screening and the development of 
and results pertaining to secondary in vivo screens as well as the development and outcome 
of an orthogonal in vivo activity screen. Current work by others focuses on following up 
several interesting hits in appropriate in vitro assays. 
5.1 HIT PEPTIDE IDENTITY 
As covered in the last chapter, hit peptides were selected from the Xgal, arabinose plate 
screen because they were contained in colonies with either a light blue or white phenotype. 
However, with this type of methodology it is likely that a fraction of the hits will be false 
positives for several reasons. Firstly, although several forms of the screen were explored 
using both solid and liquid media, the full range of possible screen conditions and results 
have not yet been explored. This may mean that the concentration of Pgal used, although 
toxic to the selection strain, may be lower than is optimal for eliminating false positives. 
Exploration of the results in this case will provide a good proof of principle for the screen, 
revealing some genuine hits as well as indicating the extent of false positive selection.  
The origin of selection tool Pgal also reveals a possible source of false positives. Pgal was 
originally used to identify mutants of the lac operon [254, 255] and it is therefore to be 
anticipated that a certain portion of hits will be stable chromosomal mutations of the 
selection strain. Potential false positive mutations are in -galactosidase, the pspA promoter 
region as well as pspF or rpoN. Appropriate follow-up screens should reveal quickly which 
peptides are likely to be false-positives and not be labour-intensive. 
For the Lib 1 library, 91 colonies were selected as initial hits, having either a light blue or 
white phenotype after plating a portion of the single round liquid selected culture on to Xgal 
plates (4.4.2.3 Single-Round Screen with Plating). The plasmids were recovered from the 
colonies and sequenced to identify the amino acid sequence of the hit peptide potentially 
responsible for the positive phenotypic change. In the case of the SGW+5 library, only 51 
colonies grew on the Xgal plate, and this was deemed a small enough number that all 
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phenotypic outcomes should be examined. Therefore, DNA was isolated from all 51 colonies 
and sequenced for further analysis. 
5.1.1 LIBRARY 1: SEQUENCE IDENTITY ANALYSIS 
Sequencing the plasmids recovered from the Lib 1 hit colonies gave 12 sequences 
containing stop codons and 63 unique sequences. Of the 63, 50 hits were found to occur 
once, with 13 occurring either twice or three times. Some of the plasmids contained 
frameshifts and one bore a silent mutation in which the initial cysteine codon was altered 
from the expected TGC, to TGT. One peptide, which occurred twice, contained an in frame 
deletion in the supposedly conserved GAFTGA motif, with the removal of the terminal 
alanine codon GCG. The full DNA and expected translated sequences of all Lib 1 peptides 
are given in the Appendix D Sequences of SICLOPPS Selected Hits 
5.1.1.1 LIBRARY 1: AMINO ACID REPRESENTATION 
To reduce the number of peptides from the initially selected 63 individuals it would be useful 
if the selection process could be reviewed and assessed for a common basis of success. It 
would also be beneficial if the number of potential hits could be narrowed to lesser number 
of individuals most likely to be genuine hits. The first step to doing this was to analyse how 
often individuals appeared in the selected hits. The WordCount software 
(http://mobyle.pasteur.fr/cgi-bin/portal.py?#forms::wordcount) counts the number of either 
amino acids or nucleotide bases, and was used to sum the number of each amino acid 
occurring outside of the GAFTGA motif. 
From 79 sequences which did not contain a stop codon, 76 contained an intact GAFTGA 
motif and one had a deletion which was in-frame (H55) leading to an alternative sequence. 
As previously mentioned, one sequence, which appeared twice, contained the motif GAFTG; 
in this case the amino acid in peptide position 9 was counted as one of the randomised 
positions (where the peptides are numbered as follows [C1X2X3G4A5F6T7G8A9X1 0X11]cyclo. 
Table 5.1 shows the number of each amino acids found in positions X2X3X1 0 and X1 1 and 
was calculated by inputting the full sequences before subtracting the numbers of G, A, F and 
T due to their appearance in the GAFTGA motif. As is true for the native genetic code, for 
members of a SICLOPPS library not all amino acids are represented by an equal number of 
codons. Table 5.1 (as well as the alternative codon chart given in the Appendix C Codon 
Chart for SICLOPPS) also shows the number of codons which represent each amino acid. 
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** For Stop, numbers were calculated from the total number selected, 91. 
Table 5.1 Amino acid usage in the Lib 1 library selection. The number of codons in the modified SICLOPPS 
genetic code for each amino acid and the probability that an amino acid will be found in one position and in all 
four randomised positions is shown. The number of each amino acid found outside of the GAFTGA motif in the 
selected 91 hits is also shown for comparison. The ratio of codon usage for the available codon(s) is given for E. 
coli WT. 
AMINO 
ACID 
NUMBER 
OF 
CODONS 
USAGE 
PROB. 
PROB. OF 
APPEARING 
IN ANY 
POSITION 
NUMBER 
EXPECTED 
IN 79 
SAMPLES** 
NUMBER 
FOUND 
RATIO OF CODON 
USAGE 
L 3 3/32 3/8 29.63 20 0.11 0.1 0.55 
R 3 3/32 3/8 29.63 17 0.37 0.08 0.03 
V 2 1/16 1/4 19.75 29 0.2 0.34 
S 2 1/16 1/4 19.75 28 0.17 0.13 
G 2 1/16 1/4 19.75 27 0.4 0.13 
P 2 1/16 1/4 19.75 18 0.1 0.55 
T 2 1/16 1/4 19.75 12 0.43 0.23 
A 2 1/16 1/4 19.75 2 0.25 0.34 
D 1 1/32 1/8 9.88 19 0.41 
M 1 1/32 1/8 9.88 18 1 
W 1 1/32 1/8 9.88 18 1 
C 1 1/32 1/8 9.88 15 0.57 
K 1 1/32 1/8 9.88 14 0.24 
Y 1 1/32 1/8 9.88 13 0.47 
F 1 1/32 1/8 9.88 12 0.49 
Stop 1 1/32 1/8 11.38 12 0.09 
I 1 1/32 1/8 9.88 9 0.46 
Q 1 1/32 1/8 9.88 8 0.69 
N 1 1/32 1/8 9.88 7 0.61 
E 1 1/32 1/8 9.88 6 0.3 
H 1 1/32 1/8 9.88 3 0.48 
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For the majority of amino acids there is only one codon, but for some there are two and for 
arginine and lysine, three codons encode the amino acid. In order to analyse the amino acid 
usage in the library it is therefore necessary to take into consideration the codon availability. 
Furthermore, Table 5.1 shows the probabilities of finding a given amino acid at one position, 
at any of the four randomised positions and the expected numbers for comparison with the 
number found. 
The reduced range of codons used includes one stop codon (TAG). This means that out of 
the total 91 selected hits, 11.38 (11 or 12) are predicted to contain a stop. The number found 
was 12, which suggests two things. The first is that the selection is not completely faultless, 
since a stop codon, unless suppressed, would usually mean that no cyclic peptide was 
produced. Although it is possible that the fusion of linear peptide up to the stop codon and IC 
intein could inhibit transcription from the pspA promoter, the likelihood is that this would be a 
non-specific interaction, reminiscent of those sometimes found for the elements used in 
phage display [111]. The second is that for the randomised element of the selected hits, we 
find the expected number of stops, suggesting that overall any differences for other amino 
acids might be attributable to the positive selection. 
The results of the WordCount in Table 5.1 reveal some potential patterns. It appears that in 
the randomised position there is under-representation of both alanine (2 codons) and 
histidine (1 codon) occurring only 2 and 3 times respectively. Contrastingly, some amino 
acids such as aspartic acid, methionine and tryptophan occur almost twice as many times as 
expected, whilst glycine, valine and serine also appear over-represented. In general, it 
appears that the over-represented amino acids are hydrophobic in nature (Val, Trp, Ty, and 
Met) which might cause increased peptide hydrophobicity and non-specific binding. It is 
difficult to say how reliable this crude method is of proving positive selection, since the 
sample size (91) is diminishingly small compared to the total library size (160,000). However, 
these data do offer encouragement that in the randomised positions some selection towards 
a few amino acids or perhaps away from others has occurred. 
5.1.1.2 SGW+5: 1 HIT WONDER? 
After a single round of library selection plus plating onto arabinose and Xgal, the SGW+5 
gave 51 individual colonies that ranged in colour from deep blue to white (4.4.2.3.2 SGW+5). 
Due to the limited number of colonies, all of the individuals were collected, with the idea that 
the colour phenotype and sequence and -galactosidase activity could be examined. 
However, sequencing of all of the hits revealed something very surprising: all of the colonies 
contained a plasmid with the same sequence, see Table 5.2. Additionally shown in Table 5.2 
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are the identities of 10 randomly selected peptides, none of which have the same sequence 
as the SGW+5 hit peptide. 
HIT NUMBER PEPTIDE SEQUENCE 
SGW+5 H1-51 S G W V I A G Y 
SGW+5 R1 S G W K G G T P 
SGW+5 R2 S G W K D I S G 
SGW+5 R3 S G W I V D F S 
SGW+5 R4 S G W T N K * G 
SGW+5 R5 S G W P A R R V 
SGW+5 R6 S G W T D V S G 
SGW+5 R7 S G W N V G Y E 
SGW+5 R8 S G W T Y * E L 
SGW+5 R9 S G W A Y E D C 
SGW+5 R10 S G W C A Y W A 
pARCBD S G G Y L P P L 
Table 5.2 Identity of SGW+5 selected hit peptide and randomly selected peptides from the library. * 
denotes stop codon. 
How can this result be explained? Since even with the best positive selection system false 
positives are expected, it appears unlikely that only one hit will be selected. Additionally, 
since not all of these hits gave an identical phenotype on the blue/ white screen plate, this 
result also undermines the reliability of the secondary selection system. 
Only 10 random individuals were selected for analysis of the SGW+5 library, a small number 
compared to the theoretical library size of 3.2 million peptides. Therefore, it is impossible to 
be certain whether selection of a single individual is a fluke or genuine selection based on 
this data alone. In order to determine the veracity of the selection follow-up screens will be 
performed, as for the Lib 1 library hits, to determine if it has any activity. Since the randomly 
selected clones do not include the selected hit peptide, it must be assumed that this is a 
genuine result, but this could also be upheld by repeating the selection to see if this hit is 
frequently found again. 
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5.2 FOLLOWING-UP THE INITIAL SELECTION 
5.2.1 THE HITS CONTAIN PEPTIDE SEQUENCES THAT OCCUR MULTIPLE TIMES 
For the Lib 1 library, the results are significantly more diverse, and probably contain some 
false positives. Before pursuing each hit, it would be helpful if the hit sequences could be 
analysed in such a way that the field were narrowed and only those more-likely to be 
genuine hits were taken forward. 
Alignment of all the hit sequences revealed that there were 13 sequences which occurring 
more than once so these were selected to be pursued. Additionally, 7 of the remaining 
sequences were selected because they were perceived to be similar to those occurring in 
multiples, either with 1 amino acid difference, or with 2 similar types of amino acid. Finally, 
two sequences with stop codons at position X3 were chosen. These two peptides only have 
one amino acid difference, but the stop codon should mean that no cyclic peptide expression 
occurs. If this is the case, these two peptides will provide a useful control for the follow-up 
experiments. All of the selected hits for further study, with the reason for their selection are 
shown in Table 5.3. 
This narrowed field of selected hits will be subjected to a series of follow-up assays, in order 
to determine whether their initial selection was the result of increased growth due to peptide 
expression, or if they are simply false positives. Due to the presence of the lacZ reporter 
gene, follow-up assays will aim to measure changes -galactosidase activity, dependent on 
peptide production. 
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HIT 
NUMBER 
 PEPTIDE SEQUENCE  
NUMBER FOUND/ 
REASON FOR INTEREST 
H1  C T W G A F T G A G C  3 
H2  C A S G A F T G A F W  1 aa different to H79 
H4  C L S G A F T G A S S  2 
H7  C L W G A F T G A P G  2 
H9  C V G G A F T G A A S  2 
H12  C V W G A F T G A D M  3 
H14  C W M G A F T G A D K  2 
H15 
 
C V * G A F T G A S E 
 1 aa different to H84 / 
stop codon control 
H17  C L K G A F T G A S R  Similarity to H80 
H18  C V F G A F T G A G F  Similarity to H25 
H20  C M P G A F T G A R K  2 
H25  C S W G A F T G A L G  2 
H35  C S N G A F T G A V D  2 
H37  C L W G A F T G A P E  1 aa different to H7 
H45  C W M G A F T G A D Q  1 aa different to H14 
H46  C Q T G A F T G A C C  2 
H49  C F K G A F T G G C   2 
H60  C L E G A F T G A V K  3 
H79  C A S G A F T G A C W  1 aa different to H2 
H80  C L R G A F T G A S I  Similarity to H17 
H84 
 
C V * G A F T G A S D 
 1 aa different to H15 / 
stop codon control 
H85 
 
C V Y G A F T G A P F 
 
2 
Table 5.3 Hit peptides from the Lib 1 library selection chosen for further study and reasoning. All peptides 
appearing more than once in the plated hits were chosen as being interesting for further study. Other peptides 
which were deemed to have a similarity to one of the multiply-selected peptides were also chosen. Two hits 
having stop codons were chosen to see if any expression could be detected, and as potential controls for follow-
up assays. Stops are indicated with an asterisk (*). The GAFTGA motif is shown in bold. Polar charged amino 
acids are in green, polar neutral in blue, aromatic residues in purples and non-polar in pink. 
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5.2.2 COMPARISON OF THE SELECTED HITS TO LOOP 1 SEQUENCES 
Analysis of the number of each amino acid occurring outside of the GAFTGA motif in the 
selected peptides revealed that not all amino acids were represented in the numbers 
expected (see Table 5.1). After the secondary selection, based on the number of times 
sequences appeared in the selection, was performed the amino acid character was 
analysed. In Table 5.3 the amino acid character of the positions outside the GAFTGA motif 
have been split into 3 groups: polar charged (green), polar neutral (blue) and non-polar 
(pink). It appears that the majority of non-polar, hydrophobic amino acids occur in peptide 
positions 2 and 3 with polar neutral amino acids making up the majority of the remainder. In 
positions 10 and 11, polar charged residues appear to prevail. 
 
To examine the amino acid conservation in 54 activators at these sites, the sequence of 
PspF was aligned using the NCBI Blast service and graphically represented using WebLogo 
[263] and the results are shown in Figure 5.1. Figure 5.1, A. shows that whilst the GAFTGA 
motif is well conserved, there is also a degree of conservation in positions 1 to 3 preceding 
GAFTGA (PspF 80-82), but little conservation in 10-12 (PspF 89-91). In these 3 conserved 
positions, (Figure 5.1) outside of GAFTGA, polar charged residues are most commonly 
found, although there is tolerance of hydrophobic residues including valine and alanine. The 
Figure 5.1 Loop 1 identity across bEBPs and examples of conserved sequences. A. Alignment of all 
sequences of 
54
 interacting proteins to the sequence PspF (NCBI Blast) and representation of sequence 
conservation in Loop 1 (WebLogo). B. Examples of sequence conservation in several well-studied bEBPs. 
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variety of amino acids tolerated in positions 10 to 12 is demonstrated both in Figure 5.1, A. 
and by comparing the sequences of 4 commonly studied bEBPs, shown in Figure 5.1, B. 
There is good sequence conservation between the 4 bEBPs up to and including the 
GAFTGA motif, but limited conservation between the 4 in the following 4 residues, 
suggesting that variety is tolerated, without compromising binding to 54. 
Comparison of the sequences for 54 activators with the hit peptides selected, shows a 
difference in the amino acid character found in positions 2 and 3, with only a few peptides 
containing a polar charge amino acid at position 3. Examination of all of the selected 
sequences reveals that, as with the selected peptides as a whole (see Table 5.1), some 
amino acids are under-represented. Whilst histidine occurred less often than expected in the 
screen hits as a whole, none of this narrowed field contains histidine. Additionally, potential 
hydrogen-bond partners asparagine and glutamine occur only once and twice respectively. 
Finally, whilst serine and cysteine are well-represented, threonine is found only twice, which 
might be attributable to increased bulk. 
Whilst none of the selected peptides contain the same conserved sequence (residues 1 to 3) 
as is found in 54 activators in general (Figure 5.1, A.) and the specific examples given in 
Figure 5.1, B., this does not mean that the peptides are not competing for the same binding 
pocket as PspF. Mutation of Loop 1 and the preceding sequence (1.1.4 Loop 1 and the 
GAFTGA Motif) showed that whilst alteration of conserved sequences was rarely tolerated 
for RPOC formation, binding of 
54 was still possible. The requirement for these peptide 
therefore to bind 54 in competition with PspF, preventing the WT Loop 1 from accessing its 
binding pocket. The peptide‟s GAFTGA motif may provide specificity, whilst the 
predominantly hydrophobic amino acids bind non-specifically to 54. 
5.2.3 HIT PEPTIDE EXPRESSION 
To test whether there was any detectable peptide expression of the selected Lib 1 hits, a 
Western blot using an anti-CBD antibody was used, and the results are shown in Figure 5.2. 
In the presence of arabinose, there are 2 visible bands for the pARCBD control, which 
correspond to the 2 species with CBD tag: IC-peptide-IN and IN. In the absence of arabinose, 
no signal is detected. As expected, the 2 hits which contain stop codons in the peptide 
sequence, H15 and H84, are not detectable by blotting for the CBD tag which is present in 
the other pre-spliced peptides, but they may still be expressed up to the stop codon. 
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For the other hit peptides, there are clear differences in the amount of expression, 
represented by the total of the 2 bands, and the amount of intein splicing, taken as the ratio 
between the 2 bands. Although not formally quantified, it appears that hits such as H49, H79 
and H80 are not well expressed. Furthermore, for some hits such as H1 there is an equal 
detectable amount of both bands. However, hits such as H2, H12, H46 and H85 have small 
detectable amounts of the lower band, which is the post-splicing product. H17 conversely, 
has larger amounts of the lower band, which may be due to rapid splicing of IC-peptide-IN. 
It is not certain what the significance of these differences is, but the identity of amino acids 
neighbouring IN has previously been shown to affect the splicing efficiency of the full length, 
processed intein [160, 264]. Scott et al. looked at the splicing of variants of pseudostellarin F 
(which the pARCBD control encodes) in which the amino acid adjacent to IN was mutated to 
a limited number of other amino acids of varying characteristics [160]. Of the 9 tested, the 
splicing of 3 was not detectable by PAGE (IN-1 = glutamic acid, asparagine and proline), and 
the peptides were not detectable by MALDI. However, processing and splicing by-products, 
such as the lariat and IC were detectable. For the Lib 1 hits, those which do not splice to the 
same extent as others do not contain any of the three amino acids in X11 (adjacent to IN) 
which were tested by Scott et al.. However, whilst Scott et al. found that pseudostellarin F 
with an N-terminal glutamic acid was unable to splice, the Lib 1 hit H37 does splice 
detectably, albeit perhaps slightly less than others. This perhaps hints that both whole 
peptide identity and N-terminal amino acid are important in the extent of splicing. 
Figure 5.2 Expression of selected Lib 1 hits, the SGW+5 hit and random peptides, detected by Western 
blotting for the CBD tag. In the absence of arabinose, no expression of pARCBD can be detected, whilst 2 
clear bands are detectable plus arabinose (lower box). According to detection by Western blot, not all Lib 1 hits 
are equally well expressed, or spliced. 
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The above peptides have been selected for activity in an in vivo screen. Therefore, it might 
perhaps be a benefit if some peptides which are apparently active are either poorly 
expressed or poorly spliced. These poorly expressed peptides may therefore prove to have 
a higher specific activity than other higher expressed peptides. 
5.2.4 A KINETIC BETA-GALACTOSIDASE ASSAY 
The pspA promoter fused to the reporter gene lacZ is deployed in a positive selection 
methodology through the use of lactose analogue Pgal and the galE deletion in the reporter 
strain. However, the most familiar and frequently used application of lacZ is in a traditional -
galactosidase activity assay, and its use would complement the positive selection protocol. 
This assay uses the chromogenic lactose analogue ONPG which causes cell lysates to turn 
yellow when it is turned over by -galactosidase. 
Traditionally, the assay is performed by growing cultures to mid-exponential phase on a few 
mL scale, taking an aliquot of 50 L as a minimum and performing the enzymatic assay on a 
1 mL scale. Although the classic -galactosidase assay [225] has been widely used to 
characterise lacZ activity performing it can be quite labour intensive. Start and end points of 
each reaction must be recorded manually, which limits the practical number which can be 
performed simultaneously. Alternatively, there have been several reports which both 
miniaturise the assay and record the data kinetically [211, 265-268]. Using 96-well plates, 
both for culture growth and assay measurement, in conjugation with a plate reader allows a 
large number of assays to be performed in one day and means that the measurement 
process is automated. Furthermore, the kinetic nature of the assay and the use of multiple 
data points to calculate activity reduces the likelihood of human error being a factor. 
The assay varies in several ways from the original. Firstly, the assay size is limited by the 
96-well plate format to 200 L, which results in an altered path length compared to the 
traditional assay, which is measured in a cuvette. Secondly, since the assay is kinetic, there 
is no requirement for the addition of the traditional stop solution 1 M Na2CO3, which deepens 
the yellow colour. Finally, several methods have been reported for lysing the cells beyond 
the traditional combination of SDS and chloroform. Since the traditional assay is so widely 
used however, it would be useful to be able to express the outcomes from the alternative 
kinetic version in the familiar Miller units. A conversion equation, including conversion factors 
which take into account altered path length in OD600, OD420 which is used to measure the 
amount of ONP formed and the lack of Na2CO3 has been reported by Thibodeau et al. [211]. 
  
165 
 
5.2.4.1 ANALYSIS OF SELECTED HIT PEPTIDES 
5.2.4.1.1 SGW+5 
Before subsequent full sequencing of all of the SGW+5 hit peptides, they were subjected to 
the secondary kinetic -galactosidase assay. The results, shown in Figure 5.3, reveal the 
limitations of the assay and do not confirm SGWVIAGY as having genuine activity. Initially, 
the assay was tested using a combination of BugbusterTM Protein Extraction Reagent 
(Novagen) and lysozyme to lyse the cells for assay, as recommended by Thibodeau et al. 
[211]. However, on comparison of this method and the traditional combination of chloroform, 
0.1% SDS and -mercaptoethanol it was found that Bugbuster did not always perform 
Figure 5.3 Results of the kinetic -galactosidase activity assay of selected SGW+5 hits in LJR04. A. The 
initial assay gave varied levels of -galactosidase, both +/- arabinose. B. Extending the lysis time gave more 
consistent results, but no effect of peptide expression on -galactosidase activity is evident. C. Assay of 
overnight cultures gave higher levels of -galactosidase, but revealed not peptide – dependent knockdown in 
activity. 
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adequately and for some replicates gave low -galactosidase activity for strains which 
should be constitutively active. This was attributed to incomplete lysis, and although the use 
of chloroform can be tricky with multi-channel pipettes and requires resistant microtitre 
plates, this method consistently lysed cells and was preferred for future use. 
Figure 5.3, A. shows the results of the initial assay using chloroform lysis and day cultures 
grown either with or without arabinose to an OD600 of approximately 0.4. What is instantly 
clear is that there are large, apparently arabinose dependent, differences in -galactosidase 
activity of some cultures. Furthermore, in several of the cultures the errors between 
biological replicates is very large, reaching almost 1000 modified Miller units for H10 + 
arabinose. Since it was subsequently confirmed that H1 – H10 is a single plasmid identity, 
these changes cannot be entirely plasmid mediated. One possible explanation is incomplete 
incubation or agitation required to achieve complete cell permeabilisation. The lysis step was 
performed in 96-well deep-well plates by addition of the lysis mix, the plates were sealed 
with Airpore Tape sheets (Qiagen) vortexed for 30 seconds and the lysed cells immediately 
aliquoted into Z-buffer for assay. After the initial variability and error problems the vortexing 
step was extended to 2 minutes to ensure complete mixing, and samples were left to settle 
for 10 minutes before the assay was performed. The results obtained after these changes 
were made are shown in Figure 5.3, B. Although the errors are still quite large, there is far 
less variability between biological repeats and across all of the SGWVIAGY cultures. 
Unfortunately these data do not support the proposal that the single SGW+5 hit is active 
against the pspAp promoter. 
Finally, to confirm the activity of SGWVIAGY, overnight cultures were also tested for -
galactosidase activity and the results are shown in Figure 5.3, C. In this assay, the overall 
levels of -galactosidase are higher, which is as expected since the cultures were allowed to 
reach a far higher OD600. Confirming the results of the assayed day cultures, there are no 
large differences in -galactosidase activity in the presence of peptide. This could be 
because the selected hit was a chance result and has no activity, or it could be due to 
insensitivity in the assay due to long lifetimes of -galactosidase, which abolishes the effects 
of small knockdowns in promoter activity due to peptide interference. 
5.2.4.1.2 LIBRARY 1 HIT PEPTIDES 
The retransformed Lib 1 hits in LJR04 were also tested in the kinetic -galactosidase assay 
and the results in the presence of arabinose are shown in Figure 5.4. Despite the inclusion 
of conversion factors, the kinetic plate-based assay does not give identical absolute values 
to those expected in the conventional full-scale assay. Differences are probably due to 
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differences in culture growth due to incubation in 2.2 mL plates instead of larger scale 
cultures [211], but since the assay does contain 2 controls, in the form of R1 and pARCBD, 
this should not be a problem. 
In the presence of arabinose, there are no large knockdowns in -galactosidase activity for 
any of the hits compared to pARCBD or R1. H85 does have a slightly lowered -
galactosidase activity compared to pARCBD; however, the experimental errors seen for 
some of the other hits make it difficult to determine what reduction in activity is enough to 
consider a significant drop. 
Interestingly, hits H12 and H80 appear to have increased -galactosidase activity. Although 
this was not selected for deliberately, it is possible that one mechanism of peptide-
dependent survival in low concentrations of Pgal could be increased -galactosidase activity. 
At the lower end of Pgal concentration toxicity, increased -galactosidase activity for a short 
period could increase survival over longer selection times. 
  
Figure 5.4 -Galactosidase activity of Lib 1 hits measured by kinetic -galactosidase assay in LJR04, in 
the presence of arabinose. None of the Lib 1 hits were able to knockdown the -galactosidase activity 
significantly compared to pARCBD. 
168 
 
5.2.4.1.3 CONCLUSIONS 
Whilst the kinetic -galactosidase assay allows a large number of cultures to be assayed 
simultaneously and with reduced possibility for human error, it appears that this assay is not 
a suitable follow-up to the Pgal selection. Although the peptides were initially selected based 
on effective -galactosidase activity, it is possible to imagine that in the liquid selection small 
changes in promoter activity will be magnified. Inactive peptides may only have marginally 
higher -galactosidase activity, but this may result in earlier death and removal from the 
selection. In this -galactosidase activity assay, the enzyme is likely to accumulate and mask 
small differences in promoter activity. 
The SGW+5 single hit aside, those Lib 1 hits selected multiple times seem likely to be 
genuine hits. Since differences in activity are not represented in this assay, an alternative 
should be sought which better represents the mode of peptide activity: growth rescue in the 
presence of Pgal. 
5.2.5 DO HIT PEPTIDES RESCUE GROWTH IN LIQUID MEDIA? 
Since the kinetic -galactosidase assay gave inconclusive results, it was necessary to use 
an alternative approach to re-confirm the selected Lib 1 hits. If the selected peptides contain 
genuine hits, they should be able to rescue growth to a degree greater than the negative 
controls, when grown in the presence of Pgal. Although the liquid selection was performed 
on a large scale, initial testing for Pgal toxicity was successful when carried out in a 96-well 
plate format. Use of a 96-well plate enables all the selected peptides plus controls to be 
screened in triplicate simultaneously, and allows automation of the measurement process.  
In order to replicate the initial selection as closely as possible, the hits were transformed into 
a clean selection strain and grown overnight either with or without arabinose in deep-well 96-
well plate format (0.5 mL culture volume in 2.2 mL wells), in triplicate. For the assay itself, 
the peptides were sub-cultured into fresh media and grown for two hours before addition of 
Pgal to a final concentration of 0.05 %. The growth of each culture was recorded, replicates 
averaged and each peptide was compared to the pARCBD and R1 negative controls in the 
presence and absence of arabinose. As shown in Figure 5.5, A., in the absence of Pgal, the 
pARCBD control grows without inhibition as expected, demonstrating that culture growth is 
unaffected by performing the assay in 96-well plates. When Pgal is added at 2 hours, 
cultures expressing both the pARCBD and randomly selected peptide R1 behave identically 
and begin to die at around 240 minutes (Figure 5.5, B.). 
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Figure 5.5 Growth of representative retransformed Lib 1 hits in LJR04 plus arabinose in 0.05% Pgal. The 
control peptide pARCBD grows dies when Pgal is added at 2 hours and the randomly selected peptide R1 behaves 
identically. In the presence of arabinose, all the retransformed Lib 1 hits behave differently. The majority behave as 
H4, and die as pARCBD but to a slightly lesser final extent. More interesting hits behave as H18, and die to a much 
lesser extent, or H37 and begin to die later and to a lesser extent. 
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In the presence of arabinose, the selected and retransformed Lib 1 hits did not behave as 
pARCBD or R1, but each followed three typical patterns of growth. The majority of the 
peptides behaved as H4 (Figure 5.5, C.) and after the addition of Pgal, began to die as 
pARCBD but did not die to the same extent. Other hit peptides behaved as H18 (Figure 5.5, 
D.) and although the reduction in OD600 began at the same time as pARCBD, the final 
OD600 reached was much higher than that of pARCBD. Finally, in some instances, 
decrease in OD600 begins later and occurs to a lesser extent than for pARCBD, as shown 
for H37 in Figure 5.5, E. The dependence of the altered growth profile on arabinose is 
demonstrated for H37 in Figure 5.5, F., with all of the hit peptides behaving as pARCBD in 
the absence of arabinose. There was also very little error between replicates and between 
uninduced cultures, suggesting there is not a large variation in growth and response to Pgal 
of the background selection strain. This supports the proposal that any differences in the 
presence of arabinose are confidently attributable to expression of the intein and the cyclic 
peptide. 
Three key quantifiable growth characteristics for each of the selected hits, as well as the 
pARCBD and R1 controls are shown in Table 5.4. For the majority of the hits, the reduction 
in OD600 associated with cell lysis begins at the same time as the pARCBD control, at 260 
minutes; additionally, there are only small differences in the highest OD600 achieved. The 
last and perhaps most expressive, quantified feature of the growth curves is the culture final 
OD600. For all of the selected hits, the reduction in OD600 was not as large as that of either 
pARCBD or R1. Whilst some have a standard deviation that takes them within the range of 
the pARCBD control, others, such as H20, H37 and H18 are much higher and with low error. 
If a peptide is able to affect transcription from the pspA promoter, less -galactosidase 
should be present in the cell when Pgal is added. Cellular turnover of Pgal should therefore 
be lower, resulting in less or delayed cell lysis, whilst any -galactosidase released through 
cell lysis is free to turnover and expend the Pgal that is free in solution. It is therefore 
possible that a higher final OD600 is the direct result of lowered pspA promoter activity. 
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PEPTIDE 
TIME OF HIGHEST 
OD600 (MINS) 
HIGHEST OD600 
FINAL 
OD600  
SD FINAL 
OD 
pARCBD 260 0.412 0.106 0.005 
R1 240 0.454 0.111 0.009 
H15 260 0.379 0.130 0.132 
H25 280 0.414 0.132 0.032 
H35 260 0.352 0.150 0.046 
H12 240 0.420 0.153 0.029 
H60 280 0.393 0.155 0.017 
H49 260 0.354 0.164 0.055 
H17 260 0.435 0.164 0.002 
H1 260 0.406 0.166 0.009 
H45 260 0.432 0.168 0.027 
H46 360 0.403 0.169 0.028 
H4 260 0.418 0.170 0.003 
H85 240 0.318 0.173 0.060 
H7 280 0.424 0.175 0.022 
H80 260 0.439 0.182 0.022 
H2 260 0.424 0.183 0.009 
H9 260 0.453 0.184 0.066 
H84 280 0.437 0.190 0.058 
H79 260 0.438 0.199 0.051 
H20 240 0.544 0.201 0.005 
H37 280 0.437 0.201 0.015 
H14 300 0.388 0.216 0.138 
H18 260 0.474 0.279 0.060 
Table 5.4 Time and value of highest OD600 achieved in growth plus Pgal and hits sorted according to 
increasing final OD600. 
5.3 IS 
54
-RNAP THE TARGET? AN ORTHOGONAL SCREEN 
It appears from the follow-up Pgal growth assay that some of the selected hits have an 
arabinose dependent effect on selection strain growth in the presence of Pgal. However, 
although they appear to increase culture survival after Pgal addition, it is unclear which part 
of the complex pathway associated with being sensitive to Pgal they might be targeting. One 
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target should be the PspF. 54 dependent activation of the pspA promoter, but it could also 
be another part of the Leloir pathway (Figure 4.3), direct inhibition of -galactosidase or 
translation of the required genes. It is also conceivable that among the hit peptides from the 
initial screen methodology exist a mixture of targets for inhibition. 
In order to further narrow the field of action of the hits, it is desirable to have a secondary 
assay with an appropriate target but with an orthogonal mode of action. This screen should 
also have 54-dependent transcription as a target but cell survival should not be dependent 
on either -galactosidase, or galactose metabolism. Since bEBPs are a family of proteins 
with high levels of conservation within the functional domains especially the GAFTGA 
containing Loop 1 (1.1.2.2 Domain Structure and Regulation of AAA+ bEBPs), some hit 
peptides from the Pgal screen should also target the interaction between 54 and an 
alternative bEBP. However, given that the peptides may be active through inhibition of -
galactosidase, an alternative reporter assay is required. 
5.3.1 TARGETING THE ALTERNATIVE BEBP NTRC 
5.3.1.1 THE NTR RESPONSE 
The nitrogen-regulated (Ntr) response consists of approximately 100 genes whose 
expression is altered under sub-optimal or nitrogen-limited growth conditions in E. coli; 
generally defined as when ammonia is not abundant [269]. In addition to ammonia, E. coli 
can utilise a variety of species as nitrogen sources, such as amino and nucleic acids. In all 
cases however, nitrogen assimilation must result in synthesis of glutamine and glutamate, 
the two major intracellular nitrogen donors [35]. Two pathways exist for glutamine and 
glutamate formation, which are activated depending on nitrogen availability and source. 
When ammonia is limited or an alternative source is present, nitrogen assimilation is 
performed by two enzymes glutamine synthetase (G.S.) and glutamate synthase in the 
reaction shown (Figure 5.6). 
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When nitrogen is freely available, basal expression of G.S. from the 70-dependent glnAp1 
promoter is sufficient. However, when nitrogen is limited, being either low ammonia or an 
alternative N-source, expression of G.S. switches to the 54-dependent glnAp2 promoter to 
produce a much higher level of the enzyme and to allow the secondary glutamine synthesis 
pathway to take over (Figure 5.6). Expression from the 54-dependent glinAp2 promoter is 
specifically activated by the bEBP Nitrogen regulatory protein C (NtrC) under low NH 
availability, which displays key similarities to PspF. 
Similarly to PspF, NtrC is a homohexamer in its active state and its activity is driven by the 
ATP-dependent movement of Loop 1 containing the GAFTGA motif [51] (1.1.4 Loop 1 and 
the GAFTGA Motif). Since the two proteins have considerable similarities in terms of 
functional motifs and mechanism it is conceivable that inhibitors of the PspF- 54 interaction 
will also be active against NtrC- 54. It is of course possible that some peptides will act 
specifically on PspF, but screening the peptides against an entirely different bEBP should 
allow the development of a truly orthogonal screen. Should the peptides have activity against 
NtrC it will also demonstrate the attractive proposition that it is possible to develop chemical 
modulators for all bEBPs, displaying one reason for the appeal of this approach. 
  
Figure 5.6 L-Glutamate and L-Glutamine exchange in E. coli. Structures are given as under cellular 
conditions. G.S. uses energy to assimilate ammonia under nitrogen-limited conditions. Glutamate and glutamine 
are the major intracellular sources of nitrogen. 
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5.3.1.2 HOW CAN NTRC BE TARGETED? PROOF OF PRINCIPLE 
The bEBP NtrC activates 54-dependent transcription from the glnAp2 promoter in response 
to nitrogen limitation. In strains lacking NtrC, growth is reduced under nitrogen-limiting 
conditions, or completely abolished when nitrogen is available only a single specific source, 
such as arginine [269]. If a hit peptide from the original screen were able to knockdown 
interaction between NtrC and 54, growth should be reduced if the cultures are grown in 
medium containing a nitrogen source, such as L-arginine, which requires activation of the 
glnAp2 promoter. 
To determine the degree of dependence on activation of the glnAp2 promoter with varying 
nitrogen sources, a proof of principle experiment was performed. A WT strain and strains 
carrying deletions of either 54 ( rpoN) or NtrC ( glnG) were grown minimal media 
containing a single nitrogen source of either 10 mM, 3 mM or 1 mM NH4Cl, or 5 mg/mL L-
arginine; the results are shown in Figure 5.7. All strains are able to grow when 10 mM NH4Cl 
is the nitrogen source, and growth is fairly uniform. A slight increase in lag time can be seen 
for the strains carrying the key ntr gene deletions, but the final achieved optical density is 
similar for all three. As the NH4Cl starting concentration is decreased (3 mM and 1 mM) all 
three cultures are able to grow, but there are differences between their growths. As before, 
the strains carrying gene deletions have slightly longer lag times compared to WT, but they 
are also able to achieve a higher final OD600. This peculiarity has been demonstrated before 
(unpublished lab data), the reasons for it are not entirely understood, but perhaps 
demonstrate the complexity of the Ntr response. 
Most striking and critical however is the difference between strain growth when ammonia is 
available and when only L-arginine is present. For L-arginine as the nitrogen source only the 
WT strain is able to grow, notwithstanding a substantially increased lag time. This increase 
in lag time might be attributed to a combination of both require 54-dependent activation of 
the glnAp2 promoter for expression of G.S., and catabolism of arginine to glutamate. Strains 
lacking either 54 or NtrC however do not grow at all, even after 800 minutes, demonstrating 
that the basal level of G.S. expression is not enough to permit survival on L-arginine. 
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Due to the previously observed toxicity of the pARCBD plasmid at high expression levels in 
minimal medium, it was important to ensure that addition of the cyclic peptide expression 
system itself would not reduce the viability of WT cells growing on L-arginine. The effect of 
expression was measured in both the WT and glnG strains by a growth test in NH4Cl and 
L-arginine. The graph in Figure 5.8 shows that high levels of expression of pARCBD are 
Figure 5.7 Growth of WT or deletion strains with varying nitrogen source. When ammonia is freely 
available, all strains grow equally well. As the amount of NH4Cl is titrated down, WT is still the fastest growing 
but does not achieve the same final OD600 and growth is affected for all strains. If the nitrogen source is 
switched to L-arginine, strains lacking the transcriptional activator NtrC ( ntrC) and transcription factor 
54
 
( rpoN) cannot grow, whilst WT grows, albeit with a longer lag time. 
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non-toxic to cells growing in Gutnick minimal medium plus either nitrogen source, unless 
they also lack NtrC, lack of which makes them unable to grow in L-arginine. These results 
mimic those seen without plasmid overexpression and no significant growth defect is evident 
due to the presence of the plasmid. 
Figure 5.8 Expression of SICLOPPS plasmid pARCBD by either WT or glnG strain utilising differing 
nitrogen sources. Plasmid pARCBD was expressed by both WT and glnG strains growing in either 10 mM 
NH4Cl or 5 mg/mL L-arginine. 
5.3.2 CAN THE HIT PEPTIDES INHIBIT NTRC. 54? 
In order to test the specificity of the hit peptides towards 54, they were expressed under 
nitrogen limiting conditions which require NtrC and 54 activity for survival. If the peptides 
target 54-dependent transcription, transcription at the glnA promoter will be reduced and 
there should be some measurable growth differences between active peptides and the 
controls, pARCBD and R1, a randomly selected peptide. 
When L-arginine is the only available nitrogen source the difference in growth between 
strains lacking either 54 or NtrC and the WT is quite large. This suggests that there could be 
a large range within which it might be possible to observe some growth knock-down due to 
peptide expression. The orthogonal screen is therefore a plate-based growth experiment in 
minimal media containing arginine. If any of the hit peptides is able to inhibit interaction 
between NtrC and 54, expression of G.S. from glnAp2 should be reduced there should be 
an observable reduction in some growth parameter. It is unlikely that any peptide will be 
sufficiently active to prevent all 54-dependent activation, so some growth is inevitable. 
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Changes in lag-time, final OD600 or growth during exponential phase however, should be 
expected. 
5.3.2.1 HIT PEPTIDE ACTIVITY AGAINST NTRC- 54 
The isolated hit peptides were transformed into an E. coli WT strain NCM3722 and grown 
overnight in rich medium supplemented with arabinose to ensure both that cyclic peptide 
was present in the inoculant, and that it had not affected cell growth. NCM3722 was used 
because it the most commonly used strain for study of NtrC. 54 in the laboratory, and 
existing knockouts of glnG and rpoN were available. After two washing steps, Gutnick 
minimal medium containing L-arginine and arabinose was inoculated with the overnights and 
cultures were grown in a 96-well plate format at 30 ºC, to reduce evaporation, with shaking. 
The effect of each peptide on culture survival was recorded by monitoring the culture OD600 
over 24 hours. 
Looking at raw data in graphical form it appears there are three broad classes of phenotypic 
responses to the plasmid based peptide expression Class I, Class II and Class III, with each 
of the peptide assigned a class and shown in Table 5.5. Class I peptides (Figure 5.9, A) 
include the randomly picked peptide R1, H15 which contains a stop codon and has no 
detectable expression and some other hits such as H79. These peptides behave as the 
pARCBD control, with no arabinose dependence. Since they were selected from the Pgal-
based screen (with the exception of R1), they may still have some activity specific to 
PspF. 54, but they appear to have no effect on NtrC. 54 dependent activation of the glnAp2 
promoter. 
Class II peptides (Figure 5.9, B) grow to a final OD600 lower than that of pARCBD, but until 
the assumed end of exponential phase growth appears similar, with comparable lag time. 
Examples of peptides in this class are hits H1, H7 and H12, which were all selected at least 
twice. Equivalent growth measurements in the absence of arabinose revealed that this 
response is arabinose dependent, with cultures growing to an equal final OD600 to the 
pARCBD in its absence (minus arabinose data for these samples is not shown). 
The final distinct class, Class III (Figure 5.9, C for + arabinose, D for – arabinose) show both 
an apparent increase in lag time and a decrease in the final OD600 reached of the cultures 
compared to the pARCBD control. Figure 5.9, C shows four example peptides H20, H35, 
H46 and H49 grown in the presence of arabinose, and graph D shows equivalent growth by 
the peptides to pARCBD in the absence of arabinose. 
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Figure 5.9 Results of the growth of select hit peptides in L-arginine +/- arabinose as indicated. A. The 
Class I peptides show no growth difference relative to the pARCBD plasmid control. B. The Class II peptides 
appear to have the same growth profile as pARCBD initially, but fail to reach the same final OD600. C. and 
D. The Class III peptides with and without arabinose. When arabinose is present, Class III have longer lag 
times and lower final OD600; this phenotype is arabinose dependent. 
In some cases, peptides appear to fall in between classes II and III, but all differences 
observed are arabinose dependent. In order to draw conclusions about which peptides are 
active against 54, it is necessary to quantify the response so each peptide can be compared 
to the pARCBD and R1 controls. This should be possible by modelling the growth curves 
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mathematically and fitting an appropriate curve such that it can be quantified in terms of lag 
time, maximal gradient of the slope (during exponential phase) and final OD600. 
5.3.2.2 MODELLING GROWTH: GROFIT ANALYSIS 
Growth curves are a common way to test the effect of a compound, inhibitor or even gene 
addition or deletion on the viability of a bacterial population. However, measuring a particular 
property of a whole population can be difficult. 
5.3.2.2.1 OUTLINE OF GROFIT 
GroFit is a growth curve modelling package that runs in the statistical analysis program R 
[212]. There are multiple methods to mathematically model growth (for a review see [270]) 
and GroFit is able to perform four types of model based fit as well as model-free spline fitting 
of data. The four models available in GroFit are logistic, Gompertz, modified Gompertz and 
Richards, which fit data to give at least 3 characteristic growth parameters as an output. 
Figure 5.10 A shows the fitting model and 3 output parameters, whether the fit is model or 
model-free. Lambda, , represents the lag time of the bacterial culture; its value is 
determined by the fitting of the tangent (shown in blue) which is fitted to the growth curve at 
the maximum growth rate. The gradient of this tangent and second output parameter is mu, 
. The final output from the each fitting is A, the final OD600 achieved by the culture. In 
addition to these 3 outputs, GroFit also calculates the area under the curve by numerical 
integration.  
Figure 5.10 A, the general growth curve model and B, the Richards model as used in GroFit. A shows the 
general expected shape of a growth curve with the parameters ,  and A marked. B shows the Richards model 
in equation form, adapted to represent bacterial growth. 
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GroFit contains 4 parametric mathematical models for growth curve fitting, and selects the 
most appropriate to apply to the input data set using the Akaike Information Criterion. In all 
cases, GroFit used the Richards model to fit the L-arg plus hit peptide data, and the model is 
shown in Figure 5.10, B. As well as the 3 traditional parameters, the Richards model also 
includes a fourth variable, , a parameter which allows alteration in the shape of the fitted 
curve. Besides fitting the data to traditional growth curve models, GroFit also produces a 
model-free spline fit to the data, producing the same output parameters, using a smoothed 
cubic spline, which is available in R as the smooth.spline function. It was expected that the 
model-free fitting would be more appropriate for data analysis; however, as discussed in the 
next section, the spline-fit did not always appear to best fit the data. 
5.3.2.2.2 THE HIT PEPTIDES IN NUMBERS 
The growth curve data of the L-arg growth was input into the GroFit package in R and the 
basic fitting command was run (for input commands see 2.2.3.5 GroFit analysis) for both 
plus and minus arabinose cultures. An advantage of R and GroFit is that input of reasonably 
large datasets is quite facile. Data must be input into GroFit in matrices, but this can be 
easily achieved by manipulating the data in Excel. Thus the workflow, from data collection by 
the spectrophotometer, export into a spreadsheet package such as Excel and finally input 
into GroFit is undemanding. For each input growth curve, GroFit produces a graphical output 
showing the trend line for both the model and model-free fitting (Figure 5.11), ensuring that 
the fitted lines are sensible. 
In some cases the model-fitted curve and the model-free spline fit match well. However, in 
some cases the line fitted to the exponential region, as seen in the Class II peptide H1 
(Figure 5.11) do not match so well. This trend line is used to derive both the maximal growth 
Figure 5.11 Graphical outputs from the GroFit package in R. An example of Class I, II and III is given. The 
graphs show both the model-fitted curve (Richards) in black, and the model-free spline fitted curve (spline fit) in 
red. 
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rate, , and the lag time, so differences may create what could be considered systematic 
errors in the results. There are two options to overcome this; the first is to determine by eye 
which trend line is most appropriate as a fit for the data, and the second is to compare the 
results of both data sets. For the most part it is thought that the Richards model fit will suffice 
and comparison of Richards and spline-fit data will reveal only a few obvious instances of 
discrepancy. For this reason the second approach was taken, with both data sets being 
compared after calculation of averages and errors from the three replicates. 
Initially, whether the Richards and spline-fitted models were similar was compared by 
looking for a difference in the fitted line on the graph. This line of best fit results in calculation 
of both  and  so errors in fitting will result in errors of these parameters. In all cases but 
one (H45 replicate 1 shown in Figure 5.12, B.) the spline either matched the Richards model 
or produced a longer lag time (shallower gradient). In some cases, this was due to an 
inflexion at the top of the exponential growth phase and so may not accurately represent , 
as shown in Figure 5.12 C and D. 
In general the spline-fit and Richards model data are comparable. The lag times given by the 
spline fit are slightly larger (data not shown), but this is uniform across all the peptides and 
the general trends are the same. The difference in lag time between fits can be attributed to 
the slightly different positioning of the line of best fit in the spline fit model as seen in Figure 
5.12. 
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5.3.2.2.2.1 USING THE RICHARDS MODEL FITTING 
Since the Richards model fittings were unaffected by inflexion points in some of the 
replicates, the data from these fittings was used to assess the effect of expressed peptide on 
the glnAp2 promoter. The parameters ,  and A for all for the hit peptides, firstly in the 
presence of arabinose, were compared to those of the pARCBD and R1 controls and are 
shown in Table 5.5. 
Figure 5.12 Output GroFit graphs showing variation between the Richards and spline fit models. Graph A 
shows the cases where the spline fit and Richards models give matching lines of best fit. Graph B shows an 
instance where the spline fit appears to be more suitable. Graphs C and D show cases where the Richards 
model appears better, due to skewing of the spline fit line by an inflexion point in the data. 
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All the selected hits have both a longer lag time and lower final OD600 compared to 
pARCBD. However, whilst R1 reaches a similar final OD600 (within standard deviation), it 
does also have a longer lag time, which is also true for the stop codon containing H15 and 
H84. These data throw into doubt the margins of difference required to show significant 
differences in growth. Furthermore, it is difficult to see any differences in the value of , the 
maximal growth rate for any of the cultures compared to the controls. 
However, some of the peptides cause much longer lag times compared to pARCBD, of up to 
908 minutes in the case of H49. The GroFit analysis also corroborates the initial classing of 
the peptides, with Class II peptides having similar or slightly longer lag times to pARCBD but 
a lower final OD600, and Class III peptides have much longer lag times and lower final 
OD600s. This pattern and classing in peptides does not extend to  suggesting that for 
those cultures with longer lag times, once they enter exponential phase they superficially 
become indistinguishable from those with shorter lag times. The other interesting point 
though, is that after leaving exponential phase, none of the Class II or Class III peptides 
reach the same final OD600 as pARCBD, demonstrating the complexity of in vivo growth 
analysis. 
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PEPTIDE 
PROVISIONAL 
CLASS 
AVERAGE 
(MINS) 
AVERAGE 
A 
(OD600) 
AVERAGE 
(X10-3)
SD  
SD 
A 
SD 
(X10-4  
pARCBD I 583.4 1.39 1.98 92.0 0.01 2.83 
H1 II 665.4 0.88 1.67 39.2 0.08 0.44 
H2 I/II 764.5 1.12 2.39 140.0 0.37 3.69 
H4 II/III 856.3 0.72 1.73 76.3 0.13 1.41 
H7 II 611.4 0.9 1.54 22.5 0.08 0.38 
H9 II 734.4 0.86 1.99 92.0 0.12 3.55 
H12 II 593.8 0.94 1.61 9.2 0.02 0.22 
H14 I 752 1.13 2.14 21.2 0.27 4.07 
H15 I 747.3 1.01 2.09 9.8 0.28 4.63 
H17 I 843.5 1.11 2.52 85.8 0.28 4.59 
H18 III 865.7 0.88 2.14 23.2 0.19 2.69 
H20 II/III 787.3 0.88 2.13 55.0 0.12 0.62 
H25 III 656.4 0.8 1.75 31.0 0.05 3.44 
H35 III 821.8 0.93 1.90 84.2 0.17 1.81 
H37 II 718.8 0.9 2.19 101.2 0.09 3.97 
H45 II/III 846.1 0.96 2.51 128.9 0.09 7.13 
H46 III 794.8 0.92 2.20 102.1 0.30 0.30 
H49 III 907.8 0.71 2.10 38.5 0.04 0.50 
H60 I 712.7 1.24 2.28 57.6 0.29 5.08 
H79 I 803.7 1.33 2.85 94.5 0.14 4.04 
H80 I 708.1 0.99 1.94 180.1 0.31 4.43 
H84 I 784.9 0.92 2.20 76.0 0.22 3.14 
H85 II/III 686.3 0.94 1.90 107.4 0.22 2.95 
R1 I 677.2 1.13 1.93 54.7 0.25 3.10 
Table 5.5 GroFit Richards Model fitted data for lambda, A and mu for cultures grown plus arabinose.  
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The lack of change in  can be rationalised. Although changes in the maximal growth rate 
might be expected if the peptides exert an effect throughout growth, it is also possible that by 
exponential growth phase, peptide inhibition of glnAp2 would be masked by other effects 
such as increased expression from the P1 promoter, or changes in post translational 
modification levels of GS. If the peptides are active, knockdown and therefore expression of 
GS will likely be incomplete and therefore, minimal expression from glnAp2 activated by 54 
will result in molecules of GS able to turnover L-arginine. Once these are transcribed and 
translated they will be able to turnover L-arg multiple times. It might be expected then, that 
until a critical number of active GS molecules become available growth will be slow or 
limited, but once a certain number are achieved, growth will be unaffected in terms of , 
maximal rate. Therefore, it seems more reasonable that knockdown of glnAp2 will result in a 
longer lag time. Finally, changes in lag time with knockout of 54 and glnG is observed in all 
concentrations of NH4Cl as demonstrated in Figure 5.7. 
Figure 5.13 Graph showing average lag times calculated using the Richards model and final OD600 of 
cultures expressing hit peptides. The hits are ordered in increasing lag time (columns) with the final OD600 
reached shown by the line-chart. pARCBD has the shortest lag time and highest final OD600, H49 has the 
longest lag time and lowest final OD600, but decreasing final OD600 does not completely correlate with 
increasing lag time. 
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Perhaps less obvious is why maximal OD600 attained should be affected. As observed in 
the proof of principle experiment shown in Figure 5.7, nitrogen source availability and related 
gene activity does affect the final OD600 achieved. However, when NH4Cl is the nitrogen 
source, it is the WT strain with the affected final optical density, although the 54 knockout is 
also affected relative to the glnG strain in 10 and 3 mM NH4Cl. 
Since the effect on final OD600 is arabinose dependent, both the extended lag times and 
lowered final optical density were considered when selecting peptides for further testing. 
Figure 5.13 shows both the lag times of cultures expressing peptides in the presence of 
arabinose (columns) and the associated final OD600 which the culture reached (red line). 
Although there are some peptides with long lag times and final OD600s within a standard 
deviation from the pARCBD control, this graphed data set does show that the cultures with 
the longest lag times are also those that achieved the lowest final OD600. Accepting that the 
L-arg growth test is an appropriate orthogonal screen for peptide activity, there appear to be 
several peptides which appear to have an arabinose dependent effect on the glnAp2 
promoter and are worth pursuing further.  
5.3.3 BACK TO THE BEGINNING: THE PEPTIDES + PGAL 
Although the Lib 1 hits were originally selected for activity against PspF. 54-dependent 
transcription, follow-up experiments targeted the similar but orthogonal NtrC. 54 interaction 
and resultant transcription. It is therefore possible that some peptides will be active in the 
original assay but not the second and this could be due to either an off target mode of action, 
such as against -galactosidase, or selectivity for PspF. 54. 
To go forward to the next stage of study, it is important to select peptides which are active in 
both original and orthogonal activity assays since they are most likely to be on-target in their 
mode of inhibition. Therefore, the peptides that were judged to show the most activity in both 
the L-arg and Pgal growth tests were selected for further in vivo study. The selected 
peptides are shown in Table 5.6, along with their L-arg lag time, final OD600 and 
performance in the Pgal growth tests. Although H18 was shown to be active in both assays, 
it was not selected for further study initially, due to the fact that in the original screen it 
appeared only once. It was selected for further investigation after sequence analysis due to 
its perceived similarity to H25, which did not show similar good activity in either follow-up 
assay. It is worth noting that there are several other peptides, such as H37 or H4, which 
showed activity in only one, the Pgal and L-arg assays respectively. Since the SGW+5 
library screen only produced one hit, this peptide was also pursued for activity in the final in 
vivo assays. 
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Initially, zone of inhibition assays for each of peptides were attempted. In these assays, 
lawns of the selection strain expressing each peptide were plated in top agar onto minimal 
media agar plus glycerol, and 4 concentrations of Pgal (0%, 0.1%, 1% and 10%) were 
spotted onto the surface. Although at higher Pgal concentrations a clear zone of inhibition 
was present, there were no measureable differences in the diameter of the zones. 
Additionally, there was no determinable difference between plates with and without 
arabinose. Visualisation was also difficult due to the colour and amount of growth achieved 
on the minimal media. 
PEPTIDE 
PGAL GROWTH L-ARG GROWTH 
MAX OD600 FINAL OD600 
LAG TIME 
(MINS) 
FINAL OD600 
pARCBD 0.412 0.106 583.4 1.39 
H2 0.424 0.183 764.5 1.12 
H20 0.544 0.201 787.3 0.88 
H35 0.352 0.150 821.8 0.93 
H45 0.432 0.168 846.1 0.96 
H46 0.403 0.169 794.8 0.92 
H49 0.354 0.164 907.8 0.71 
H79 0.438 0.199 803.7 1.33 
Lib R1 0.454 0.111 677.2 1.13 
Table 5.6 Hit peptides selected for further study. Previous in vivo follow-up data are shown. 
To try to improve the visualisation and see larger differences between the selected hits and 
control, serial dilutions (10X) of overnight cultures of the hits were plated onto LB agar plus 
varying additives. Figure 5.14 shows the growth of some of the hits on LB agar containing 
arabinose, arabinose and Xgal, or arabinose and 1% Pgal. Although there are some 
differences in growth between cultures on LB agar plus arabinose, all cultures grow 
approximately well. When plated onto Xgal and arabinose containing media, the cultures 
grow as expected but 3 hit peptides show some difference in -galactosidase activity 
compared to the pARCBD and R1 controls. For H20, the -galactosidase activity seems 
much reduced and some individual colonies in the highest dilution are white. For H35 and 
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H49, although all the spots are blue, the pARCBD and R1 controls appear a deeper blue in 
all dilutions. When plated onto 1% Pgal and arabinose, the pARCBD and R1 controls are 
unable to grow, even at the lowest dilution. Hits H20 and H49 however, are able to plate out 
for growth up to the 8th and 7th dilution respectively, although the growth is less than in the 
absence of Pgal for all dilutions. H35 is also able to grow on the Pgal plate, although only at 
the highest cell density plated. The other hits chosen to be followed up after the two in vivo 
assays were also plated, but none were able to grow on Pgal, or showed differences in 
colour when plated on Xgal (data not shown). 
The above experiment confirms the activity of these hits against Pgal toxicity and makes a 
key link to -galactosidase activity. Furthermore, the activity of these hits validates the 
selection method and the two follow-up methods for quantifying and confirming hits. That 
they were also identified as active in the orthogonal L-arg growth assay suggests that the 
target is E 54 but further work would be required to pinpoint the exact mechanism of 
inhibition. In order to confirm these results further, in vitro assays using synthetic versions of 
the peptides should be performed. The types of assay most appropriate are discussed in 
Chapter 6 Conclusions. 
5.4 SUMMARY AND CONCLUSIONS 
In this chapter, the outcomes of the single round liquid selection screens (link to SICLOPPS I 
segment) have been discussed. The selected hits from each library were sequenced and the 
amino acid distribution analysed. For the Lib 1 library, there were marked differences in the 
numbers found versus numbers expected for some amino acids. However, given the sample 
size, it is not possible to say whether the appearance of some sequences more than once is 
statistically significant. In the case of the SGW+5 library, surprisingly only one hit was found. 
Figure 5.14 Growth of selected hit peptides and controls on various media. Overnight cultures of pARCBD, 
Lib 1 H20, H35, H49 and R1 were plated onto LB agar plus arabinose, arabinose and Xgal and arabinose and 
1% Pgal. Whist all dilutions of each culture grow on cm, ara and cm, ara, Xgal, only H20, H35 and H49 grow on 
1% Pgal. Hit growth on Xgal also shows varying -galactosidase activity. 
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Working on the basis that any peptides appearing more than once have been actively 
selected for, the hits were narrowed down to a further group of hits. To analyse peptide 
expression dependent -galactosidase activity in the selection strain, a kinetic 96-well plate 
based assay was developed, but was not suitable as a secondary screen for the hit 
peptides. Although the assay was functional, it seems that it was not sensitive enough to 
measure differences in -galactosidase activity, which may be due to accumulation of -
galactosidase over time. 
The peptides were subjected to a secondary screen, which involved measuring growth 
curves in 96 well plates in the presence of the selective component Pgal. This assay showed 
clear differences in growth for some peptides which was peptide expression dependent. The 
results of this experiment demonstrate that the initial selection did isolate some peptides 
able to reduce the toxic effect of Pgal in the growth medium. In order to assess whether 
these peptides were targeting 54 and PspF, an orthogonal growth assay was developed 
based on the bEBP NtrC. In this assay, some peptides altered the growth parameters of a 
WT E. coli strain grown under nitrogen limiting conditions in an expression dependent 
manner. 
The results of both of these secondary screens suggest that the initial selection has resulted 
in some false positives having no effect on either promoter tested, but additionally some 
genuine hits were isolated. The effect of these hits can be seen in altered growth profiles in 
both assays and are arabinose dependent. Finally, drop spotting of serial dilutions of some 
selected hits on solid media containing Pgal validated some hits by showing the ability of 
H49, H20 and H35 to grow when the pARCBD and R1 controls were unable to. 
This chapter has outlined work which developed secondary screening tools for determining 
peptide activity. Although the kinetic -galactosidase assay was not useful in this instance, 
should an alternative selection strain be used with perhaps lower activity, it could still be 
useful. 
5.4.1 SEQUENCE ANALYSIS OF H20, H35 AND H49 
The sequences of the hit peptides which were able to rescue growth in cultures spotted onto 
1% Pgal on LB agar are shown in Table 5.7. Without further information on their mechanism 
of action it is difficult to attribute activity to specific residues. Whilst there appears to be 
variety in positions 2 and 3, H49 contains lysine at position 3, which is often found in bEBPs 
(Figure 5.1). Furthermore, whilst there is variance in the amino acids found at positions 10 
and 11 (Figure 5.1, A.), examination of the sequences of select bEBPs, including PspF and 
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NtrC shows that in the positions following the GAFTGA motif, the basic amino acids lysine 
and arginine are often found, as they are in H20. Limited structural data is available showing 
the chemical nature of the contacts made between 54 and PspF so further characterisation 
of the binding of these peptides could be useful for analysis of the WT protein-protein 
interaction. 
PEPTIDE  SEQUENCE  OCCURRENCE 
H20  C M P G A F T G A R K  2 
H35  C S N G A F T G A V D  2 
H49  C F K G A F T G G C   2 
Table 5.7 Sequences of the Lib 1 hits active against 1% Pgal on LB agar, and the number of times they 
were selected. As before, polar charged aas are shown in green, polar neutral in blue, aromatic in purple and 
non-polar in pink. 
5.4.2 THE SIGNIFICANCE OF GAFTGG 
Originally, the Lib 1 library was cloned to include a fixed GAFTGA motif, around which 4 
amino acid residues were altered. This was seen in all the sequenced plasmid, both 
positively and randomly selected, except for 2 instances where the same sequence was 
found. H49 has deletion of the final GAFTGA A and resulting in a shortened peptide and a 
GAFTGG motif. With the data in hand, it is not possible to assess the significance or 
chances of selecting the GAFTGG motif but working on the basis that obtaining any 
sequence more than once is due to positive selection, the GAFTGG sequence should be 
considered noteworthy. Furthermore, this was a peptide which showed activity in the Pgal 
and L-arg growth tests, as well as the final growth on solid media, but what is the possible 
significance of the mutation A→G? 
Out of over 200 sequenced and aligned 54 activators [271], only 9 with recognisable 
GAFTGA motifs, do not have alanine at position 6 of the „GAFTGA‟ (or equivalent) motif. 
Table 5.8 gives details of the 54 activator, the organism of origin and the sequence of the 
GAFTGA motif or equivalent. 
In PspF, the effects of mutating A88 have not been explored, but for alternative bEBPs NifA, 
NtrC and DtcD some directly relevant work has been done. For NifA, mutation of the 
equivalent position, A310, to N/ D/ G and S was explored, with only the mutant A310S able 
to activate transcription [92]. Additionally, for NtrC and DtcD, the substitution of the 
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equivalent alanine by threonine abolishes the ability of the protein to activate transcription in 
complex with 54, whilst DNA binding is unaffected [96, 97]. 
 
54 ACTIVATOR ORGANISM MOTIF 
PP3467 Pseudomonas putida KT2440 GAFTGS 
PrpR Pseudomonas aeruginosa GAFSGS 
PrpR Bordetella paraperussis GAFTGS 
Putative Thiobacillus denitrificans GAFSGS 
DctD Shewanella oneidensis GAFSGS 
VVI2880 Vibro vulnificus GSFTGS 
PhkR Burkholderia kuruviensis GAYTGS 
PSPTO_3046 Pseudomonas syringae pv. Tomato GAFTGS 
PrpR Salmonella typhimurium GAFTGS 
Table 5.8 
54
 activators which do not have alanine at GAFTGA position 6 (PspF A88) and their ‘GAFTGA’ 
motif sequences. 
It is clear that A88 is highly conserved and is critical for transcriptional activation. It appears 
that in vivo this peptide interferes with both NtrC- and PspF- dependent activation of 54. To 
pursue and confirm this further, the next step is an in vitro study. Future work on this peptide 
and the others identified, and further characterisation of the assays developed will be 
discussed in Chapter 6 Conclusions. 
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6 CONCLUSIONS 
6.1 ACHIEVEMENT OF AIMS AND PERSPECTIVES 
This project aimed to study the interaction between PspF, a bEBP, and 54, a bacterial 
transcriptional activator unique in its mechanism, using a novel chemical genetic approach. 
This system has been well studied using a classical genetic approach (for review see [20, 
43, 59]), which has identified key residues and motifs within PspF as well as 54, where 
PspF activity links the hydrolysis state of ATP in its catalytic site to the isomerisation of E 54 
bound to promoter DNA. PspF Loop 1, containing the highly conserved GAFTGA motif, was 
identified as a key motif, whose integrity is required for a functional interaction with 54 [1, 3]. 
This work aimed to recapitulate the PspF Loop 1 functionality using peptides, both synthetic 
made using SPPS, and as products of in vivo expression. Peptides based on Loop 1 and 
able to interact with 54 would potentially be able to reveal aspects of the interaction 
inaccessible by classical genetics, such as the number of Loop 1. 54 interactions, 
determinants of its affinity, impacts on RPCC, and would additionally be founding molecules 
for the development of potential novel antimicrobials [33, 34, 100]. 
6.1.1 THE INTERACTION BETWEEN PSPF FRAGMENT 4 AND 54 
Fragment 4 is a 25 amino acid peptide that was originally investigated as a fusion to MBP. It 
contains the GAFTGA motif, critical for a meaningful interaction with 54 and was shown to 
form a complex with 54 in the presence of early melted DNA (1.1.5 PspF Fragments 4 and 
2) [1]. An early aim of this thesis was to establish an in vitro assay in which the interaction 
between synthetic F4 and 54 was detectable. F4 would therefore be available as a positive 
control for binding against which other interesting peptides could be compared. 
6.1.1.1 FRAGMENT 4 FORMS A DETECTIBLE INTERACTION WITH 54 IN VITRO 
Initially, an in vitro binding assay based on the environmental fluorophore, dansyl, was 
developed. In the presence of 5 M synthetic d-F4, the intensity fluorescence intensity 
increases approximately two-fold, but λmax does not change. That the control peptide d-
F4 T86A has no effect suggests that the change is due to peptide. 54 interaction. Alteration 
of fluorescence intensity and λmax is a result of changes in the solvent exposure of the dansyl 
moiety [220]. For the linear d-F4, positioning of the dansyl group could be sub-optimal for 
observing changes in the environment surrounding it. Whilst this assay does demonstrate 
peptide binding and could be used to calculate interaction strengths, it gives no indication 
whether the peptide binds in such a way to disrupt 54-dependent transcriptional activation. 
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Likewise, initial ITC experiments suggest that the synthetic F4 (untagged) is able to interact 
with 54 and measures the Kd of the interaction to be in the micro molar range. These two 
assays are the first instance in which interaction between F4 and 54 alone (i.e. not as a 
fusion to MBP) has been detected. 
The activity of the peptide as an inhibitor was also characterised in vitro using full-length and 
abortive transcription assays using purified components. These assays measure the number 
of open complexes able to be formed by PspF.E 54 on promoter DNA. The ability of PspF1-
275 to activate transcription was challenged with MBP-F4/ T86A/ T86S, MBP-F2/ T86A/ T86S 
and synthetic F4. Some knockdown in both the full-length and abortive transcription assays 
was observable in the presence of MBP-F4. Although this fusion protein had been detected 
interacting with 54 on promoter DNA [1], it had not been previously shown as able to reduce 
the number of transcripts formed when PspF1-275 was present. Synthetic F4 did not induce 
the same level of reduction in transcription, which may be due to conformational differences 
between it and the MBP fused peptide, or due to inaccuracies in the peptide concentration 
determination, a common problem when peptides are untagged. 
6.1.1.1.1 CHARACTERISATION OF FRAGMENT 4 HAS IMPLICATIONS FOR PEPTIDE 
INHIBITORS OF 54 
Using ITC, the interaction between F4 and 54 was measured to be approximately 10 M. It 
was also found to inhibit full-length transcription as an MBP-fusion, after being allowed to 
pre-form an interaction with 54 before addition of PspF. It is not clear whether the MBP-
fusion and untagged peptide form interactions with 54 in the same way, i.e. the same 
number, same binding pocket, but if the interactions are similar, the Kd for binding between 
54 and PspF must be higher than 10 M. 
Selection from libraries using an in vivo screen might not be expected to isolate protein 
binding partners with the highest binding affinities, since no steps are taken to ensure strong 
binding, only final activity. It might therefore be expected that the isolated peptides also have 
activities in a similar range to that of Fragment 4. 
6.1.1.2 IN VIVO DETECTION OF FRAGMENT ACTIVITY REQUIRES ASSAY DEVELOPMENT 
-galactosidase assays using F4 and MBP-F4 to challenge activation of the pspAp promoter 
fused to lacZ were investigated using several approaches. The original experimental design 
gave no measurable activity that was attributable to fragment activity. The set-up was altered 
such that it became more robust and sensitive. Creation of the himA assay strain LJR01 
produced small F4 dependent differences in -galactosidase activity. Further investigation of 
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the experimental set-up such as the fragment expression time could be critical in improving 
assay sensitivity. A further improvement would be to repress the pspAp-lacZ fusion using an 
inducible repressor, so -galactosidase expression from the target promoter could be 
stopped until fragment expression is induced, so allowing more clearly examination of the 
effects of the peptides upon rates of expression from the target promoter. 
6.1.2 DESIGN AND DEVELOPMENT OF SICLOPPS LIBRARIES AND A SELECTION 
SYSTEM FOR PSPF. 54 INHIBITORY PEPTIDES 
SICLOPPS is a plasmid-based system that allows the design of large libraries of cyclic 
peptides which can be expressed and formed in vivo [5]. Cyclic peptides are potentially good 
mimics for PspF Loop 1, and the constraint should reduce the entropic barrier to peptide 
binding to 54 [236] and increase peptide biostability [235]. Since the WT interaction at the 
pspAp promoter occurs between a PspF hexamer and single 54 in complex with RNAP 
(1.1.1 70 and 54 Dependent Transcription Initiation), it was considered that a RTH screen 
would not accurately reflect the native interaction. Whilst it would be suitable to isolate 
peptide inhibitors of PspF hexamerisation, the target of this work was Loop 1, which is 
positioned on the upper face of PspF for interaction with 54. Therefore, a significant task 
was to design and develop an appropriate positive selection screen which targeted the WT 
pspAp promoter complex as closely as possible. 
Two libraries were created; one with 5 randomised positions and not specifically targeted 
towards a bEBP. 54 interaction, and a second library with 4 randomised positions. The 
second library was also engineered to contain the GAFTGA motif, highly conserved across 
bEBPs [1, 46]. Potentially, this second library would be suitable for screening for inhibitors of 
other bEBPs specifically, and peptides isolated in this screen may have activity against other 
bEBPs. 
6.1.2.1 POSITIVE SELECTION USING LACZ ACTIVITY IS POSSIBLE USING PGAL AND A 
GALE SELECTION STRAIN 
A selection system was designed based on an existing reporter construct of the pspAp 
promoter fused to lacZ. In this part of the project, conditions under which expression of lacZ 
is toxic were established using the lactose analogue Pgal. A selection strain, lacking the 
gene for galactose epimerase, galE, was created and was shown to be sensitive in its 
growth to Pgal. Addition of Pgal during the exponential growth phase results in cell lysis, 
which can be monitored via a drop in OD600. Cell death was shown to be dependent on 
both the galE knockout and 54-dependent activation of the pspAp-lacZ fusion using an rpoN 
knockout.  
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Tests on solid media showed that the rigour of the selection using Pgal is dependent upon 
the available sugar source. On LB agar, escape and cell growth is more common than on 
minimal media plus glucose, which is in turn less selective than glycerol. Additionally, the 
concentration of arabinose, added to induce intein expression, had a toxic effect on growth 
at high concentrations. Repetitions of solid selection screens also revealed variability in the 
number of background colonies formed, which could lead to selection of higher numbers of 
false positives. 
To try to ensure that as many genuine hits were selected, a liquid selection strategy using 
Pgal was investigated. Firstly, a multi-round approach was taken in which Pgal was added to 
growing cultures expressing a library and after 3 hours plasmid DNA from surviving cells was 
isolated and transformed into a clean selection strain and the process repeated a total of 4 
times. Positive selection should be observable by monitoring the OD600s of cultures 
expressing pre-selected plasmids compared to the controls. After 4 rounds of selection, 
some small changes in OD600 were seen, but a concern was loss of potential hit plasmid 
through the isolation steps over the selection rounds. To pursue this type of selection, further 
rounds of grow out should be completed. 
A second liquid selection strategy was used which complemented a single round of liquid 
selection with blue/white screening on solid media using Xgal. Colonies having a white or 
light blue phenotype were selected for the Lib 1 library, due to the number of colonies plated. 
For the SGW+5 library, only 51 colonies plated successfully, so all were selected, despite 
varying phenotypes. 
6.1.2.2 THE SGW+5 SINGLE HIT 
From the SGW+5 library, a single hit – SGWVIAGY was selected. This was despite selecting 
colonies that had varying phenotype and the large size of the original library. The single 
identity in spite of plate phenotype suggests that some hits could be missed due to blue 
colony colour on Xgal. White colonies could be false positives, i.e. from mutation of the 
selection strain, or contain peptides able to reduce -galactosidase activity in some way. It 
should not be possible that cells with active -galactosidase activity are unable to hydrolyse 
Xgal contained in the media. However, it might be possible for a reduced -galactosidase 
activity to still result in a blue phenotype. 
This SGWVIAGY hit was investigated further using the kinetic -galactosidase activity assay, 
but using this method it was not possible to determine if it was a genuinely active peptide. It 
was also plated in serial dilution onto LB agar containing 1% Pgal, but was unable to grow 
and did not display reduced -galactosidase activity on Xgal containing media. Library 
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diversity was assessed to a small degree by sequencing 10 random clones, none of which 
were the same identity as the selected hit. Repetition of the library selection and comparison 
with cultures transformed and grown but not subjected to Pgal selection would help to 
confirm both the library integrity and selection process using this library. 
6.1.2.3 THE LIB 1 LIBRARY SELECTION IDENTIFIES ACTIVE PEPTIDES 
6.1.2.3.1 ANALYSIS OF THE SELECTED SEQUENCES REVEALS POSITIVE SELECTION 
Sequencing of the 91 selected hit peptides from the Lib 1 library revealed more diversity 
than the SGW+5, but also that some hits occurred more than once. Simple analysis of the 
numbers of amino acids found versus the expected numbers showed that several amino 
acids, such as alanine, histidine and arginine, appeared fewer times than expected. 
Conversely, others such as valine, serine and tryptophan appeared more often, suggesting 
that positive selection had occurred. 
To attempt to validate and quantify the selected hits, a kinetic -galactosidase activity assay 
was used, based on a method reported by Thibodeau et al. [211]. Similarly to the cuvette-
based -galactosidase assays used to assess the MBP-F4 fragments, the assay was not 
suitable to detect small changes in lacZ activity. During the selection process, cells 
containing the highest level of -galactosidase activity are likely to die first, and be removed 
from the system. However, this type of assay allows accumulation of -galactosidase, even 
in cells where peptide activity to inhibit the pspAp promoter are active. In this case, the 
effects of the peptide may be masked by the time-frame over which the assay is performed. 
An alternative secondary screen was therefore required to confirm the activity of the 
peptides. The chosen screen mimicked the original selection process by growing the 
individually re-transformed hits with Pgal, but in a 96-well plate so that more hits could be 
tested simultaneously in triplicate. Cultures grown in this format appeared not to be 
detrimentally affected by the small scale and arabinose dependent growth in Pgal was 
observed for several of the hits, confirming their activity. 
To assess what the in vivo target might be, an alternative, orthogonal assay was developed. 
In this assay, activation of the 54-dependent glnAp2 promoter was challenged with the 
peptides when L-arginine (L-arg) was the only available nitrogen source. Under these 
conditions, growth of E. coli is dependent on the production of glutamine synthetase (G.S.) 
expressed from 54-dependent glnAp2 [35]. The glnAp2 promoter is requires ATP hydrolysis 
by the bEBP NtrC, which has structural similarity to PspF, for initiation of transcription. Key 
characteristics of growth curves for cultures expressing selected Lib 1 peptides were 
analysed using the package GroFit, which runs in R [212]. Peptide activity in both the Pgal 
197 
 
and L-arg growth tests was quantified and placed them into 3 broad categories. Finally, 
select hits highlighted by both the Pgal and L-arg growth tests were spotted onto LB agar 
containing 1 % Pgal and were found to rescue growth. 
Whilst the L-arg orthogonal assay determines that the active peptides are not targeting -
galactosidase, it does not confirm that the peptides are specific inhibitors for the PspF/ NtrC 
interaction with 54, or that the cyclic peptide is the active species. Possible other targets 
include the 54.RNAP interaction, RNAP alone, the promoter, mRNA or the ribosome. The 
next stage of the project should be to determine the both the active species and the cellular 
target. Testing whether the target is RNAP or the ribosome could be simply achieved by 
growth experiments in the absence of Pgal, since peptides targeting the ribosome or single 
bacterial RNAP would be expected to have an effect on universal growth. Further 
determination of the active species and its target is discussed in the next section 6.2.Future 
Directions. 
In conclusion, this thesis has developed a novel positive selection method that could be 
applied to many lacZ reporter fusions but in this instance was used to select for peptides 
able to inhibit 54-dependent activation of the pspAp promoter. It also outlines secondary 
screening methodologies specific for bEBPs and explores potential in vitro assays, both 
activity based and binding, for studying the interaction between peptide and 54. 
6.2 FUTURE DIRECTIONS 
In the last chapter (5 SICLOPPS II: Hit Peptide Confirmation And Analysis) hit peptides from 
the Lib 1 library screen were tested in 2 secondary in vivo screens which enabled 
identification of several hit peptides with apparent in vivo activity. 3 of these were further 
confirmed as worthwhile pursuing in spot dropping tests on solid media with added Pgal. In 
order to pursue this project further with respect to the existing hits, there are 3 initial steps to 
be taken: i) the active species and its specific target should be determined in vitro, ii) the 
mechanism of activity discovered, i.e. identification of the peptide binding surface and iii) 
what is the efficacy of the peptides both in vivo and in vitro? 
6.2.1 IN VITRO PROSPECTS TO IDENTIFY PEPTIDE BINDING TARGETS 
6.2.1.1 IN VITRO TRANSCRIPTION ASSAYS 
As discussed above, there are multiple possible targets for the peptides in vivo which could 
result in apparent knockdown of the pspAp or glnAp2 promoters. Additionally, whilst the 
cyclic peptides are the product of intein splicing from the SICLOPPS plasmid (Figure 1.10), 
other species are present in the cell (see [160] and as detected by Western blot). To confirm 
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both what the active species is, and to determine its target, in vitro activity assays must be 
performed. 
Currently, synthetic versions of several of the selected hits are in the process of being made. 
Once this is achieved, in vitro transcription assays should verify that it is the peptides which 
reduce 54-dependent transcription. Reduced levels of transcript should be attributable to 
peptide binding to the E 54.promoter complex, but not disrupting it, although such action 
cannot be rigorously discounted without directly testing effects of inhibitory peptides on 
holoenzyme formation and promoter binding. Since the peptides were selected based on 
their activity in both screens utilising both PspF and NtrC to remodel E 54, they might not be 
expected to bind to the bEBP but their effect on bEBP activity should be discernible through 
ATPase activity assays. Hexamerisation might be more difficult to examine, since it is 
traditionally tested using gel filtration chromatography or gel electrophoresis and a 
peptide.protomer interaction may not survive these methods. An alternative approach would 
be to use a functional transcription assay, but to first incubate PspF with the synthetic 
peptide, before adding to E 54.DNA as was done for the fragment MBP-F2, which inhibited 
PspF hexamer formation [194]. 
Various DNA promoter probes which mimic different parts of the initiation complex are 
available to explore the efficacy of peptide inhibition at each stage of E 54 conformational 
change towards RPO. Complementary to this are the nucleotide analogues ADP.BeFX and 
ADP.AlFX which trap the conformation of bEBP.E
54.promoter complex in the ground state 
and transition states respectively. Use of these two types of nucleotide could reveal the 
stage of the forming initiation competent complex which is inhibited. Showing the peptides 
do not down regulate 70-dependent transcription would also be a sensible objective as far 
as demonstrating specificity of action is concerned. 
6.2.1.1.1 ITC TO DETERMINE BINDING STRENGTHS 
ITC should be used to measure the interaction between synthetic peptide and 54 directly. 
As well as reporting the strength of interaction as a binding constant KB, the reaction 
stoichiometry will be elucidated, which if the peptide binds in a similar fashion to PspF, will 
have significance for the study of all bEBPs. 
6.2.1.1.2  FLUORESCENCE-BASED ASSAYS 
6.2.1.1.2.1 SINGLE-MOLECULE FRET 
Single-molecule FRET (smFRET) was recently used to examine the movements of the 
RNAP jaw as transcription is activated from both 70 and 54-dependent promoters [15]. This 
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methodology could help to locate and characterise the binding surface between peptide and 
E 54 by placing one FRET partner on the inhibitory peptide, and the other on E 54. Studies 
with the untagged peptide using the existing FRET pair, located on the  and ‟ RNAP 
subunits, and PspF1-275 bound to nucleotide analogues to mimic each stage of the initiation 
process could also identify the stage of RPOC formation which the peptide target for 
inhibition. 
6.2.1.1.2.2 SINGLE-MOLECULE FLUORESCENCE CO-LOCALISATION (COSMOS) 
Single-molecule fluorescence co-localisation (CoSMoS) is also a fluorescence based 
approach. It uses dye labels which are spectroscopically distinguishable, and has been used 
to tag an immobilised 54-dependent promoter, E 54 and oligonucleotides with different 
probes [272]. This technique allows examination of the kinetics of RPOC formation and 
although in this example uses a constitutively active mutant of NtrC, could be used to study 
potential PspF.peptide. 54 interactions. 
6.2.2 FURTHER IN VIVO PROSPECTS 
The in vivo activity of the peptides could be further investigated by looking at their effect on 
the WT, induced psp response. In the Pgal screen, the peptides were asked to challenge the 
pspAp promoter only and the effect reported using a lacZ fusion. In the WT system, the 
levels of the of the psp response could be assessed using quantitative real time PCR 
(rtPCR) to look at mRNA levels and Western blotting for protein expression. 
6.2.3 DELIVERY OF PEPTIDES IN VIVO 
Key to the establishment of the 54 inhibitors as antimicrobials will be their cell delivery. In E. 
coli, small peptides are naturally taken into the cell via the peptide permeases [273]. These 
permeases are typically able to transport small peptides with masses below ca.650 Da, but 
peptide hydrophobicity and charge also influence uptake [273-276]. Microcin J25 is a 21 
amino acid peptide antimicrobial (Figure 1.12) which is too large to enter E. coli via the 
peptide permease machinery. Instead, Microcin J25 interacts with the outer membrane 
protein FhuA [277, 278] and inner membrane transporters TonB, ExbD, ExbB and SmbA 
[279]. Microcin J25 does have two charged residues, a His located within the lactam ring, 
and the carboxyl-terminal glycine, but these may have direct interactions with the transport 
proteins [280]. 
The peptides selected for activity from the Lib 1 library (H20, H35 and H49) all have at least 
one charged residue and are larger than the permease threshold, which is likely to block 
their transport across the E. coli membrane. An alternative approach delivering the peptides 
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in vivo is to tag the peptides with another molecule, which is itself the target of an E. coli 
transporter system such as biotin. Addition of biotin to peptides up to 31 amino acids in 
length has been shown to deliver the peptides via the biotin transport system [276]. 
6.2.4 THIS WORK IN CONTEXT 
The majority of this work has focused on the development and use of a novel selection 
methodology to identify cyclic peptides capable of disrupting transcriptional activation at 54 
dependent promoters. Furthermore, interactions between linear peptides were examined in 
vitro with the aim of development of further methods for characterising the interaction 
between peptide and 54. In both aspects, this work has contributed to the field in several 
ways. 
6.2.4.1 TARGETING 54.RNAP 
RNAP is an established drug target with both naturally occurring antibiotics such as the 
treatment for tuberculosis, rifampicin (Rif), or the synthetic CBR703 and SB series. However, 
existing antibiotics are active against either RNAP itself, or the RNAP. 70 complex [162, 
171]. Up until this work 54 has remained unprobed by both small molecule and drug 
discovery approaches despite some evidence that it has a role in specific types of bacterial 
pathogenicity [33, 34]. 
Until now, 54 structure and mechanism of action has been targeted by classical biochemical 
and structural biological approaches. For example, point mutations in 54 and DNA 
transcription promoter probes have been used extensively to examine individual amino acids 
within 54 that are involved at various points along the route to open complex formation [23, 
59, 216]. Additionally, this method has also identified key residues on PspF required for a 
meaningful interaction with 54. Thus far, structural studies on 54 have yielded a structure of 
the protein in complex with a PspF hexamer using cryo-EM. Despite extensive efforts, a 
crystal structure of 54 has so far been elusive but structures of the monomer of PspF are 
available bound to various nucleotides. The lack of detailed structural data about 54 is the 
limiting step in the next stage of understanding its mechanism. 
This work has identified several new peptide ligands thought to target the RNAP. 54 complex 
specifically. Additionally, the cyclic peptide nature of the ligands should mean they will prove 
to have increased biostability over simple linear peptides identified by a fragmentation 
approach. Targeting of 54 using cyclic peptides has isolated small biostable molecules for 
the first time which are 54 promoter specific and could potentially be useful tools for further 
study of 54 scope of influence and requirement in vivo. Furthermore, these peptides are 
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novel tools able to fit into existing and well established transcriptional activation assays to 
probe E 54OC formation in a novel way. 
6.2.4.2 SICLOPPS AND PGAL SELECTION 
This work was the first instance in which a promoter bound transcriptional activation complex 
has been targeted for selection of cyclic peptides by SICLOPPS. Previously, Pgal (4.3.1.2 
Phenyl-Beta-D-Galactoside is a Lactose Analogue Toxic to Cells Lacking GalE) has been 
used in an -complementation approach for plasmids bearing lacZ but this work has 
established Pgal as a positive selection method for knockdown of lacZ directly fused to a 
promoter of interest. This now establishes the possibility of diversification and using Pgal to 
examine many commonly pre-existing lacZ promoter fusions. 
6.2.5 PROSPECTS BEYOND PSPF.E 54 
This work has established the commonly used reporter lacZ as a method for positive 
selection for peptide inhibitors. The lacZ reporter gene has been widely used since it was 
first reported as a fusion in 1980 [281, 282] and has previously used to select for genetic 
mutation with Pgal but its use to identify cyclic peptide inhibitors is a novel chemical genetic 
approach. This reporter system also has direct implications for the study of other bEBPs 
which have diverse cellular activities (1.1.2 Features of the Bacterial Enhancer Binding 
Protein) and on 54, the development of novel antimicrobials to target it, and the general 
study of transcriptional activation in bacteria. 
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APPENDICES 
A. TRANSCRIPTION ASSAY  
The nifA early-melted promoter sequence. 
 
I. Α-32P NUCLEOTIDES 
α-32P GTP and UTP were purchased from Perkin Elmer 
α-32P GTP 
Specific Activity: 3000 Ci (111TBq)/mmol 
Concentration: 10 mCi/mL 
B. ANTIBODIES FOR WESTERN BLOTTING 
PROTEIN 
TARGET 
PRIMARY 
ANTIBODY 
DILUTION SECONDARY 
ANTIBODY 
REFERENCE/ 
SOURCE 
PspA Anti-PspA 1:1000 anti-rabbit HRP [63] 
MBP Anti-MBP  1:2000 anti-mouse HRP NEB 
CBD Anti-CBD  1:2000 anti-mouse HRP NEB 
Table B.1 Primary and secondary antibodies used in this work. Secondary antibodies were used at 
1:10,000 dilution and were purchased from Promega. 
  
-26                            -14                                   +1
5‟TTTCAGACGGCTGGCACGACTTTTGCACTCGACTAAAGGGGCGC3‟
3‟AAAGTCTGCCGACCGTGCTGAAAACGTGCTAGTCGGGACCCGCG5’
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C CODON CHART FOR SICLOPPS 
Table C.1 Codon chart for NNS residues in the creation of SICLOPPS libraries. 
D  SEQUENCES OF SICLOPPS SELECTED HITS 
(I) LIBRARY 1 
HIT 
NUMBER 
INSERTED DNA SEQUENCE 
TRANSLATED 
SEQUENCE 
FRAMESHIFT
/ STOP? 
Lib H1 
TGCACCTGGGGGGCGTTTACCGGTGCGGGGTG
CTGC 
CTWGAFTGAGCC N 
Lib H2 
TGCGCGTCGGGGGCGTTTACCGGTGCGTTCTG
GTGC 
CASGAFTGAFWC N 
Lib H3 
TGCAAGGCCGGGGCGTTTACCGGTGCGCGCG
GCTGC 
CKAGAFTGARGC FS 
Lib H4 
TGCTTGTCCGGGGCGTTTACCGGTGCGTCGAG
CTGC 
CLSGAFTGASSC N 
Lib H5 
TGCCAGACCGGGGCGTTTACCGGTGCGGACAC
CTGC 
CQTGAFTGADTC N 
Lib H6 
TGCTTCTAGGGGGCGTTTACCGGTGCGATGTA
CTGC 
CF*GAFTGAMYC Stop 
Lib H7 
TGCCTCTGGGGGGCGTTTACCGGTGCGCCGGG
GTGC 
CLWGAFTGAPGC N 
Lib H8 TGCATGTAGGGGGCGTTTACCGGTGCGGGCAT CM*GAFTGAGMC Stop 
 
CODON AA CODON AA 
CODO
N 
AA 
CODO
N 
AA 
 
U 
UUC Phe (F) UCC Ser (S) UAC Tyr (Y) UGC Cys (C) C 
UUG Leu (L) UCG Ser (S) UAG STOP UGG Trp (W) G 
C 
CUC Leu (L) CCC Pro (P) CAC His (H) CGC Arg (R) C 
CUG Leu (L) CCG Pro (P) CAG Gln (Q) CGG Arg (R) G 
A 
AUC Ile (I) ACC Thr (T) AAC Asn (N) AGC Ser (S) C 
AUG Met (M) ACG Thr (T) AAG Lys (K) AGG Arg (R) G 
G 
GUC Val (V) GCC Ala (A) GAC Asp (D) GGC Gly (G) C 
GUG Val (V) GCG Ala (A) GAG Glu (E) GGG Gly (G) G 
 U C A G  
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GTGC 
Lib H9 
TGCGTCGGGGGGGCGTTTACCGGTGCGGCCTC
CTGC 
CVGGAFTGAASC N 
Lib H10 
TGCCTCGTGGGGGCGTTTACCGGTGCGGACAC
CTGC 
CLVGAFTGADTC N 
Lib H11 
TGCACCTGGGGGGCGTTTACCGGTGCGGGGTG
CTGC 
CTWGAFTGAGCC N 
Lib H12 
TGCGTCTGGGGGGCGTTTACCGGTGCGGACAT
GTGC 
CVWGAFTGADMC N 
Lib H13 
TGCAGCGACGGGGCGTTTACCGGTGCGTTCGG
GTGC 
CSDGAFTGAFGC N 
Lib H14 
TGCTGGATGGGGGCGTTTACCGGTGCGGACAA
GTGC 
CWMGAFTGADKC N 
Lib H15 
TGCGTCTAGGGGGCGTTTACCGGTGCGTCGGA
GTGC 
CV*GAFTGASEC Stop 
Lib H16 
TGCCAGATCGGGGCGTTTACCGGTGCGCGCTA
GTGC 
CQIGAFTGAR*C Stop 
Lib H17 
TGCCTGAAGGGGGCGTTTACCGGTGCGTCCAG
GTGC 
CLKGAFTGASRC N 
Lib H18 
TGCGTCTTCGGGGCGTTTACCGGTGCGGGCTT
CTGC 
CVFGAFTGAGFC N 
Lib H19 
TGCAGGAAGGGGGCGTTTACCGGTGCGATGG
CCTGC 
CRKGAFTGAMAC N 
Lib H20 
TGCATGCCCGGGGCGTTTACCGGTGCGCGGAA
GTGC 
CMPGAFTGARKC  N 
Lib H21 
TGCAACGGCGGGGCGTTTACCGGTGCGTACAT
CTGC 
CNGGAFTGAYIC N 
Lib H22 
TGCCGCAGGGGGGCGTTTACCGGTGCGGGGC
GGTGC 
CRRGAFTGAGRC N 
Lib H23 
TGTCAGTAGGGGGCGTTTACCGGTGCGGGCGT
GTGC 
CQ*GAFTGAGVC 
Stop and silent 
mutation TGC 
to TGT 
Lib H24 
TGCGGCGGCGGGGCGTTTACCGGTGCGATGC
AGTGC 
CGGGAFTGAMQC N 
Lib H25 
TGCTCCTGGGGGGCGTTTACCGGTGCGTTGGG
CTGC 
CSWGAFTGALGC N 
Lib H26 
TGCGTCGTGGGGGCGTTTACCGGTGCGTGCCG
GTGC 
CVVGAFTGACRC N 
220 
 
Lib H27 sequence unclear Frameshift  Frameshift 
Lib H28 
TGCAACGCCGGGGCGTTTACCGGTGCGTTCCT
CTGC 
CNAGAFTGAFLC N 
Lib H29 
TGCCTCGTGGGGGCGTTTACCGGTGCGTACGA
CTGC 
CLVGAFTGAYDC N 
Lib H30 
TGCGTCTGGGGGGCGTTTACCGGTGCGGACAT
GTGC 
CVWGAFTGADMC N 
Lib H31 
TGCGTCTGGGGGGCGTTTACCGGTGCGGACAT
GTGC 
CVWGAFTGADMC N 
Lib H32 
TGCAGCAAGGGGGCGTTTACCGGTGCGACCGT
CTGC 
CSKGAFTGATVC N 
Lib H33 
TGCAGGGACGGGGCGTTTACCGGTGCGTGGTT
CTGC 
CRDGAFTGAWFC N 
Lib H34 
TGCCCGTGCGGGGCGTTTACCGGTGCGTGCAC
GTGC 
CPCGAFTGACTC N 
Lib H35 
TGCTCCAACGGGGCGTTTACCGGTGCGGTCGA
CTGC 
CSNGAFTGAVDC N 
Lib H36 
TGCCTCTGGGGGGCGTTTACCGGTGCGCCGGG
GTGC 
CLWGAFTGAPGC N 
Lib H37 
TGCCTGTGGGGGGCGTTTACCGGTGCGCCGGA
GTGC 
CLWGAFTGAPEC N 
Lib H38 
TGCCTGAACGGGGCGTTTACCGGTGCGTACAC
TGGT 
CLNGAFTGAYTG 
FS in insert, 
deletion of TGC 
– no C 
Lib H39 
TGCCGTCGGGGGCGTTTACCGGTGCGAGCATG
TGC 
TGCCGTCGGGGGCGTTTACCGGTGCGAGCATG
TGC 
 FS in insert - G 
Lib H40 
TGCATCTAGGGGGCGTTTACCGGTGCGAAGAG
GTGC 
CI*GAFTGAKRC stop 
Lib H41 
TGCATGCCCGGGGCGTTTACCGGTGCGCGGAA
GTGC 
CMPGAFTGARKC N 
Lib H42 
TGCCAGGCGGGGGCGTTTACCGGGTGCGAAG
CAGTGC 
CQAGAFTGCEAV FS in insert 
Lib H43 
TGCCCGTCCGGGGCGTTTACCGGTGCGGTGGA
GTGC 
CPSGAFTGAVEC N 
Lib H44 sequence unclear Frameshift  Frameshift 
Lib H45 TGCTGGATGGGGGCGTTTACCGGTGCGGACCA CWMGAFTGADQC N 
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GTGC 
Lib H46 
TGCCAGACGGGGGCGTTTACCGGTGCGTGCTG
CTGC 
CQTGAFTGACCC N 
Lib H47 
TGCATGCCCGGGGCGTTTACCGGTGCGAAGCC
CTGC 
CMPGAFTGAKPC N 
Lib H48 
TGCTCGAGCGGGGCGTTTACCGGTGCGCACCG
GTGC 
CSSGAFTGAHRC  N 
Lib H49 
TGCTTCAAGGGGGCGTTTACCGGTGGCTGTTG
C 
CFKGAFTGGCC 
FS deletion of 
GCG 
Lib H50 
TGCCCCTCGGGGCGTTTACGGTGCGTAGTCGT
GC 
CPSGRLRCVVV 
FS immediately 
before insert 
Lib H51 
TGCATGAACGGGGCGTTTACCGGTGCGTACGC
TGC 
CMNGAFTGAYA FS in insert 
Lib H52 
TGCATCTGCGGGGCGTTTACCGGTGCGGTCGA
CTGC 
CICGAFTGAVDC N 
Lib H53 
TGCTAGCCGGGGGCGTTTACCGGTGCGAACCA
GTGC 
C*PGAFTGANQC stop 
Lib H54 
TGCGCGAACGGGGCGTTTACCGGTGCGGACTG
CTGC 
CANGAFTGADCC N 
Lib H55 
TGCGGCAGCGGGCGTTTACCGGTGCGCTCACC
TGC 
CGSGRLPVRSP FS 
Lib H56 
TGCGGGTACGGGGCGTTTACCGGTGCGCACTA
GTGC 
CGYGAFTGAH*C stop 
Lib H57 
TGCTCCAACGGGGCGTTTACCGGTGCGGTCGA
CTGC 
CSNGAFTGAVDC N 
Lib H58 
TGCTTGCACGGGGCGTTTACCGGTGCGGCGAG
CTGC 
CLHGAFTGAASC N 
Lib H59 
TGCGTGCCGGGGGCGTTTACCGGTGCGTTCAT
CTGC 
CVPGAFTGAFIC N 
Lib H60 
TGCCTCGAGGGGGCGTTTACCGGTGCGGTCAA
GTGC 
CLEGAFTGAVKC N 
Lib H61 
TGCTGGAACGGGGCGTTTACCGGTGCGNNNTC
TGGC 
 
FS/ sequence 
unclear 
Lib H62 
TGCTACTACGGGGCGTTTACCGGTGCGATCTG
CTGC 
CYYGAFTGAICC N 
Lib H63 
TGCGGCAAGGGGGCGTTTACCGGTGCGCTCTT
CTGC 
CGKGAFTGALFC 
2 Poor quality 
bases in L and 
F 
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Lib H64 
TGCTGGAGCGGGGCGTTTACCGGTGCGAGGG
GCTGC 
CWSGAFTGARGC 
FS before 
insert 
Lib H65 
TGCATGTAGGGGGCGTTTACCGGTGCGGGCAT
GTGC 
CM*GAFTGAGMC stop 
Lib H66 
TGCACGAGGGGGGCGTTTACCGGTGCGGACG
GCTGC 
CTRGAFTGADGC N 
Lib H67 
TGCTAGAGCGGGGCGTTTACCGGTGCGCCCGA
CTGC 
C*SGAFTGAPDC stop 
Lib H68 
TGCCTGGTGGGGGCGTTTACCGGTGCGGGGTA
GTGC 
CLVGAFTGAG*C stop 
Lib H69 
TGCAGCGGGGGGGCGTTTACCGGTGCGGTCC
CCTGC 
CSGGAFTGAVPC N 
Lib H70 
TGCGTCTACGGGGCGTTTACCGGTGCGCCCTT
CTGC 
CVYGAFTGAPFC N 
Lib H71 
TGCCTCGAGGGGGCGTTTACCGGTGCGGTCAA
GTGC 
CLEGAFTGAVKC  N 
Lib H72 
TGCATCTACGGGGCGTTTACCGGTGCGATGTA
CTGC 
CIYGAFTGAMYC N 
Lib H73 
TGCGTCGGGGGGGCGTTTACCGGTGCGGCCTC
CTGC 
CVGGAFTGAASC N 
Lib H74 
TGCATCGTGGGGGCGTTTACCGGTGCGTGGGG
CTGC 
CIVGAFTGAWGC N 
Lib H75 
TGCCCCATGGGGGCGTTTACCGGTGCGTACCT
GTGC 
CPMGAFTGAYLC N 
Lib H76 
TGCTTCAGGGGGGCGTTTACCGGTGGCNNNTG
CT 
 
sequence 
unclear/ 
frameshift 
Lib H77 
TGGCGACCCCGGGGCGTTTACCGGTGCGGTCG
TGTGC 
WRPRGVYRCGRV FS 
Lib H78 
TGCTTCGTGGGGGCGTTTACCGGTGCGTACGG
GTGC 
CFVGAFTGAYGC N 
Lib H79 
TGCGCCTCGGGGGCGTTTACCGGTGCGTGCTG
GTGC 
CASGAFTGACWC N 
Lib H80 
TGCTTGAGGGGGGCGTTTACCGGTGCGTCCAT
CTGC 
CLRGAFTGASIC N 
Lib H81 
TGCCAGACGGGGGCGTTTACCGGTGCGTGCTG
CTGC 
CQTGAFTGACCC N 
Lib H82 
TGCACCTGGGGGGCGTTTACCGGTGCGGGGTG
CTGC 
CTWGAFTGAGCC N 
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Lib H83 
TGCTGGATGGGGGCGTTTACCGGTGCGGACAA
GTGC 
CWMGAFTGADKC N 
Lib H84 
TGCGTCTAGGGGGCGTTTACCGGTGCGTCGGA
CTGC 
CV*GAFTGASDC stop 
Lib H85 
TGCGTCTACGGGGCGTTTACCGGTGCGCCCTT
CTGC 
CVYGAFTGAPFC N 
Lib H86 
TGCCAGAANGGGGCGTTTACCGGTGCGNNCAN
CTGC 
 
sequence 
unclear 
Lib H87 
TGCTTCAAGGGGGCGTTTACCGGTGGCTGTTG
C 
CFKGAFTGGCC 
FS-deletion of 
GAFTGA GCG 
Lib H88 
TGCAGGTGCGGGGCGTTTACCGGTGCGGACAC
CTGC 
CRCGAFTGADTC N 
Lib H89 
TGCTTGTCCGGGGCGTTTACCGGTGCGTCGAG
CTGC 
CLSGAFTGASSC N 
Lib H90 
TGCCTCGAGGGGGCGTTTACCGGTGCGGTCAA
GTGC 
CLEGAFTGAVKC N 
Lib H91 
TGCTCCTGGGGGGCGTTTACCGGTGCGTTGGG
CTGC 
CSWGAFTGALGC N 
Table D.1 Sequences of Lib 1 hits from the single-round liquid selection. 
E EXAMPLE GROFIT INPUT COMMANDS 
R version 2.14.2 (2012-02-29) 
Copyright (C) 2012 The R Foundation for Statistical Computing 
ISBN 3-900051-07-0 
Platform: i386-pc-mingw32/i386 (32-bit) 
 
R is free software and comes with ABSOLUTELY NO WARRANTY. 
You are welcome to redistribute it under certain conditions. 
Type 'license()' or 'licence()' for distribution details. 
 
  Natural language support but running in an English locale 
 
R is a collaborative project with many contributors. 
Type 'contributors()' for more information and 
'citation()' on how to cite R or R packages in publications. 
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Type 'demo()' for some demos, 'help()' for on-line help, or 
'help.start()' for an HTML browser interface to help. 
Type 'q()' to quit R. 
 
> local({pkg <- select.list(sort(.packages(all.available = TRUE)),graphics=TRUE) 
+ if(nchar(pkg)) library(pkg, character.only=TRUE)}) 
> local({pkg <- select.list(sort(.packages(all.available = TRUE)),graphics=TRUE) 
+ if(nchar(pkg)) library(pkg, character.only=TRUE)}) 
xlsReadWrite version 1.5.4 (826aa0)
1
 
Copyright (C) 2010 Hans-Peter Suter, Treetron, Switzerland. 
 
This package can be freely distributed and used for any 
purpose. It comes with ABSOLUTELY NO GUARANTEE at all. 
xlsReadWrite has been written in Pascal and contains binary 
code from a proprietary library. Our own code is free (GPL-2). 
 
Updates, issue tracker and more info at http://www.swissr.org. 
> data <-read.table("Lib1araindiv240212.csv", header = FALSE, sep = ",", dec = ".") 
> time <-read.table("Largtime.csv", header = FALSE, sep = ",", dec = ".") 
> dim(data) 
[1] 3 39 
> dim(time) 
[1] 3 36 
> Run2 = grofit(time, data, FALSE) 
 
                                                 
1
 xlsReadWrite is a package which enables the output of R packages to be written to Excel files for 
easy export of data.
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= 1. growth curve ================================= 
---------------------------------------------------- 
--> Try to fit model logistic....... OK 
--> Try to fit model richards....... OK 
--> Try to fit model gompertz....... OK 
--> Try to fit model gompertz.exp... ERROR in nls(). For further information see help(gcFitModel)
2
 
 
Are you satisfied (y/n)?y 
Well was (more ore less) o.k. 
 
= 2. growth curve ================================= 
---------------------------------------------------- 
--> Try to fit model logistic....... OK 
--> Try to fit model richards....... OK 
--> Try to fit model gompertz....... OK 
--> Try to fit model gompertz.exp... ERROR in nls(). For further information see help(gcFitModel) 
 
Are you satisfied (y/n)?y 
Well was (more ore less) o.k. 
 
= 3. growth curve ================================= 
---------------------------------------------------- 
--> Try to fit model logistic....... OK 
--> Try to fit model richards....... OK 
--> Try to fit model gompertz....... OK 
--> Try to fit model gompertz.exp... ERROR in nls(). For further information see help(gcFitModel) 
 
                                                 
2
 The error status is usually produced due to infinite values generated from the non-linear squares 
function and indicates that a particular model is not appropriate for the fitting of a data set. 
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Are you satisfied (y/n)?y 
Well was (more ore less) o.k. 
 
Warning message: 
In gcFitModel(acttime, actwell, gcID, control) : 
  gcFitModel: Unable to fit this curve parametrically! 
> IndivTable240212 <- summary(Run2$gcFit) 
> write.xls(IndivTable240212,"C:/IndivTable240212.xls") 
> save.image("C:\\Documents and Settings\\ljr107\\Desktop\\R analysis\\Indivaraanalysis120412") 
 
F MALDI-TOF OF SYNTHETIC PEPTIDES 
 
Figure F.1 MALDI-TOF of F4 N and C termini capped. 
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Figure F.2 MALDI-TOF of F4 T86A N and C termini capped. 
 
Figure F.3 MALDI-TOF spectrum of dansyl-F4 
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Figure F.4 MALDI –TOF spectrum of dansyl-F4 T86A 
 
Figure F.5 MALDI-TOF spectrum of dansyl-Loop 1 
